pre14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule
14a-101)
SCHEDULE
14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
þ |
|
Preliminary Proxy Statement |
o |
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
o |
|
Definitive Proxy Statement |
o |
|
Definitive Additional Materials |
o |
|
Soliciting Material Pursuant to §240.14a-12 |
Express Scripts, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ |
|
No fee required. |
o |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
|
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
|
|
|
|
|
|
|
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was
determined): |
|
|
|
|
|
|
|
|
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
|
|
|
|
|
|
|
|
|
(5) |
|
Total fee paid: |
|
|
|
|
|
|
|
|
|
o |
|
Fee paid previously with preliminary materials. |
|
o |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2)
and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its
filing. |
|
(1) |
|
Amount Previously Paid: |
|
|
|
|
|
|
|
|
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
|
|
|
|
(3) |
|
Filing Party: |
|
|
|
|
|
|
|
|
|
|
|
(4) |
|
Date Filed: |
|
|
|
|
|
|
|
|
|
PRELIMINARY COPY
EXPRESS SCRIPTS, INC.
One Express Way
Saint Louis, Missouri 63121
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
May 28, 2008
The 2008 Annual Meeting of Stockholders of EXPRESS SCRIPTS,
INC., a Delaware corporation (the Company), will
be held at the principal executive offices of the Company, One
Express Way, Saint Louis, Missouri 63121, on Wednesday,
May 28, 2008, at 9:30 a.m. Central Time (the
meeting), to consider and act upon the following
matters:
|
|
|
|
1.
|
to elect eleven (11) directors to serve until the next
Annual Meeting of Stockholders or until their respective
successors are elected and qualified;
|
|
|
2.
|
to approve and ratify an amendment to the Companys Amended
and Restated Certificate of Incorporation to increase the number
of authorized shares of the Companys common stock from
650,000,000 shares to 1,000,000,000 shares;
|
|
|
3.
|
to approve and ratify an increase in the number of shares of the
Companys common stock authorized for issuance under the
Express Scripts, Inc. Employee Stock Purchase Plan from
2,000,000 shares to 3,500,000 shares;
|
|
|
4.
|
to ratify the appointment of PricewaterhouseCoopers LLP as the
Companys independent registered public accountants for the
Companys current fiscal year;
|
|
|
5.
|
to transact such other business as may properly come before the
meeting or any adjournments or postponements thereof.
|
Only stockholders of record at the close of business on
March 31, 2008, are entitled to notice of and to vote at
the meeting. At least ten days prior to the meeting, a complete
list of stockholders entitled to vote will be available for
inspection by any stockholder for any purpose germane to the
meeting, during ordinary business hours, at the office of the
Secretary of the Company at One Express Way, Saint Louis,
Missouri 63121. As a stockholder of record, you are cordially
invited to attend the meeting in person. Regardless of whether
you expect to be present at the meeting, please either complete,
sign and date the enclosed proxy and mail it promptly in the
enclosed envelope, or vote electronically via the Internet or
telephone as described in greater detail in the proxy statement.
Returning the enclosed proxy, or voting electronically or
telephonically, will not affect your right to vote in person if
you attend the meeting.
By Order of the Board of Directors
Thomas M. Boudreau
Executive Vice President, Law & Strategy and
Corporate Secretary
One Express Way
Saint Louis, Missouri 63121
April [14], 2008
Even though you may plan to attend the meeting in person,
please vote by telephone or the Internet, or execute the
enclosed proxy card and mail it promptly. A return envelope
(which requires no postage if mailed in the United States) is
enclosed for your convenience. Telephone and Internet voting
information is provided on your proxy card. Should you attend
the meeting in person, you may revoke your proxy and vote in
person.
Table of
Contents
|
|
|
|
|
|
|
Page
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
5
|
|
|
|
|
7
|
|
|
|
|
9
|
|
|
|
|
10
|
|
|
|
|
11
|
|
|
|
|
13
|
|
|
|
|
13
|
|
|
|
|
23
|
|
|
|
|
23
|
|
|
|
|
24
|
|
|
|
|
26
|
|
|
|
|
27
|
|
|
|
|
29
|
|
|
|
|
30
|
|
|
|
|
30
|
|
|
|
|
39
|
|
|
|
|
40
|
|
|
|
|
42
|
|
|
|
|
42
|
|
|
|
|
43
|
|
|
|
|
43
|
|
|
|
|
45
|
|
|
|
|
46
|
|
|
|
|
50
|
|
|
|
|
51
|
|
|
|
|
51
|
|
|
|
|
51
|
|
|
|
|
52
|
|
PRELIMINARY COPY
EXPRESS SCRIPTS, INC.
One Express Way
Saint Louis, Missouri 63121
2008
ANNUAL MEETING OF STOCKHOLDERS
This proxy statement is furnished in connection with the
solicitation of proxies by the Board of Directors of Express
Scripts, Inc., a Delaware corporation, which we refer to as the
Company, to be voted at our 2008 Annual Meeting of
Stockholders, which we refer to as the annual
meeting or the meeting, and any adjournment or
postponement of the meeting. The meeting will be held at our
principal executive offices, One Express Way, Saint Louis,
Missouri 63121, on Wednesday, May 28, 2008, at
9:30 a.m. Central Time, for the purposes contained in
the accompanying Notice of Annual Meeting of Stockholders and in
this proxy statement. This proxy statement and the accompanying
proxy will be first sent or given to stockholders on or about
April [14], 2008.
ABOUT THE
MEETING
Why Did I
Receive This Proxy Statement?
Because you were a stockholder of our company as of
March 31, 2008, or the record date, and are
entitled to vote at the annual meeting, our board of directors
is soliciting your proxy to vote at the meeting.
This proxy statement summarizes the information you need to know
to vote at the meeting. This proxy statement and form of proxy
were first mailed or made available to stockholders on or about
April [ ], 2008.
What Am I
Voting On?
You are voting on four items:
1. Election of directors (see page 5);
2. Approval and ratification of an amendment to the
Companys Amended and Restated Certificate of Incorporation
to increase the number of authorized shares of the
Companys common stock from 650,000,000 shares to
1,000,000,000 shares (see page 45);
3. Approval and ratification of an increase in the number
of shares of the Companys common stock authorized for
issuance under the Express Scripts, Inc. Employee Stock Purchase
Plan (the ESPP) from 2,000,000 shares to
3,500,000 shares (see page 46); and
4. Ratification of PricewaterhouseCoopers LLP as
independent registered public accountants for 2008 (see
page 50).
How Do I
vote?
Stockholders of Record: If you are a
stockholder of record, there are four ways to vote:
|
|
|
|
|
by toll-free telephone at
1-800-690-6903
|
|
|
|
by Internet at www.proxyvote.com
|
|
|
|
by completing and returning your proxy card
|
|
|
|
by written ballot at the meeting
|
1
Street Name Holders: Shares which are held in
a brokerage account in the name of the broker are said to be
held in street name. If your shares are held in
street name you should follow the voting instructions provided
by your broker. You may complete and return a voting instruction
card to your broker, or vote via the telephone or internet.
Check your proxy card for more information. If you hold your
shares in street name and wish to vote at the meeting, you must
obtain a legal proxy from your broker and bring that proxy to
the meeting.
Regardless of how your shares are registered, if you complete
and properly sign the accompanying proxy card and return it to
the address indicated, or vote via the telephone or internet,
your shares will be voted as you direct.
What Are
The Voting Recommendations Of The Board Of Directors?
Our board recommends the following votes:
1. FOR each of the nominees as directors;
2. FOR the approval and ratification of an amendment to the
Companys Amended and Restated Certificate of Incorporation
to increase the number of authorized shares of the
Companys common stock from 650,000,000 shares to
1,000,000,000 shares;
3. FOR the approval and ratification of an increase in the
number of shares of the Companys common stock authorized
for issuance under the ESPP from 2,000,000 shares to
3,500,000 shares; and
4. FOR the ratification of the appointment of
PricewaterhouseCoopers LLP as independent registered public
accountants for 2008.
Unless you give instructions on your proxy card, the persons
named as proxy holders will vote your shares in accordance with
the recommendations of our board of directors.
Will Any
Other Matters Be Voted On?
We do not know of any other matters that will be brought before
the stockholders for a vote at the annual meeting. If any other
matter is properly brought before the meeting, your signed or
electronic proxy card gives authority to George Paz and Thomas
M. Boudreau to vote on such matters in their discretion.
Who Is
Entitled To Vote At The Meeting?
Only stockholders of record at the close of business on the
record date are entitled to receive notice of and to participate
in the annual meeting. If you were a stockholder of record on
that date, you will be entitled to vote all of the shares that
you held on that date at the meeting, or any postponements or
adjournments of the meeting.
How Many
Votes Do I Have?
You will have one vote for every share of our common stock you
owned on the record date.
How Many
Votes Can Be Cast By All Stockholders?
Approximately [253,000,000], consisting of one vote for each
share of our common stock outstanding on the record date. There
is no cumulative voting.
How Many
Votes Must Be Present To Hold The Meeting?
The holders of a majority of the aggregate voting power of our
common stock outstanding on the record date, or approximately
[126,500,000] votes, must be present in person, or by
proxy, at the meeting in order to constitute a quorum necessary
to conduct the meeting.
If you vote, your shares will be part of the quorum. Abstentions
and broker non-votes will be counted in determining the quorum.
A broker non-vote occurs when a bank or broker holding shares in
street name submits a proxy that states that the broker does not
vote for some or all of the proposals, because the broker has
not received
2
instructions from the beneficial owners on how to vote on the
proposals and does not have discretionary authority to vote in
the absence of instructions.
We urge you to vote by proxy even if you plan to attend the
meeting so that we will know as soon as possible that a quorum
has been achieved.
What Vote
Is Required To Approve Each Proposal?
In the election of directors, the affirmative vote of a
plurality of the votes present in person or by proxy and
entitled to vote at the meeting is required. A proxy that has
properly withheld authority with respect to the election of one
or more directors will not be voted with respect to the director
or directors indicated, although it will be counted for the
purposes of determining whether there is a quorum.
For the proposal to approve and ratify the Amendment to the
Companys Amended and Restated Certificate of
Incorporation, the affirmative vote of a majority of the
outstanding shares of common stock entitled to vote at the
meeting will be required for approval. Accordingly, abstentions
and broker non-votes will have the effect of votes against this
proposal.
For each of the proposal to approve and ratify the increase of
shares authorized for issuance under the ESPP and the proposal
to ratify the appointment of PricewaterhouseCoopers LLP as our
independent registered public accountants, the affirmative vote
of the holders of a majority of the shares represented in person
or by proxy and entitled to vote on the proposal will be
required for approval. An abstention with respect to each of
these proposals will not be voted, although it will be counted
for the purposes of determining whether there is a quorum.
Accordingly, an abstention will have the effect of a negative
vote. Broker non-votes on a proposal (shares held by brokers
that do not have discretionary authority to vote on the matter
and have not received voting instructions from their clients)
are not counted or deemed present or represented for determining
whether stockholders have approved that proposal. Please note
that brokers that have not received voting instructions from
their clients cannot vote on their clients behalf on the
proposal to approve the increase of shares available under the
ESPP.
Can I
Change My Vote Or Revoke My Proxy?
Yes. Just send in a new proxy card with a later date, or cast a
new vote by telephone or Internet, or send a written notice of
revocation to our Corporate Secretary at the address on the
cover of this proxy statement. Also, if you attend the meeting
and wish to vote in person, you may request that your previously
submitted proxy not be used.
Why
Havent I Received a Printed Copy of the Proxy or Annual
Report?
This year we are taking advantage of the new Securities and
Exchange Commission (SEC) rules that allow companies
to furnish proxy materials to stockholders via the Internet. If
you received a Notice of Internet Availability of Proxy
Materials, or Notice, by mail, you will not receive
a printed copy of the proxy materials, unless you specifically
request one. The Notice instructs you on how to access and
review all of the important information contained in the proxy
statement and annual report as well as how to submit your proxy
over the Internet. If you received the Notice and would still
like to receive a printed copy of our proxy materials, you
should follow the instructions for requesting these materials
included in the Notice. We plan to mail the Notice to
shareowners by April , 2008.
Who Can
Attend The Annual Meeting?
Any Express Scripts stockholder as of March 31,
2008 may attend the meeting. If you own shares in street
name, you should ask your broker or bank for a legal proxy to
bring with you to the meeting. If you do not receive the legal
proxy in time, bring your most recent brokerage statement so
that we can verify your ownership of our stock and admit you to
the meeting. However, you will not be able to vote your shares
at the meeting without a legal proxy.
If you submit a proxy card without indicating your vote, your
shares will be voted as follows:
|
|
|
|
|
for the nominees for director named in this proxy statement;
|
3
|
|
|
|
|
for the approval and ratification of the amendment to the
Companys Amended and Restated Certificate of Incorporation
which would increase the number of authorized shares of the
Companys common stock from 650,000,000 shares to
1,000,000,000;
|
|
|
|
for the approval and ratification of an increase in the number
of shares of the Companys common stock authorized for
issuance under the ESPP from 2,000,000 shares to
3,500,000 shares;
|
|
|
|
for the ratification of the appointment of
PricewaterhouseCoopers LLP as our independent registered public
accountants for 2008; and
|
|
|
|
in accordance with the recommendation of management on any other
matter that may properly be brought before the meeting and any
adjournment or postponement of the meeting.
|
4
I. ELECTION
OF DIRECTORS
The current term of office of all of our directors expires at
the meeting or when their successors are duly elected and
qualified. The Corporate Governance Committee of our board has
nominated eleven of our current directors to be elected to serve
until the next Annual Meeting of Stockholders or until their
successors are duly elected and qualified. Howard Waltman is
retiring from the board upon the expiration of his current term,
but will continue to serve as a non-voting emeritus member of
the board. Mr. Waltmans retirement will result in one
vacancy on the board. The Corporate Governance Committee of the
board is currently in the process of identifying a candidate to
fill this vacancy. Proxies cannot be voted for a greater number
of persons than the number of nominees named below. Unless
otherwise specified, all proxies will be voted in favor of the
eleven nominees listed below for election as directors of our
company.
Our board of directors has no reason to expect that any of the
nominees will be unable to stand for election on the date of the
meeting or will not serve. If a vacancy occurs among the
original nominees prior to the meeting, the proxies will be
voted for a substitute nominee named by our board and for the
remaining nominees. Directors are elected by a plurality of the
votes present in person or by proxy and entitled to vote at the
meeting. Our board has determined that, in its judgment, with
the exception of Mr. Paz, who is also an executive officer
of our company, and Mr. Toan, who retired as an executive
officer of our company in March 2005, all of the members of our
board of directors are independent, as defined by the listing
standards of The Nasdaq Global Select Market, as of the date of
this Proxy Statement.
The following information is furnished as of March 1, 2008,
for each of the nominees for our Board of Directors:
Name,
Position and Principal Occupation
Gary G. Benanav, 62, was elected a director of Express
Scripts in January 2000. Mr. Benanav served as Vice
Chairman and a Director of New York Life Insurance Company or
New York Life, a life insurance and financial
services company, from November 1999 until his retirement in
March 2005. Mr. Benanav also served as Chairman and Chief
Executive Officer of New York Life International from December
1997 until his retirement in March 2006. He is also a director
of Barnes Group, Inc.
Frank J. Borelli, 72, was elected a director of Express
Scripts in January 2000. Mr. Borelli has been a Senior
Advisor to Stone Point Capital, an investment management company
and formerly a wholly-owned subsidiary of Marsh &
McLennan Companies, Inc. or M&MC, a global
professional services firm, since his retirement from M&MC
in January 2001 where he served as Senior Vice President, among
other positions.. He is also a director and Audit Committee
Chairman of Genworth Financial, Inc. and is a director of the
Interpublic Group of Companies and a director of Signal Holdings
Inc., an investee company of Trident Fund, which is managed by
Stone Point Capital LLC.
Maura C. Breen, 52, was elected a director of Express
Scripts in July 2004. Ms. Breen is Senior Vice President
and General Manager for the New York Region for Verizon
Communications, Inc. or Verizon, a provider of
communications services, a post to which she was appointed in
March 2006. Previously, Ms. Breen was Senior Vice
President/Support Services, Network Services Group for Verizon,
from December 2003 through March 2006. Ms. Breen also
served as Senior Vice President & Chief Marketing
Officer, Retail Market Groups for Verizon from July 2001 through
December 2003.
Nicholas J. LaHowchic, 60, was elected a director of
Express Scripts in July 2001. Mr. LaHowchic has served as
President and Chief Executive Officer of Limited Logistics
Services, Inc. or LLS, from October 1997, and as
Executive Vice President for Limited Brands, Inc., a retail
apparel company and the parent of LLS, from April 2004 until his
retirement in February 2007. LLS provides supply chain,
compliance and procurement services to retailers including
Limited Brands, Inc. Mr. LaHowchic is also a director of
Advance Auto Parts Inc.
Thomas P. Mac Mahon, 61, was elected a director of
Express Scripts in March 2001. Mr. Mac Mahon served as
President and Chief Executive Officer and a member of the
Executive and Management Committees of Laboratory Corporation of
America Holdings or LabCorp, the second largest
independent clinical laboratory company in the U.S., from
January 1997 until his retirement on December 31, 2006.
Mr. Mac Mahon, who has been
5
a director of LabCorp since April 1995, continues to serve as
Chairman of the Board of LabCorp, a position he has held since
April 1996. Mr. Mac Mahon also serves as a director of
Pharmerica Corporation and Golden Pond Healthcare, Inc.
Woodrow A. Myers Jr., M.D., 54, was elected a
director of Express Scripts in May 2007. Dr. Myers has
served as the Managing Director of Myers Ventures, LLC, a
healthcare consulting company, since December 2005. Previously,
Dr. Myers served as Executive Vice President and Chief
Medical Officer of Wellpoint, Inc, a health benefits company,
from September 2000 through December 2005. Dr. Myers is
also a director of Genomic Health, Inc. and ThermoGenesis
Corp.
John O. Parker, Jr., 63, was elected a director of
Express Scripts in July 2001. Mr. Parker has served as a
Venture Partner with Rho Ventures LLC, a venture capital firm,
since January 2002. Mr. Parker also serves on the boards of
PHT Corporation and Medical Present Value, Inc., both privately
held companies.
George Paz, 52, was elected a director of Express Scripts
in January 2004 and has served as Chairman of the Board since
May 2006. Mr. Paz was first elected President of Express
Scripts in October 2003 and also assumed the role Chief
Executive Officer of Express Scripts on April 1, 2005.
Mr. Paz joined Express Scripts and was elected Senior Vice
President and Chief Financial Officer in January 1998 and
continued to serve as Express Scripts Chief Financial
Officer following his election to the office of President until
his successor joined Express Scripts in April 2004.
Samuel K. Skinner, 69, was elected a director of Express
Scripts in February 2004. Mr. Skinner has been Of Counsel
with the law firm of Greenberg Traurig, LLP since 2004.
Mr. Skinner previously served as President, Chief Executive
Officer and a director of USF Corporation (formerly
USFreightways Corporation) or USF, a transportation,
freight forwarding and supply chain management company, from
2000 until his retirement in 2003. Mr. Skinner was also
Chairman of the Board of USF from 2001 until his retirement.
Mr. Skinner is also a director of Navigant Consulting,
Inc., Midwest Air Group, Inc., Diamond Management and Technology
Inc., Dade Behring Holdings, Inc., and the Chicago Board Options
Exchange.
Seymour Sternberg, 64, was elected a director of Express
Scripts in March 1992. Mr. Sternberg currently is the
Chairman of the Board and Chief Executive Officer of New York
Life and has served in this capacity since April 1997. From
October 1995 until October 2002, he was the President of New
York Life, and from October 1995 until March 1997 he also held
the position of Chief Operating Officer of New York Life.
Mr. Sternberg is also a director of CIT Group, Inc., and is
a director/manager of various New York Life subsidiaries.
Barrett A. Toan, 60, was elected a director of Express
Scripts in October 1990 and served as Chairman of the Board from
November 2000 until May 2006. Mr. Toan was Express
Scripts Chief Executive Officer from March 1992 until his
retirement in March 2005. Mr. Toan was an executive
employee of Express Scripts from May 1989 until his retirement
and served as President of Express Scripts from October 1990 to
April 2002. Mr. Toan is also a director of Sigma-Aldrich
Corporation, a specialty chemical company, and Genworth
Financial, Inc., an insurance and financial services company.
The Board of Directors unanimously recommends a vote FOR the
election of each of the nominees listed above.
Director
Emeritus
Our bylaws authorize the board to elect one or more directors
emeritus to serve at the pleasure of the board. Each director
emeritus serves as an advisor and consultant to the board, and
may also be appointed by the board to serve as an advisor and
consultant to one or more committees of the board. A director
emeritus is invited to attend meetings of the board and any such
committees, and may participate in discussions during such
meetings. However, no director emeritus shall be entitled to
vote on any business that comes before the board or any
committee.
Howard L. Waltman, 75, is retiring from the board at the
end of his current term, which expires on the date of the annual
meeting. The Board currently intends to elect Mr. Waltman
to serve as Director Emeritus following his retirement.
Mr. Waltman has been a director of Express Scripts since
its inception in September 1986, and has served as Presiding
Director since October 2006. Mr. Waltman served as Chairman
of the Board of Express Scripts from March 1992 until November
2000. Mr. Waltman is also a director of Emergent Group, Inc.
6
THE BOARD
OF DIRECTORS AND ITS COMMITTEES
Our board of directors is responsible for establishing broad
corporate policies and for overseeing the overall management of
the Company. In addition to considering various matters which
require board approval, our board provides advice and counsel
to, and ultimately monitors the performance of, our senior
management.
Committees of the Board. Our board has four
standing committees of the Board of Directors: the Audit
Committee, the Compensation and Development Committee or the
Compensation Committee, the Corporate Governance
Committee, and the Compliance Committee. Each committee has a
written charter and is composed entirely of directors deemed to
be, in the judgment of our board, independent in accordance with
Nasdaq listing standards. Our board of directors met 14 times in
2007. Each director attended at least 75% of the total number of
meetings of the board and the board committees of which he or
she was a member in 2007. While we do not have a formal policy
requiring members of the board to attend the annual meeting, we
encourage all directors to attend. All of the boards
twelve members attended the annual meeting in 2007. The
following table lists the members, primary functions and number
of meetings held for each of the committees:
|
|
|
|
|
|
|
|
|
|
|
Meetings
|
|
Members
|
|
Principal Functions
|
|
in 2007
|
|
|
|
Audit Committee
Frank J. Borelli (Chair)*
Maura C. Breen
Nicholas J. LaHowchic
John O. Parker, Jr.
|
|
Assist the board in its oversight of (i) the
integrity of our financial statements; (ii) our compliance with
securities laws, including financial and disclosure
requirements; (iii) our system of internal controls and the
performance of our internal audit function; and (iv) the
qualifications, independence and performance of our independent
accountants.
|
|
|
7
|
|
* Mr. Borelli has been
determined by the Board, in
its judgment, to be an audit
committee financial expert, as
defined under applicable SEC rules
|
|
Select, retain and oversee our independent accountants.
Review our annual and interim financial statements.
Establish procedures for the receipt and handling of complaints regarding accounting, internal accounting controls or auditing matters.
|
|
|
|
|
|
|
Compensation & Development
Committee
Gary G. Benanav (Chair)
Thomas P. Mac Mahon
Howard L. Waltman
|
|
Review and approve our stated compensation
strategy.
Review annually the performance of our Chief
Executive Officer.
Review and approve compensation, and set performance
criteria for compensation programs, for all of our senior
executives.
Review and make recommendations to the Corporate
Governance Committee regarding compensation of directors.
Approve forms of employment agreements for our
senior executives.
Approve and oversee the administration of our
employee benefit plans and incentive compensation programs.
|
|
|
5
|
|
|
|
|
|
|
|
|
|
|
Compliance Committee
Nicholas J. LaHowchic (Chair)
Woodrow A. Myers, Jr.
Samuel K. Skinner
Seymour Sternberg
|
|
Review and make recommendations to the board addressing our legal and regulatory compliance practices generally (other than SEC and financial reporting matters).
Review our Corporate Code of Conduct at least annually and make recommendations to the board with respect to changes to the Code of Conduct.
Meet regularly with our management to assess our compliance policies and procedures.
Review and approve a Code of Business Conduct and Ethics, and oversee implementation by management of procedures intended to ensure compliance with such Code.
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
Corporate Governance Committee
Howard L. Waltman (Chair)
Frank J. Borelli
John O. Parker, Jr.
Seymour Sternberg
|
|
Establish criteria for membership on our board of
directors and its committees.
Select and nominate candidates for election or
reelection as directors at our annual stockholders
meeting.
Consider stockholder recommendations for and
nominations of candidates for election as directors.
Recommend candidates to fill any vacancies on our
board of directors.
Review and make recommendations to the board
regarding our Corporate Governance Guidelines and the nature and
duties of the committees of the board.
Approve and make adjustments to our policies
regarding compensation of directors.
|
|
|
5
|
|
|
|
|
|
|
|
|
|
|
The Board also formed a special Transaction Committee to
consider matters related to our efforts to acquire Caremark Rx,
Inc. in early 2007. Messrs. Borelli, Mac Mahon and Waltman
served on the Transaction Committee, which is no longer active.
7
Presiding Director. Our corporate governance
guidelines were revised in October 2006 to call for the
selection of a Presiding Director of the board at such times as
the position of chairman of the board is held by a member of
management. The Presiding Director is a non-employee director
selected by the other non-employee directors whose duties
include the following:
|
|
|
|
|
chair all meetings or executive sessions of the non-employee or
independent directors; and
|
|
|
|
review and provide input to the scheduling of, and agendas for,
the board and committee meetings.
|
Mr. Waltman was elected as Presiding Director of our board
in October 2006. A new Presiding Director will be selected
following Mr. Waltmans retirement.
8
DIRECTORS
COMPENSATION
Directors who are employed by our company or its subsidiaries do
not receive compensation for serving as directors. Directors who
are not employees of our company or its subsidiaries are
entitled to receive:
|
|
|
|
|
an annual retainer as follows:
|
|
|
|
|
|
$45,000 for the Audit Committee Chairperson,
|
|
|
|
$40,000 for the Compensation and Development Committee
Chairperson,
|
|
|
|
$35,000 for other Committee Chairpersons, and
|
|
|
|
$30,000 for the other non-employee directors;
|
|
|
|
|
|
a meeting fee of $2,000 for each meeting attended in person; and
|
|
|
|
a meeting fee of $1,000 for each meeting attended telephonically.
|
We also reimburse non-employee directors for out-of-pocket
expenses incurred in connection with attending board and
committee meetings.
Our non-employee directors also receive equity awards under our
2000 Long-Term Incentive Plan, as amended or the 2000
LTIP, as follows:
|
|
|
|
|
an equity grant with a notional value of $115,000 on the date of
the first board meeting each such director attends as a
non-employee director, and
|
|
|
|
annual equity grants with a notional value of $200,000 granted
on the date of each annual meeting of stockholders, with new
directors who have taken office since the previous annual
meeting receiving a pro-rated grant for the partial first year.
|
The equity grants are divided between shares of restricted stock
and stock-settled stock appreciation rights, or
SSARs, as follows:
|
|
|
|
|
One-third of the value of the equity grant in shares of
restricted stock, valued based on the fair market value of our
common stock as of the grant date; and
|
|
|
|
Two-thirds of the value of the equity grant in SSARs, valued
using the method we utilize in valuing the grants for financial
reporting purposes (currently the Black-Scholes valuation model).
|
Historically we have granted non-qualified stock options or
stock options to our non-employee directors instead
of SSARs and we may consider returning to the use of stock
options in the future. All of the SSARs and stock options
granted to the non-employee directors under the 2000 LTIP have
an exercise price of 100% of the fair market value of the shares
on the date they are granted, and a seven-year term. The SSARs
and restricted stock vest ratably over three years, with
accelerated vesting upon the directors retirement,
provided that the directors combined age and years of
service on the Board total at least 75, or upon the failure by
the Company to renominate the director for election.
9
The following table provides information regarding our
compensation of non-employee directors for 2007:
DIRECTOR
COMPENSATION IN 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees Earned or
|
|
|
|
|
|
|
|
|
|
|
|
|
Paid in Cash
|
|
|
Stock Awards
|
|
|
Option Awards
|
|
|
Total
|
|
Name
|
|
($)(1)
|
|
|
($)(2)
|
|
|
($)(3)
|
|
|
($)
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(h)
|
|
|
Gary Benanav(4)
|
|
$
|
68,000
|
|
|
$
|
53,081
|
|
|
$
|
133,084
|
|
|
$
|
254,165
|
|
Frank Borelli(5)
|
|
$
|
84,000
|
|
|
$
|
53,081
|
|
|
$
|
137,577
|
|
|
$
|
274,658
|
|
Maura Breen(6)
|
|
$
|
60,000
|
|
|
$
|
53,081
|
|
|
$
|
138,416
|
|
|
$
|
251,497
|
|
Nicholas LaHowchic(7)
|
|
$
|
70,000
|
|
|
$
|
53,081
|
|
|
$
|
136,054
|
|
|
$
|
259,135
|
|
Thomas P. Mac Mahon(8)
|
|
$
|
61,000
|
|
|
$
|
53,081
|
|
|
$
|
137,577
|
|
|
$
|
251,658
|
|
Woodrow A. Myers(9)
|
|
$
|
34,000
|
|
|
$
|
42,764
|
|
|
$
|
73,118
|
|
|
$
|
149,882
|
|
John O. Parker(10)
|
|
$
|
71,000
|
|
|
$
|
53,081
|
|
|
$
|
136,054
|
|
|
$
|
260,135
|
|
Samuel K. Skinner(11)
|
|
$
|
55,000
|
|
|
$
|
53,081
|
|
|
$
|
139,351
|
|
|
$
|
247,432
|
|
Seymour Sternberg(12)
|
|
$
|
61,000
|
|
|
$
|
53,081
|
|
|
$
|
133,084
|
|
|
$
|
247,165
|
|
Barrett Toan(13)
|
|
$
|
50,000
|
|
|
$
|
53,081
|
|
|
$
|
92,364
|
|
|
$
|
195,445
|
|
Howard Waltman(14)
|
|
$
|
76,000
|
|
|
$
|
53,081
|
|
|
$
|
137,577
|
|
|
$
|
266,658
|
|
|
|
|
(1)
|
|
This column reports the amount of
cash compensation received for 2007 Board and committee service.
|
|
(2)
|
|
Each director received a Restricted
Stock award on May 23, 2007 of 1,352 shares which
vests
331/3%
per year on each of the first three anniversaries of the date of
the grant. Grant date fair value was $66,627. In addition, on
May 23, 2007, in accordance the Companys policy for
new non-employee directors attending their first board meeting,
Mr. Myers also received 778 shares of Restricted
Stock. Grant date fair value was $38,340. Stock awards have been
valued in the same manner as described in footnote 1 to the
Summary Compensation Table on page 24.
|
|
(3)
|
|
Each director received a grant of
8,484 SSARs on May 23, 2007, which vests
331/3%
per year on each of the first three anniversaries of the date of
the grant. Grant date fair value was $132,084. In addition, on
May 23, 2007, in accordance with the Companys policy
for new non-employee directors attending their first board
meeting, Mr. Myers also received 4,878 SSARs. Grant date
fair value was $76,658. SSARs have been valued in the same
manner as described in footnote 2 to the Summary Compensation
Table on page 24.
|
|
(4)
|
|
At year-end, Mr. Benanav held
55,232 vested options, 8,000 unvested options, 2,588 shares
of unvested Restricted Stock, 3,124 vested SSARs and 14,730
unvested SSARs.
|
|
(5)
|
|
At year-end, Mr. Borelli held
224,000 vested options, 8,000 unvested options,
2,588 shares of unvested Restricted Stock, 3,124 vested
SSARs and 14,730 unvested SSARs.
|
|
(6)
|
|
At year-end, Ms. Breen held 0
vested options, 8,000 unvested options, 2,588 shares of
unvested Restricted Stock, 3,124 vested SSARs and 14,730
unvested SSARs.
|
|
(7)
|
|
At year-end, Mr. LaHowchic
held 0 vested options, 8,000 unvested options, 2,588 shares
of unvested Restricted Stock, 3,124 vested SSARs and 14,730
unvested SSARs.
|
|
(8)
|
|
At year-end, Mr. Mac Mahon
held 40,000 vested options, 8,000 unvested options,
2,588 shares of unvested Restricted Stock, 3,124 vested
SSARs and 14,730 unvested SSARs.
|
|
(9)
|
|
At year-end, Mr. Myers held 0
vested options, 0 unvested options, 2,130 shares of
Restricted Stock, 0 vested SSARs and 13,362 unvested SSARs.
|
|
|
|
(10)
|
|
At year-end, Mr. Parker held
16,000 vested options, 8,000 unvested options, 2,588 shares
of unvested Restricted Stock, 3,124 vested SSARs and 14,730
unvested SSARs.
|
|
(11)
|
|
At year-end, Mr. Skinner held
0 vested options, 8,000 unvested options, 2,588 shares of
unvested Restricted Stock, 3,124 vested SSARs and 14,730
unvested SSARs.
|
|
(12)
|
|
At year-end, Mr. Sternberg
held 23,232 vested options, 8,000 unvested options,
2,588 shares of unvested Restricted Stock, 3,124 vested
SSARs and 14,730 unvested SSARs.
|
|
(13)
|
|
At year-end, Mr. Toan held
591,200 vested options, 0 unvested options, 2,588 shares of
unvested Restricted Stock, and 3,124 vested SSARs and 14,730
unvested SSARs.
|
|
(14)
|
|
At year-end, Mr. Waltman held
40,000 vested options, 0 unvested options, 2,588 shares of
unvested Restricted Stock, 3,124 vested SSARs and 14,730
unvested SSARs.
|
Compensation for any director emeritus is established by the
board at the time such director emeritus is elected to serve.
10
CORPORATE
GOVERNANCE
Corporate Governance Guidelines and Committee
Charters. We have adopted Corporate Governance
Guidelines to outline our corporate governance structure and
address significant corporate governance issues. Copies of these
Guidelines as well as the Charters for each of our board
committees can be found on the Corporate Governance page in the
Investor Information section of our website at
www.express-scripts.com (information on our
website does not constitute part of this proxy statement).
Code of Ethics. We have adopted a Code of
Ethics which applies to all of our directors, officers, and
employees including our senior financial officers. A copy of the
Code of Ethics is available in the Investor Information section
of our website at www.express-scripts.com. We will post any
amendments to the Code of Ethics, or any waivers of the Code of
Ethics for any of our directors, executive officers or senior
financial officers, in the same section of our website.
Communicating with the Directors. Stockholders
wishing to communicate with our board of directors or with an
individual board member with respect to our company may do so by
writing to the board or the specific board member, and mailing
the correspondence to: Attention: Corporate Secretary, Express
Scripts Inc., One Express Way, Saint Louis, Missouri 63121. The
outside of the envelope should clearly indicate that it contains
a stockholder communication. Our board of directors has approved
a process pursuant to which the office of the Corporate
Secretary will review and forward the correspondence to the
appropriate person or persons for response, with the exception
of correspondence which is inappropriate or unrelated to the
duties and responsibilities of the board.
Selection of Nominees for the Board of
Directors. The Corporate Governance Committee is
responsible for evaluating potential candidates to serve on our
board of directors, and for selecting nominees to be presented
for election to the board at our annual meeting of stockholders.
In evaluating potential director candidates, the Corporate
Governance Committee considers the skills and characteristics
possessed by each candidate in the context of the perceived
needs of the board at that point in time. Among the factors
considered by the Corporate Governance Committee in considering
a potential nominee are the following:
|
|
|
|
|
the nominees independence;
|
|
|
|
the nominees relevant professional skills and depth of
business experience;
|
|
|
|
the nominees character, judgment, and personal and
professional integrity;
|
|
|
|
the nominees ability to read and understand corporate
financial statements;
|
|
|
|
the nominees willingness to commit sufficient time to
attend to his or her duties and responsibilities as a member of
the board;
|
|
|
|
the nominees qualifications for membership on certain
committees of the board;
|
|
|
|
any potential conflicts of interest involving the
nominee; and
|
|
|
|
the make up and diversity of our existing board.
|
In identifying potential candidates for the board, the Corporate
Governance Committee relies on recommendations from a number of
possible sources, including current directors and officers. The
Corporate Governance Committee may also retain outside
consultants or search firms to help in identifying potential
candidates for membership on the board. In the past, the
Corporate Governance Committee has engaged the firm of Spencer
Stuart to assist with director searches. The Corporate
Governance Committee will also consider candidates recommended
by stockholders on the same basis as other candidates.
Any stockholder wishing to recommend a candidate for
consideration by the Corporate Governance Committee to become a
nominee for election to the board may do so by submitting a
written recommendation to the committee in accordance with our
procedures for the submission of Stockholder
Proposals, as set out in our
11
Bylaws (see Stockholder Proposals beginning on
page 51). For a nominee to be considered, the following
information must be submitted in accordance with the required
procedures:
|
|
|
|
|
the name, age, business and residence addresses, principal
occupation or employment of both the nominee and the
recommending stockholder;
|
|
|
|
the nominees general biographical information, including
the identification of any other boards on which the nominee
serves;
|
|
|
|
with respect to our common stock, the current ownership
information and trading history over the preceding
24 months for both the nominee and the recommending
stockholder;
|
|
|
|
a description of any transactions or relationships between the
nominee
and/or the
recommending stockholder on one hand, and our company or our
management on the other hand;
|
|
|
|
a description of any material proceedings to which the nominee
or the recommending stockholder, or either of their associates
or affiliates, is a party that are adverse to our company;
|
|
|
|
a description of all arrangements and understandings between the
stockholder and the nominee or any other person (including their
names) pursuant to which the nomination is made; and
|
|
|
|
any other information relating to the nominee or the
recommending stockholder that is required to be disclosed in
solicitations for proxies for election of directors pursuant to
Section 14 of the Securities Exchange Act of 1934, as
amended, and the rules and regulations thereunder.
|
The request for nomination must also be accompanied by a written
consent of the proposed nominee to being named as a nominee and
to serve as a director if elected. Our Corporate Secretary will
review all such stockholder recommendations, and will forward
those that comply with the above-described requirements to the
Corporate Governance Committee for evaluation and consideration.
12
EXECUTIVE
COMPENSATION
Overview
The Compensation Discussion and Analysis provides a narrative
commentary on the companys compensation policies, programs
and practices for our Chief Executive Officer, Chief Financial
Officer and other members of our executive management team.
Throughout this Proxy Statement we will refer to our Chief
Executive Officer, Chief Financial Officer and the three other
officers named in the Summary Compensation Table on
page 24 as the named executives or the
named executive officers.
The broad topics discussed in this analysis include:
|
|
|
|
|
our compensation philosophy and objectives
alignment, pay for performance and retention;
|
|
|
|
how we implement our compensation objectives, including the role
of the Compensation and Development Committee (the
Committee), management and the Committees
compensation consultant;
|
|
|
|
our primary compensation vehicles, including base salary, the
annual cash bonus and long-term equity awards; and
|
|
|
|
compensation decisions for 2007.
|
Compensation
Philosophy and Objectives
Aligning Compensation with Stockholder
Interests. The primary goal of our compensation
structure is to align the interests of our executives with our
stockholders through compensation vehicles which reward the
achievement of established intermediate and long-term goals with
the ultimate objective of increasing long-term stockholder
value. The elements utilized to help achieve this goal of
alignment include the following:
|
|
|
|
|
grants of time-vested non-qualified stock options (stock
options) or stock settled stock appreciation rights
(SSARs) and time-vested restricted stock awards
under the Express Scripts, Inc. 2000 Long Term Incentive Plan
(the 2000 LTIP);
|
|
|
|
grants of performance shares (the Performance
Shares) which are intended to focus the executives on
actions which are likely to enhance stockholder return, growth
in earnings per share and return on invested capital;
|
|
|
|
executive stock ownership guidelines under which executives are
expected to maintain significant holdings of Express Scripts
Stock; and
|
|
|
|
an annual cash incentive bonus plan (the Annual Bonus
Plan) the funding and calculation of which is dependent
upon the achievement of certain key, financial measures which
are drivers of stockholder value.
|
Rewarding Annual and Long-Term
Performance. Our compensation structure is also
intended to reward the achievement of certain annual and
long-term performance objectives by the individual executives,
the Companys business units, and the Company overall. This
objective, in many ways, overlaps the alignment objective and is
achieved through the same compensation vehicles. The elements
intended to reward annual
and/or
long-term performance include the following:
|
|
|
|
|
the Annual Bonus Plan, which is designed to focus the executives
on individual, business unit
and/or
company-wide annual workplan goals, and which requires the
achievement of certain key financial goals for funding;
|
|
|
|
the Performance Share grants which are contingent upon our
performance against a peer group of companies in certain key
financial metrics over a three-year period; and
|
|
|
|
the grants of stock options or SSARs and restricted stock
grants, the value of which is dependent upon growth of the
Companys stock price over a period of several years.
|
13
Attracting and Retaining Talented
Executives. In a constantly growing and changing
business, it is vital that we be able to continually attract and
retain superior employees in key executive positions. The key
compensation elements aimed at attracting and retaining
executives include the following:
|
|
|
|
|
a compensation package consisting of base salary, potential
Annual Bonus Plan awards, and equity grants, which is, both as a
whole and by component, competitive with that offered by a peer
group of companies;
|
|
|
|
equity awards which vest over time and thus encourage retention;
|
|
|
|
employment agreements with our key executives containing
severance and change in control provisions; and
|
|
|
|
an Executive Deferred Compensation Plan (the EDCP)
which provides a tax-advantaged method for executives to save
for their retirement and under which we have historically made
cash awards that do not vest for three years (subject to
acceleration upon eligibility for retirement, as described
below).
|
Implementing
our Compensation Objectives
Compensation Committee Members and the Compensation Committee
Charter. The Committee is responsible for
establishing, overseeing and reviewing executive compensation
policies and for approving, validating and benchmarking the
compensation and benefits for named executive officers. The
Committee includes three independent Directors Gary
G. Benanav (Chair), Thomas P. Mac Mahon and Howard L. Waltman.
Each of these Directors satisfies the independence requirements
of the Nasdaq Stock Market. A Charter for the Compensation
Committee was adopted in November 2000 and amended in December
2002. A copy of the Charter can be found on the Corporate
Governance page in the Investor Information section of the
website at www.express-scripts.com.
The Committees principal functions under the Charter
include:
|
|
|
|
|
Review and approve the Companys compensation strategy.
|
|
|
|
Annually review the performance of the Chief Executive Officer.
|
|
|
|
Review and approve compensation for all senior executives.
|
|
|
|
Set performance criteria for senior executive compensation
programs.
|
|
|
|
Review and make recommendations to the Corporate Governance
Committee regarding Director compensation.
|
|
|
|
Approve employment agreements with our senior executives.
|
|
|
|
Approve and oversee the administration of the employee benefit
plans and incentive compensation programs.
|
The Charter is reviewed at least annually by both the Committee
and the Corporate Governance Committee of the Board. The
Committee is scheduled to meet four times per year to consider
compensation activities applicable to senior executives and
other matters. Additional meetings may be scheduled as required
by the Committee.
Role of Management in Establishing
Compensation. At the direction of the Chair of
the Committee, management generally prepares the meeting
materials for the Committee in advance of its meetings. The
compensation consultant retained by the Committee may also
prepare materials depending on the topics to be covered. In the
meetings, the Committee will consider for approval compensation
changes for senior executives and equity grants for newly hired
or promoted senior executives. Management may also ask that
additional issues involving compensation policies or design be
considered. During the annual evaluation process, the Chief
Executive Officer is given the opportunity to evaluate senior
executives for purposes of annual merit increases, annual
incentive payments and long term equity grants. The Committee
makes all compensation decisions for the named executives and
other members of our senior management team. However, the Chief
Executive Officer and certain other members of management may
also provide recommendations to the Committee on these matters.
Management may be asked to assist in conducting the meetings and
to provide applicable data, information and other resources. The
Committees independent compensation consultant also
participates as requested by the
14
Committee. As part of their regular meetings, Committee members
generally meet in executive session during which members of
management are not present.
In consultation with the Committee, management establishes
compensation parameters below the senior executive level which
generally reflect the compensation philosophy and direction
established by the Committee in setting compensation for senior
management.
Role of the Compensation Consultant. The
Committee has traditionally engaged a nationally recognized
consulting firm to review alternatives and to provide advice
regarding appropriate compensation levels for the senior
executive officers (the Compensation Consultant). As
requested, the Compensation Consultant also provides data and
analysis to support its recommendations and advice. The current
Compensation Consultant, Watson Wyatt Worldwide, was selected in
2005 following a detailed RFP process managed by the Committee.
The Committee considered several national consulting firms and,
following interviews and evaluation by the Committee, Watson
Wyatt Worldwide was retained. The Committee is solely
responsible for commissioning the work of the Compensation
Consultant. The Compensation Consultant is independent of
management and does no other executive compensation work for the
company, although the Compensation Consultant has provided
salary survey information to management other than for senior
executives. In February 2008 the Committee adopted a policy
requiring the approval of the Committee Chair, or, at the
Chairs discretion, the entire Committee, before the
Compensation Consultant can be utilized to perform any other
services for the Company other than those required under its
engagement by Committee. The Committee has authority to hire and
dismiss the Compensation Consultant and budgetary authority to
establish engagements with the consultant. Management is copied
on the work by the Compensation Consultant and discusses work in
progress at the discretion of the Committee. The bills for
consulting work go first to the Committee and then to the
Company for payment. As requested, a representative of the
Compensation Consultant may attend the meetings of the Committee
in person or by telephone.
The role of the Compensation Consultant is to provide
independent, expert advice to the Committee on the design and
level of compensation paid to our senior executives. The
Compensation Consultant compares the compensation elements for
the senior executive officers, including the Chief Executive
Officer, with the compensation received by executives in
comparable positions at a peer group of companies. The Committee
considers these peer group pay levels as one of the factors
utilized in arriving at its final compensation decisions. It is
the Committees current intention to conduct a benchmark
study annually to assure that the senior executives are
compensated appropriately from a competitive and design
perspective. Following its analysis, the Compensation Consultant
makes recommendations for consideration by the Committee. In
2005 the Compensation Consultant conducted a review of the
long-term incentive compensation and recommended changes in the
program design that were approved by the Committee and are
reflected in the Components of Executive Compensation section
that follows.
Management does not currently engage a separate executive
compensation consultant.
Benchmarking of Executive Compensation
Programs. Our compensation approach is to combine
base pay, annual incentive pay, and long-term incentive awards
to create a total package that is, in general, approximately at
the median compensation level for executive officers of a peer
group of companies if financial and non-financial objectives are
achieved, and that can be at or above the 75th percentile
of such compensation level if stretch financial and
non-financial goals are achieved.
Analysis by the Compensation Consultant identified a group of
13 companies judged to be comparable to the company (the
Peer Group Companies) based on their revenue and
market capitalization, industry, similarity to the Company and
complexity. In 2007 one of the prior Peer Group Companies
(Caremark Rx, Inc.) was acquired resulting in a reevaluation of
the mix of companies chosen for the peer group. As a result of
such reevaluation, three new companies were added to the peer
group CVS/Caremark Corporation, Becton, Dickinson
and Company,
15
and Cigna Corporation. This change was also applied to previous
grants of performance shares which included Caremark Rx, Inc.
within the peer group. The Peer Group Companies are:
|
|
|
AmerisourceBergen Corp.
|
|
Humana, Inc.
|
Becton, Dickinson and Company
|
|
Laboratory Corporation of America Holdings
|
Cigna Corporation
|
|
Medco Health Solutions, Inc
|
Coventry Health Care, Inc.
|
|
Omnicare, Inc.
|
CVS/Caremark Corporation
|
|
Patterson Companies Inc.
|
Health Net, Inc.
|
|
Quest Diagnostics, Inc.
|
Henry Schein, Inc.
|
|
|
The Peer Group Companies recommended by the Compensation
Consultant and approved by the Committee include companies which
are different from those in the peer group index in the Stock
Performance Graph included in the Companys annual report
to stockholders. All of the Peer Group Companies are public
companies in the health care industry. The Committee expects it
will be necessary, as a result of mergers, acquisitions and
other changes, to update the list of Peer Group Companies
periodically in order to maintain a sufficient number of
companies for pay comparisons.
The Committee annually reviews and assesses the compensation
levels provided by the Compensation Consultant for executive
officers at the Peer Group Companies, and also evaluates the
financial and market performance of the Peer Group Companies in
making compensation decisions. In addition, the Committee also
reviews public compensation information available through SEC
filings and published survey information provided by various
consulting firms. This review constitutes one of the factors the
Committee uses in determining the appropriate pay levels for the
senior executives. The review involves compensation received by
executives in comparable positions and looks at the various
elements of the compensation package and how these elements
support corporate objectives.
Components
of Executive Compensation
The Committee has structured an executive compensation program
comprised of three primary components: base pay, annual
incentive pay, and long-term incentive pay. Segmenting and
stratifying the elements of executive compensation helps focus
compensation resources where they are expected to be most
effective. In developing the mix of components, the Committee
has sought to balance the need for fixed compensation provided
in base pay with variable compensation provided in the annual
and long-term incentive plans.
Base Pay. Adequate and competitive base pay
allows for the recruitment of high caliber executives and helps
to reduce turnover. The Committee uses base pay at the Peer
Group Companies as a reference point for equivalent or similar
positions with the Company. The Committee determines the salary
for each of the executive officers by considering the value and
performance of the executive, recommendations by management (for
executives other than the Chief Executive Officer) and the
Compensation Consultant, the level and scope of responsibilities
of the position, and the pay levels of similarly positioned
executive officers in the Peer Group Companies. Competitive pay
levels are represented in median pay for the positions at the
Peer Group Companies and other sources as well as recommended
pay range alternatives provided by the Compensation Consultant.
At the senior executive level, results applicable to the
business unit or functional division headed by the executive are
also factored into decisions related to changes in the base pay
of the executive.
Salary levels are typically reviewed annually as part of our
performance review process or upon a promotion or significant
change in an executives responsibilities. Salary increases
are based on both individual performance and changes in our
overall budget for compensation. Changes in salary for the named
executives and other members of senior management are approved
by the Committee and annual changes are generally effective each
year as of April 1.
Annual Incentive Bonus Pay. The Annual Bonus
Plan provides the Company with a powerful tool to assist in
focusing the executive on accomplishing current operational and
financial objectives over a one-year period. Each executive has
a bonus target which is stated as a percentage of his or her
annual base salary. The targets are set by the
16
Committee taking into consideration the annual incentive pay
levels existing at the Peer Group Companies for similar
positions and other factors. Payouts under the annual incentive
program are determined as follows:
|
|
|
|
|
Each year during the fourth quarter, the Board of Directors
meets and approves a Company-wide budget for the next calendar
year which includes budgeted targets for earnings per share
(EPS) and earnings before interest, taxes,
depreciation and amortization (EBITDA). The
Committee also meets during the fourth quarter at which time it
establishes the EPS and EBITDA targets for the Annual Bonus Plan
based on the budgeted numbers, as well as separate EBITDA
targets for our various operating groups. For the 2007
performance year, the Committee also approved certain key
non-financial corporate goals to be considered in determining
the actual payouts under the Annual Bonus Plan.
|
|
|
|
Funding of the bonus pool is first dependent on achievement of
the EPS target. If the EPS target is achieved or exceeded, then
funding of the bonus pool is initially set at 100%. If the EPS
target is not achieved then an adjusted bonus pool may be
submitted to the Committee for approval.
|
|
|
|
Assuming the EPS target is achieved or exceeded, funding above
or below the 100% funding level is governed by the
Companys performance against the EBITDA target. If the
EBITDA target is exceeded, then 50% of incremental EBITDA is
used to supplement the bonus pool up to a maximum of 200%. If
the EBITDA target is not met, the pool is reduced by 50% of the
EBITDA shortfall until the EBITDA target is achieved.
|
|
|
|
The bonus pool remaining after any required adjustment is
further adjusted by operating group (pharmacy benefit
management, specialty and ancillary services, and Canadian
operations) to reflect the attainment of each such groups
individual EBITDA goals.
|
|
|
|
Actual bonus awards for executive officers are determined based
on the following factors:
|
|
|
|
|
|
the appropriate operating groups bonus pool funding
factor, which can range from 0% to 200% based on financial
results for the operating group and the Company as a
whole; and
|
|
|
|
the executive officers respective bonus targets, which
range from 60% to 130% of base salary. Each individuals
award can be adjusted from 0% to 150% of target based on
performance against individual goals as determined through an
evaluation by the Committee (and, in the case of senior
executives, also by the Chief Executive Officer) of the extent
to which non-financial goals were achieved.
|
|
|
|
|
|
Once all of the factors have been determined, each
executives individual award (between 0% and 150% of
target) is multiplied by the percentage factor for the Company
target, or the relevant operating group (in either case between
0% and 200%) with a maximum of payout of 200% of target for the
chief executive officer and 250% of target for the other
executive officers.
|
In 2006, the 2000 LTIP was amended to permit cash awards to be
granted under the plan. This permits the Company to enhance the
tax deductibility of Annual Bonus Plan awards made to the named
executive officers (see Deductibility of Compensation on
page 22). Annual bonus awards for 2007 made under the 2000
LTIP have a maximum achievable level (i.e. 250% of target for
named executive officers and 200% of target for the CEO), are
conditioned upon the achievement of a minimum EPS target, and
are subject to the downward discretion of the Committee.
Long-Term Incentive Awards. The Committee
believes that our long-term compensation program should orient
and align senior executives with the interests of stockholders
and focus the executives efforts on our long-term success.
The long-term incentive awards are designed to retain executives
and motivate them toward results that exceed those of the Peer
Group Companies. The long-term compensation program consists of
grants of stock options, restricted stock and performance shares
(in some previous years the Company has granted SSARs in lieu of
stock options). These equity grants increase in value if the
market value of the stock appreciates over time. For that
reason, the executives are motivated to engage in behaviors that
will increase the long-term value of the stock and thereby
benefit all stockholders.
Each executive officer receives an equity grant upon employment
(or upon promotion to senior executive status) and, in the past,
typically has received an additional annual equity grant each
succeeding year. The
17
Committee believes that providing equity compensation
opportunities provides a clear and powerful motivation to the
executive team to achieve financial and operational objectives
that will, over time, increase the market price of the stock.
Several of the senior executives have also received special
grants of non-qualified stock options, SSARs
and/or
restricted stock in connection with their entering into
employment agreements. The purpose of these grants for
newly-hired executives is to provide incentive for high
potential individuals to join the company
and/or to
compensate them for compensation they may have forfeited when
leaving their prior employer.
In connection with the 2005 executive compensation study, the
Committee revised its approach with respect to long term
incentive compensation. Factors involved in determining the
appropriate equity vehicles to use included consideration of the
prevalence of equity grants in the Peer Group Companies and
general industry, the desired equity mix, rewarding share price
improvement, retention, and relative stock and financial
performance. Starting in 2006, the Committee implemented a
long-term compensation program under which senior executives
receive annual grants of long-term equity compensation divided
among three different types of equity grants. The annual awards
are approved by the Committee based on the dollar value of the
entire equity package, which is allocated among the forms of
equity as follows:
|
|
|
|
|
50% of the equity package is awarded in the form of time-vested
stock options. The stock options have an exercise price equal to
the fair market value of the stock on the grant date. They vest
in three equal annual installments and expire seven years from
the date of grant. Stock options only provide compensation value
if the stock price increases after they are granted. The actual
number of stock options awarded is determined by applying the
method utilized by the Company to value the stock options for
financial reporting purposes (currently the Black-Scholes
valuation model).
|
|
|
|
25% of the equity package is awarded in the form of time-vested
restricted stock which vests in three equal, annual
installments. The Committee believes that grants of restricted
stock closely align the executive with the position of
stockholders because restricted stock represents equity value
regardless of whether the price of the stock falls below its
value at the date of grant. The actual number of shares of
restricted stock granted is determined based on the fair market
value of the stock on the date of grant.
|
|
|
|
The final 25% of the equity package is awarded in the form of
performance share awards, which are settled in shares of the
stock on a share-for-share basis, with the actual number of
shares of stock to be delivered upon settlement of the
performance shares based upon the Companys performance
over a specified period versus the Peer Group Companies selected
by the Committee. One of the peer group companies, Medco Health
Solutions, Inc., is weighted more heavily than the others in the
peer group because the Committee has determined that it
represents a more direct business competitor. Given the
acquisition of Caremark Rx, Inc. (which had also been a more
heavily-weighted company) by CVS Corporation, the Committee
decided to replace it in the peer group with three new
companies. The period for measurement of the performance shares
is three years commencing as of January 1 of the year during
which they are granted. The number of shares of the stock
ultimately delivered is determined based on performance against
the Peer Group Companies in three performance categories: total
stockholder return, three-year compound annual growth in
earnings per share, and three-year average return on invested
capital. Assuming the Companys performance for the
performance period is at the 40th percentile, the actual
shares of stock issued will equal 35% of the award targeted for
the participating executive; at the 50th percentile, the
actual shares of stock issued will equal 100% of the award
targeted for the executive; and at the 80th percentile, the
actual shares of common stock issued will equal 250% of the
targeted award which is the maximum number of shares that can be
awarded. If the performance falls between these percentile
rankings, the actual shares of stock issued will be determined
by interpolation. Realization of the performance share awards
and their actual value, if any, will depend on the applicable
targets being met and the market value of the stock on the date
the performance share awards are settled. The actual target
number of performance shares granted is determined based on the
fair market value of the stock on the date of grant.
|
The Committee grants all three types of awards in order to meet
several objectives. The Committee believes that measuring
performance against the Companys competitors with respect
to important financial metrics adds a significant dimension to
the long-term program design. By including performance shares,
the program provides motivation both to achieve results that
will be positively responded to in the marketplace and to
produce results that
18
will exceed equivalent measures among the competitors. The
weighting of the equity components that comprise the long-term
plan package is subject to change based on the Committees
evaluation and discretion.
In February 2008, the Committee concluded that it was
appropriate to bring the chief executive officers total
direct compensation (base pay, annual incentive bonus pay and
long term incentives) up to or near the 50th percentile
among the Peer Group Companies. However, in keeping with the
Companys increased emphasis on pay-for-performance, the
Committee concluded that a larger portion of the chief executive
officers long term incentive grant (35%) should be
represented by performance shares, as compared to the 25% for
the Companys other executive officers. As a result,
Mr. Pazs 2008 long term incentive awards were
allocated as follows: 40% stock options, 25% restricted stock,
and 35% performance shares.
The Committee has discretion to determine the vesting schedule
for each time-based equity grant and generally makes grants that
become exercisable in equal amounts over three years. Except in
the cases of retirement, disability or death, in general,
executives must be employed by the company at the scheduled
vesting time for their equity awards in order for such vesting
to occur.
The Committee has historically made annual equity grants
(including stock options and SSARs) during the first calendar
quarter, following the finalization of our year-end financial
results. By making grants at this time the Committee is able to
consider the previous year financial performance in determining
the size and structure of such grants, both in the aggregate and
with respect to individual executives. Additionally, by making
the awards during the first quarter, such grants are coordinated
with the annual bonus awards and annual salary adjustments.
The size of an executives equity compensation award is
based upon the evaluation by the Committee and, for executives
other than the Chief Executive Officer, regarding the
contribution that the executive officer is expected to make to
the overall growth and profitability during the vesting period.
The Committee also considers long-term incentive compensation
levels at the Peer Group Companies. While the Company maintains
stock ownership guidelines, the Committee does not take into
account existing stock ownership levels of individual executives
in determining the amount of equity awards.
If a business transaction occurs that would change the basis for
determining the results for incentive compensation payments, the
Committee may adjust the metrics to reflect the new business
circumstances in a manner that provides equivalent opportunity
and results requirements. The Committee may also make similar
adjustments to account for changes in accounting principles or
practices, changes in the number of shares outstanding, and
similar changes, and may determine whether adjustments should be
made for one-time or extraordinary items, prior period
adjustments, discontinued operations and similar items. Such
adjustments could occur for the metrics in the Annual Bonus Plan
or the performance share portion of the equity grants.
Perquisites. In accordance with the
compensation philosophy to pay for results, no perquisites are
provided to the senior executive officers that we would be
required to report under the rules applicable to this Proxy
Statement. In fact, the only perquisite available to the named
executives is a Company-paid comprehensive physical examination
and wellness recommendations at a nationally recognized medical
facility. These examinations are available to our senior
executives every two years before age 50 and annually
thereafter. The estimated value of this program is about $5,000
per examination.
Deferred Compensation. The Company provides an
opportunity for executives to participate in the EDCP, a
deferred compensation program that is intended to comply with
the rules provided under section 409A of the Internal
Revenue Code. Under the EDCP participating executives can elect
to defer up to 50% of their annual base pay and up to 100% of
their annual bonus. In addition, we have historically made
contributions to each executives account under the EDCP
equal to 6% of the executives annual cash compensation,
with the contributions subject to a cliff vesting at the end of
the third calendar year following the year for which they are
awarded. At such time as an executive becomes eligible for
retirement under the EDCP (which occurs upon reaching a minimum
of age 55 and having a combined age plus years of service
with the Company of 65), all contributions made to such
executives account under the EDCP immediately become
vested. Other than the 6% annual cash contribution to the EDCP
and the opportunity to participate in the ESI qualified 401(k)
plan, the Company provides no retirement benefit to its
executives.
19
Deferred compensation gives executives a tax favored method of
accumulating assets for current or retirement living expenses.
The three-year vesting schedule that applies to the Company
contributions is intended to serve as a retention device for the
executives. Amounts contributed to the EDCP by either the
participant or the Company are assumed to have been invested in
one or more of a number of publicly available mutual funds and a
Company Common Stock Fund. The plan is not formally funded and
the returns that are paid on the participants accounts are
equal to the gain or loss on the hypothetical market
investments. As a result, the Committee believes that the
Company has not promised to pay above-market returns on any
participants account under the EDCP.
2007
Compensation Decisions
Base Pay. During 2005, the Committee evaluated
how we were paying our executive officers in comparison to the
Peer Group Companies and determined, based upon the
recommendation of the compensation consultant, that they were
generally paid below the market median. As a result, in 2006,
the Committee decided to increase the pay of the named executive
officers, including the Chief Executive officer, to better align
them with the pay for comparable jobs at the Peer Group
Companies and as disclosed in various compensation surveys. The
Committee determined that these salary adjustments should be
implemented over two years, with the initial market-based
increase put in place in 2006. The adjustments effective
April 1, 2007, as set out in the chart below, reflect the
second portion of the market-based increase as well standard
merit adjustments resulting from our annual review process and
an assessment of each individuals performance.
In addition, during 2007 the Company reorganized certain
internal operations resulting in the assumption of additional
duties by certain members of our senior management team,
including Mr. Boudreau and Mr. Ignaczak. In May 2007,
the Committee determined that these additional duties warranted
certain compensation adjustments (effective as of May 21,
2007) which are also reflected in the chart below.
2007
Salary Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective Date
|
|
Base Salary
|
|
Increase %
|
|
George Paz
|
|
|
January 1, 2006
|
|
|
$
|
780,000
|
|
|
|
|
|
|
|
|
April 1, 2007
|
|
|
$
|
920,000
|
|
|
|
17.95
|
%
|
David Lowenberg
|
|
|
January 1, 2006
|
|
|
$
|
482,000
|
|
|
|
|
|
|
|
|
April 1, 2007
|
|
|
$
|
496,000
|
|
|
|
2.90
|
%
|
Edward Stiften
|
|
|
January 1, 2006
|
|
|
$
|
409,000
|
|
|
|
|
|
|
|
|
April 1, 2007
|
|
|
$
|
445,000
|
|
|
|
8.80
|
%
|
Thomas Boudreau
|
|
|
January 1, 2006
|
|
|
$
|
411,000
|
|
|
|
|
|
|
|
|
April 1, 2007
|
|
|
$
|
440,000
|
|
|
|
7.06
|
%
|
|
|
|
May 21, 2007
|
|
|
$
|
465,000
|
|
|
|
5.68
|
%
|
Edward Ignaczak
|
|
|
July 1, 2006
|
|
|
$
|
294,800
|
|
|
|
|
|
|
|
|
April 1, 2007
|
|
|
$
|
311,000
|
|
|
|
5.50
|
%
|
|
|
|
May 21, 2007
|
|
|
$
|
350,000
|
|
|
|
12.54
|
%
|
Annual Incentive Bonus Program. As described
above, each named executive officers bonus target under
the Annual Bonus Plan for 2007 was determined based on a
percentage of his base salary, and the bonus potential for each
of the named executive officers for 2007 ranged from 0% to 250%
of such target (other than for Mr. Paz for whom the range
was 0% to 200% of target). Generally, the bonus payouts for
performance below the threshold performance level, at the
threshold performance level, and at the target performance level
for 2007 would have been 0%, 25% and 100% respectively, and the
maximum payout for the achievement of stretch
performance goals
20
would have been 250% of the target payout (200% of the target
payout for Mr. Paz). For the 2007 performance period, the
various bonus targets and payouts for the named executive
officers (paid in March 2008) were as follows:
2007
Incentive Bonus Payouts
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Target
|
|
|
Payout
|
|
|
|
|
|
|
|
|
|
|
Actual
|
|
|
|
Payout as
|
|
|
Range as
|
|
Target
|
|
|
Maximum
|
|
|
Actual
|
|
|
Award as
|
|
|
|
a % of
|
|
|
a % of
|
|
Bonus
|
|
|
Bonus
|
|
|
Bonus
|
|
|
a % of
|
|
Name
|
|
Salary
|
|
|
Target
|
|
Award ($)(a)
|
|
|
Award ($)
|
|
|
Award ($)
|
|
|
Target
|
|
|
G. Paz
|
|
|
120
|
%
|
|
0%-200%
|
|
$
|
1,062,000
|
|
|
$
|
2,124,000
|
|
|
$
|
2,124,000
|
|
|
|
200
|
%
|
D. Lowenberg
|
|
|
75
|
%
|
|
0%-250%
|
|
$
|
369,375
|
|
|
$
|
923,438
|
|
|
$
|
0
|
|
|
|
0
|
%
|
E. Stiften
|
|
|
80
|
%
|
|
0%-250%
|
|
$
|
348,800
|
|
|
$
|
872,000
|
|
|
$
|
697,600
|
|
|
|
200
|
%
|
T. Boudreau
|
|
|
70
|
%
|
|
0%-250%
|
|
$
|
313,075
|
|
|
$
|
782,688
|
|
|
$
|
626,150
|
|
|
|
200
|
%
|
E. Ignaczak
|
|
|
69
|
%(b)
|
|
0%-250%
|
|
$
|
228,445
|
|
|
$
|
571,113
|
|
|
$
|
456,890
|
|
|
|
200
|
%
|
|
|
|
(a)
|
|
In determining the target bonus
award each executives target bonus percentage is applied
to his base salary, with the effect of any salary adjustments
during the year pro-rated for the portion of the year during
which they were in effect.
|
|
(b)
|
|
Mr. Ignaczaks target
bonus percentage as of January 1, 2007 was 60% of his base
salary, and was increased to 75% as of May 21, 2007. This
change was pro-rated over the portion of the year during which
it was in place, resulting in a target bonus payout of
approximately 69% for the full year.
|
The payouts under the Annual Bonus Plan for 2007 were based on
our actual EPS of $2.15 versus a budgeted EPS of $1.98, and
actual EBITDA of $1,115.7 million against a budgeted EBITDA
of $1,045.5 million.
2007 Long Term Incentive Awards. Specific 2007
long term incentive awards to the named executive officers are
contained in the table under the caption Grants of Plan
Based Awards Table on page 26. The awards include
regular awards, granted in February 2007, along with special
grants of performance shares and restricted stock made in May
2007. These special grants were authorized by the Committee to
make up for an error in calculating the peer group benchmarking
data for use in determining the annual grants.
Other
Compensation Related Matters
Additional Benefits. Except as specifically
described in this Compensation Discussion and Analysis, the
executive officers participate in employee benefit plans
generally available to all employees on the same terms as
similarly situated employees, including our 401(k) plan and
health and welfare plans. The Company provides equivalent health
insurance to all of our employees, and the employee paid
portions of the premiums on such insurance are tiered such that
more highly compensated employees pay higher premiums in order
to subsidize the premiums for lower paid employees. As a result,
the employee contributions paid by our executives are more than
300% higher than those paid by our lower paid employees.
All of the executives have offices that are no larger than those
of the regular offices in our headquarters building and reserved
parking is not provided for employees at any level. No financial
counseling programs are provided and the Company does not permit
personal use of corporate aircraft without express prior
approval of the Committee, which approval has never been sought
nor granted.
Employment Agreements. We have entered into
employment agreements with our CEO and each of our Executive
Vice Presidents, which also contain severance and change in
control provisions. The Committee believes these agreements are
appropriate for a number of reasons including the following:
|
|
|
|
|
the agreements assist in attracting and retaining executives as
we compete for talented employees in a marketplace where such
agreements are commonly offered;
|
|
|
|
the severance provisions require terminated executives to
execute a release in order to receive severance benefits and
such benefits are conditioned upon compliance with various terms
of the agreement including those related to non-competition,
non-solicitation and non-disparagement; and
|
|
|
|
the change in control and severance provisions help retain key
personnel during rumored or actual acquisitions or similar
corporate changes.
|
21
These agreements do not materially affect the Committees
annual compensation determinations, as they only restrict its
ability to reduce base salary. All of the employment agreements
with the exception of the agreement with Mr. Paz were
re-executed in 2006 in order to make them consistent among the
executive officers. Mr. Paz executed a new employment
agreement effective April 1, 2008, which replaced an
agreement entered into in April 2005. Additional information
about the severance and change in control provisions of the
agreements can be found under the caption Employment
Agreement and Potential Payments Upon Termination or Change in
Control on page 30.
Deductibility of Compensation. The goal for
the deductibility of compensation is to comply with the
requirements of Section 162(m) of the Internal Revenue Code
of 1986, as amended, to the extent deemed practicable or
appropriate by the Committee. Section 162(m) places a limit
of $1 million on the amount of compensation that a
publicly-traded company may deduct in any one year for any of
its named executive officers. This limitation does
not apply to performance-based compensation meeting certain
requirements (including the requirement that such compensation
be paid under a stockholder approved plan). For 2007 the grants
of SSARs and performance shares were designed to satisfy the
deductibility requirements of Section 162(m).
As discussed above, in 2006, the stockholders approved
amendments to the 2000 LTIP which, among other things, provided
for the annual bonus awards to be awarded and paid under the
plan, thus satisfying the requirement under Section 162(m)
that performance based compensation be paid pursuant to a
stockholder approved plan. Accordingly, the Committee intends
for these awards under the annual incentive program to be
deductible in 2008 and future years.
Stock Ownership Guidelines. In 2001, the
Committee established guidelines for stock ownership among its
executive group. The purpose of the guidelines is to have each
executive assert his or her commitment to the company and to the
stockholders by holding a prescribed number of full value shares
or restricted stock. While restricted stock, performance shares
and phantom stock equivalents under the EDCP are included in
determining compliance with these thresholds, stock options and
SSARs, whether vested or unvested are not included. Even though
these guidelines are not mandatory, each executives status
with respect to stock ownership is annually reviewed and
communicated. Each executive has five years from the time of
becoming an executive officer to attain the recommended
ownership level. The guidelines require each individual to hold
a number of eligible shares with a value at least equal to a
multiple of his or her base annual salary as follows: 4.0x for
the Chief Executive Office, 3.5x for the Chief Operating
Officer, 3.0x for all Executive Vice Presidents, 2.5x for all
Senior Vice Presidents, and 1.5x for all Vice Presidents. In
2007 the Committee increased the ownership requirements for
Senior Vice Presidents from 2x to 2.5x.
As of December 31, 2007, each of the Named Executive
Officers has met his stock ownership requirements through
holdings of shares of the stock, including restricted stock,
performance shares or share equivalents beneficially owned under
the deferred compensation plan.
Option Granting Policy. Effective in November
2006, the Committee adopted a Policy for Grant Approvals and for
Establishing Grant Date for Equity Grants. Under this policy:
|
|
|
|
|
annual awards of equity will be approved by the Committee during
the first quarter of each fiscal year, or at a special meeting,
normally in advance of the annual earnings release, with an
effective grant date as of the third trading date following the
date of the earnings release;
|
|
|
|
special awards for new hires, retention, promotional and special
recognition may be granted during an open window
trading period or, if the Chief Executive Officer or the
Committee acts outside of such a period, with an effective date
as of the third trading date following the next succeeding
annual earnings release (the Chief Executive Officer may only
approve grants to employees below the level of Vice President);
|
|
|
|
the exercise price of stock options and stock appreciation
rights will be not less than the closing trading price of the
stock on the grant date; and
|
|
|
|
equity grants with a prospective grant date will be made on a
nominal value basis consistent with the method the Company uses
to value options for financial reporting purposes under
FAS 123R.
|
22
Derivatives Trading. Because a primary goal of
equity-based incentive compensation is to align the interests of
our executives with our stockholders, Company policy prohibits
the trading of derivative securities related to the stock.
REPORT OF
THE COMPENSATION AND DEVELOPMENT COMMITTEE
ON EXECUTIVE COMPENSATION
The Compensation Committee and Development Committee of Express
Scripts, Inc. has reviewed and discussed the Compensation
Discussion and Analysis section of this Proxy Statement with
management, and based on such review and discussions the
Committee recommended to the Board of Directors that the
Compensation Discussion and Analysis be included in this Proxy
Statement.
March 31, 2008
COMPENSATION AND DEVELOPMENT COMMITTEE
Gary Benanav, Chairman
Thomas P. Mac Mahon
Howard Waltman
COMPENSATION
COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The Compensation and Development Committee is comprised of Gary
Benanav (Chair), Thomas Mac Mahon and Howard Waltman, none of
whom are employees or current or former officers of our company,
or had any relationship with our company required to be
disclosed under Certain Relationships and Related Party
Transactions.
23
SUMMARY
COMPENSATION TABLE
The following table summarizes the compensation of our
named executive officers listed in the table for the
year ended December 31, 2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change In
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonqualified
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Equity
|
|
Deferred
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
Option
|
|
Incentive Plan
|
|
Compensation
|
|
All Other
|
|
|
|
|
|
|
Salary
|
|
Bonus
|
|
Awards
|
|
Awards
|
|
Compensation
|
|
Earnings
|
|
Compensation
|
|
Total
|
Name and Principal Position
|
|
Year
|
|
($)
|
|
($)
|
|
(1)($)
|
|
(2)($)
|
|
(3)($)
|
|
($)
|
|
($)
|
|
($)
|
(a)
|
|
(b)
|
|
(c)
|
|
(d)
|
|
(e)
|
|
(f)
|
|
(g)
|
|
(h)
|
|
(i)
|
|
(j)
|
|
George Paz
|
|
|
2007
|
|
|
$
|
882,308
|
|
|
|
|
|
|
$
|
2,552,140
|
|
|
$
|
2,290,983
|
|
|
$
|
2,124,000
|
|
|
|
|
|
|
$
|
114,732
|
(4)
|
|
$
|
7,964,163
|
|
President, Chief Executive
|
|
|
2006
|
|
|
$
|
780,000
|
|
|
|
|
|
|
$
|
1,513,542
|
|
|
$
|
1,826,498
|
|
|
$
|
842,400
|
|
|
|
|
|
|
$
|
129,680
|
(5)
|
|
$
|
5,092,120
|
|
Officer, Chairman
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward Stiften(6)
|
|
|
2007
|
|
|
$
|
435,308
|
|
|
|
|
|
|
$
|
999,747
|
|
|
$
|
870,048
|
|
|
$
|
697,600
|
|
|
|
|
|
|
$
|
45,996
|
(7)
|
|
$
|
3,048,699
|
|
Former Executive Vice
|
|
|
2006
|
|
|
$
|
409,000
|
|
|
|
|
|
|
$
|
755,788
|
|
|
$
|
870,345
|
|
|
$
|
331,290
|
|
|
|
|
|
|
$
|
51,878
|
(7)
|
|
$
|
2,418,301
|
|
President, Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David A. Lowenberg(8)
|
|
|
2007
|
|
|
$
|
492,231
|
|
|
|
|
|
|
$
|
815,557
|
|
|
$
|
735,893
|
|
|
$
|
0
|
|
|
|
|
|
|
$
|
49,460
|
(9)
|
|
$
|
2,093,141
|
|
Former President, Chief
|
|
|
2006
|
|
|
$
|
482,000
|
|
|
|
|
|
|
$
|
619,834
|
|
|
$
|
1,008,755
|
|
|
$
|
144,600
|
|
|
|
|
|
|
$
|
78,875
|
(10)
|
|
$
|
2,334,064
|
|
Executive Officer, CuraScript, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thomas M. Boudreau
|
|
|
2007
|
|
|
$
|
447,096
|
|
|
|
|
|
|
$
|
614,579
|
|
|
$
|
510,498
|
|
|
$
|
626,150
|
|
|
|
|
|
|
$
|
55,387
|
(11)
|
|
$
|
2,253,710
|
|
Executive Vice President,
|
|
|
2006
|
|
|
$
|
411,000
|
|
|
|
|
|
|
$
|
369,230
|
|
|
$
|
616,459
|
|
|
$
|
288,522
|
|
|
|
|
|
|
$
|
65,270
|
(12)
|
|
$
|
1,750,481
|
|
Law and Strategy, General Counsel
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward B. Ignaczak
|
|
|
2007
|
|
|
$
|
329,888
|
|
|
|
|
|
|
$
|
436,950
|
|
|
$
|
487,034
|
|
|
$
|
456,890
|
|
|
|
|
|
|
$
|
40,161
|
(13)
|
|
$
|
1,750,923
|
|
Executive Vice President,
|
|
|
2006
|
|
|
$
|
294,800
|
|
|
|
|
|
|
$
|
471,754
|
|
|
$
|
284,927
|
|
|
$
|
157,626
|
|
|
|
|
|
|
$
|
48,770
|
(14)
|
|
$
|
1,257,877
|
|
Sales and Account Management
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
The amounts in column (e)
represent the dollar amount of expense recognized for financial
statement reporting purposes in stated year for the fair value
of restricted stock and performance share awards granted in
stated year and in prior years, in accordance with
SFAS 123R. Pursuant to SEC rules, the amounts shown exclude
the impact of estimated forfeitures related to service-based
vesting conditions. These amounts reflect our accounting expense
for these awards and do not correspond to the actual value that
will be recognized by the named executives. For restricted stock
and performance share awards, fair value is calculated using the
closing price of our common stock on the date of grant. For
additional information regarding stock-based compensation, refer
to the Note 11 to the Consolidated Financial Statements
included in the financial statements in our Annual Report on
Form 10-K
for the year ended December 31, 2007 (our 2007
10-K)
and Note 10 to the Consolidated Financial Statements
included in the financial statements in our Annual Report on
Form 10-K
for the year ended December 31, 2006 (our 2006
10-K).
|
|
(2)
|
|
The amounts in column (f)
represent the dollar amount of expense recognized for financial
statement reporting purposes in the stated year for the fair
value of stock options and SSARs granted in the stated year and
in prior years, in accordance with SFAS 123R. Pursuant to
SEC rules, the amounts shown exclude the impact of estimated
forfeitures related to service-based vesting conditions. These
amounts reflect our accounting expense for these awards and do
not correspond to the actual value that will be recognized by
the named executives. The fair value of options and SSARs
granted is estimated on the date of grant using a Black-Scholes
multiple option-pricing model. For additional information
regarding stock-based compensation, including the assumptions
used in the Black-Scholes model, refer to the Note 11 to
the Consolidated Financial Statements included in the financial
statements in our 2007
10-K and
Note 10 to the Consolidated Financial Statements included in the
financial statements in our 2006
10-K.
|
|
(3)
|
|
The amounts in column (g)
reflect the cash awards paid to the named executives under our
annual bonus plan, as discussed in the Compensation Discussion
and Analysis above. These amounts were paid in March 2008 and
March 2007 for performance during 2007 and 2006, respectively.
|
|
(4)
|
|
Consists of (i) basic company
credit contribution of $103,482 by the Company under the EDCP
and (ii) $11,250 matching contribution in connection with
the Companys 401(k) Plan.
|
|
(5)
|
|
Consists of (i) basic company
credit contribution of $118,680 by the Company under the EDCP
and (ii) $11,000 matching contribution in connection with
the Companys 401(k) Plan.
|
|
(6)
|
|
Mr. Stiften has announced his
intention to retire from the Company. His last day as Chief
Financial Officer was March 31, 2008.
|
|
(7)
|
|
Reflects the basic company credit
contribution made by the Company under the EDCP.
|
|
(8)
|
|
Mr. Lowenbergs last day
as an employee of the Company was March 1, 2008. In
connection with his termination Mr. Lowenberg forfeited a
total of 61,499 unvested SSARs which were granted during 2006
and 2007, and 14,941 invested
|
24
|
|
|
|
|
shares of restricted stock
originally granted between 2004 and 2007. Mr. Lowenberg
also forfeited a portion of his performance share grants from
2006 and 2007. The total number of performance shares forfeited
would be 13,158 based on an assumed award of the targeted number
of shares following the end of the relevant performance periods
(or 32,895 performance shares assuming the maximum award).
|
|
(9)
|
|
Consists of (i) basic company
credit contribution of $38,210 by the Company under the EDCP and
(ii) $11,250 matching contribution in connection with the
Companys 401(k) Plan.
|
|
(10)
|
|
Consists of (i) basic company
credit contribution of $67,875 by the Company under the EDCP and
(ii) $11,000 matching contribution in connection with the
Companys 401(k) Plan.
|
|
(11)
|
|
Consists of (i) basic company
credit contribution of $44,137 by the Company under the EDCP and
(ii) $11,250 matching contribution in connection with the
Companys 401(k) Plan.
|
|
(12)
|
|
Consists of (i) basic company
credit contribution of $54,270 by the Company under the EDCP and
(ii) $11,000 matching contribution in connection with the
Companys 401(k) Plan.
|
|
(13)
|
|
Consists of (i) basic company
credit contribution of $28,911 by the Company under the EDCP and
(ii) $11,250 matching contribution in connection with the
Companys 401(k) Plan.
|
|
(14)
|
|
Consists of (i) basic company
credit contribution of $35,501 by the Company under the EDCP and
(ii) $13,269 matching contribution in connection with the
Companys 401(k) Plan, $2,269 of which is a
catch-up
contribution for 2005.
|
25
GRANTS OF
PLAN-BASED AWARDS IN 2007
The following table provides additional information about awards
of restricted stock, stock-settled stock appreciation rights and
performance shares granted to the named executive officers in
2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
|
|
All Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
Option
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
Awards:
|
|
Exercise
|
|
|
|
|
|
|
Estimated Future Payouts Under
|
|
|
|
|
|
|
|
Number of
|
|
Number of
|
|
or Base
|
|
|
|
|
|
|
Non-Equity Incentive Plan
|
|
Estimated Future Payouts Under
|
|
Shares of
|
|
Securities
|
|
Price of
|
|
Grant Date Fair
|
|
|
|
|
Awards(1)
|
|
Equity Incentive Plan Awards(2)
|
|
Stock or
|
|
Underlying
|
|
Option
|
|
Value of Stock
|
|
|
Grant
|
|
Threshold
|
|
Target
|
|
Maximum
|
|
Threshold
|
|
Target
|
|
Maximum
|
|
Units(3)
|
|
Options(4)
|
|
Awards
|
|
Option Awards(5)
|
Name
|
|
Date
|
|
($)
|
|
($)
|
|
($)
|
|
(#)
|
|
(#)
|
|
(#)
|
|
(#)
|
|
(#)
|
|
($/Sh)
|
|
($)
|
(a)
|
|
(b)
|
|
(c)
|
|
(d)
|
|
(e)
|
|
(f)
|
|
(g)
|
|
(h)
|
|
(i)
|
|
(j)
|
|
(k)
|
|
(l)
|
|
George Paz
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,238
|
|
|
|
34,966
|
|
|
|
87,415
|
|
|
|
|
|
|
|
|
|
|
$
|
39.325
|
|
|
$
|
3,437,595
|
|
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34,966
|
|
|
|
|
|
|
$
|
39.325
|
|
|
$
|
1,375,038
|
|
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
205,074
|
|
|
$
|
39.325
|
|
|
$
|
2,750,042
|
|
|
|
|
5/23/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,458
|
|
|
|
|
|
|
$
|
49.28
|
|
|
$
|
170,410
|
|
|
|
|
5/23/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,992
|
|
|
|
5,692
|
|
|
|
14,230
|
|
|
|
|
|
|
|
|
|
|
$
|
49.28
|
|
|
$
|
701,254
|
|
|
|
|
|
|
|
$
|
0
|
|
|
$
|
1,062,000
|
|
|
$
|
2,124,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward Stiften
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,560
|
|
|
|
10,172
|
|
|
|
25,430
|
|
|
|
|
|
|
|
|
|
|
$
|
39.325
|
|
|
$
|
1,000,035
|
|
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,172
|
|
|
|
|
|
|
$
|
39.325
|
|
|
$
|
400,014
|
|
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
59,658
|
|
|
$
|
39.325
|
|
|
$
|
800,014
|
|
|
|
|
5/23/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,006
|
|
|
|
|
|
|
$
|
49.28
|
|
|
$
|
49,576
|
|
|
|
|
5/23/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
580
|
|
|
|
1,656
|
|
|
|
4,140
|
|
|
|
|
|
|
|
|
|
|
$
|
49.28
|
|
|
$
|
204,019
|
|
|
|
|
|
|
|
$
|
0
|
|
|
$
|
348,800
|
|
|
$
|
872,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David A. Lowenberg
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,783
|
|
|
|
10,808
|
|
|
|
27,020
|
|
|
|
|
|
|
|
|
|
|
$
|
39.325
|
|
|
$
|
1,062,562
|
|
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,808
|
|
|
|
|
|
|
$
|
39.325
|
|
|
$
|
425,025
|
|
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
63,386
|
|
|
$
|
39.325
|
|
|
$
|
850,006
|
|
|
|
|
5/23/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,068
|
|
|
|
|
|
|
$
|
49.28
|
|
|
$
|
52,631
|
|
|
|
|
5/23/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
616
|
|
|
|
1,760
|
|
|
|
4,400
|
|
|
|
|
|
|
|
|
|
|
$
|
49.28
|
|
|
$
|
216,832
|
|
|
|
|
|
|
|
$
|
0
|
|
|
$
|
369,375
|
|
|
$
|
923,438
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thomas M. Boudreau
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,781
|
|
|
|
7,946
|
|
|
|
19,865
|
|
|
|
|
|
|
|
|
|
|
$
|
39.325
|
|
|
$
|
781,191
|
|
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,946
|
|
|
|
|
|
|
$
|
39.325
|
|
|
$
|
312,476
|
|
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
46,608
|
|
|
$
|
39.325
|
|
|
$
|
625,013
|
|
|
|
|
5/23/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
786
|
|
|
|
|
|
|
$
|
49.28
|
|
|
$
|
38,734
|
|
|
|
|
5/23/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453
|
|
|
|
1,294
|
|
|
|
3,235
|
|
|
|
|
|
|
|
|
|
|
$
|
49.28
|
|
|
$
|
159,421
|
|
|
|
|
|
|
|
$
|
0
|
|
|
$
|
313,075
|
|
|
$
|
782,688
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward B. Ignaczak
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,669
|
|
|
|
4,768
|
|
|
|
11,920
|
|
|
|
|
|
|
|
|
|
|
$
|
39.325
|
|
|
$
|
468,754
|
|
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,768
|
|
|
|
|
|
|
$
|
39.325
|
|
|
$
|
187,502
|
|
|
|
|
2/22/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27,964
|
|
|
$
|
39.325
|
|
|
$
|
374,997
|
|
|
|
|
5/23/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
472
|
|
|
|
|
|
|
$
|
49.28
|
|
|
$
|
23,260
|
|
|
|
|
5/23/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
272
|
|
|
|
776
|
|
|
|
1,940
|
|
|
|
|
|
|
|
|
|
|
$
|
49.28
|
|
|
$
|
95,603
|
|
|
|
|
|
|
|
$
|
0
|
|
|
$
|
228,445
|
|
|
$
|
571,113
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
The amounts in columns (c),
(d) and (e) represent the threshold, target and
maximum payouts under the annual bonus plan for 2007. The actual
payouts for 2007 can be found in our Compensation Discussion and
Analysis on page 13.
|
(2)
|
|
The amounts in columns (f),
(g) and (h) represent the threshold, target and maximum
payouts under the performance share grants made to the named
executives for the January 1, 2007 through January 1,
2010 performance period. The number of shares of our common
stock to be delivered upon settlement of the performance shares
will be determined based upon our performance over a set period
versus the peer group companies identified in our Compensation
Discussion & Analysis on page 13. For our 2007
performance awards, in order for any shares to be issued under
the performance share awards, our composite performance over the
three year period commencing in 2007 is required to rank in at
least the 40th percentile in relation to the peer group
companies. Assuming our composite performance for the
performance period is/was at the 40th percentile, the
actual shares of common stock issued will equal 35% of the award
targeted for the named executive officer; at the
50th percentile, the actual shares of common stock issued
will equal 100% of the award targeted for the named executive
officer; and at the 80th percentile, the actual shares of
common stock issued will equal 250% of the award targeted for
the named executive officer, which is the maximum number of
shares that can be awarded. If our composite performance falls
between these percentile rankings, the actual shares of common
stock issued will be determined by interpolation. Realization of
the performance share awards and their actual value, if any,
will depend on the applicable targets being met and the market
value of our common stock on the date the performance share
awards are settled.
|
(3)
|
|
The numbers in column (i)
represent the restricted stock awards granted to the named
executives on February 22, 2007 and May 23, 2007. For
each of these grants one-third of these restricted stock awards
are scheduled to vest on each of February 22, 2008,
February 22, 2009 and February 22, 2010, subject to
acceleration under the terms of the 2000 LTIP. The restricted
stock awards include the right to receive all dividends paid on
the shares and the right to vote the shares.
|
(4)
|
|
The numbers in column (j)
represent the SSAR awards granted to the named executives on
February 22, 2007. The SSARs have an exercise price of
$39.325 (the closing price of our common stock on the grant
date), are scheduled to vest on each of the first three
anniversaries of the date of grant subject to acceleration under
the terms of the 2000 LTIP, and will expire seven years
following the grant.
|
(5)
|
|
The amounts in column (l) for
restricted stock and performance share awards are based on the
market value of our common stock on the grant date ($39.325 per
share on February 22, 2007, and $49.28 on May 23,
2007), with the Maximum number of performance shares used. The
amounts in column (l) for SSARs is estimated on the date of
grant using a Black-Scholes multiple option-pricing model. For
additional information regarding stock-based compensation,
including the assumptions used in the Black-Scholes model, refer
to the Note 11 to the Consolidated Financial Statements
included in the financial statements in our 2007
10-K.
|
26
OUTSTANDING
EQUITY AWARDS AT 2007 FISCAL YEAR-END
The following table provides information on vested and unvested
equity awards held by the named executive officers as of
December 31, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
Stock Awards
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
Awards:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
Market or
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
Payout
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
Value of
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
|
|
|
|
|
|
|
|
|
Market
|
|
|
Unearned
|
|
|
Unearned
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
|
|
|
|
|
|
Number of
|
|
|
Value of
|
|
|
Shares,
|
|
|
Shares,
|
|
|
|
|
|
|
Number of
|
|
|
Number of
|
|
|
Number of
|
|
|
|
|
|
|
|
|
Shares or
|
|
|
Shares or
|
|
|
Units or
|
|
|
Units or
|
|
|
|
|
|
|
Securities
|
|
|
Securities
|
|
|
Securities
|
|
|
|
|
|
|
|
|
Units of
|
|
|
Units of
|
|
|
Other
|
|
|
Other
|
|
|
|
|
|
|
Underlying
|
|
|
Underlying
|
|
|
Underlying
|
|
|
Option
|
|
|
|
|
|
Stock That
|
|
|
Stock That
|
|
|
Rights That
|
|
|
Rights That
|
|
|
|
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Exercise
|
|
|
Option
|
|
|
Have Not
|
|
|
Have Not
|
|
|
Have Not
|
|
|
Have Not
|
|
|
|
|
|
|
Options
|
|
|
Options
|
|
|
Unearned
|
|
|
Price
|
|
|
Expiration
|
|
|
Vested
|
|
|
Vested
|
|
|
Vested
|
|
|
Vested
|
|
Name
|
|
Grant
|
|
|
Exercisable
|
|
|
Unexercisable
|
|
|
Options
|
|
|
($)
|
|
|
Date
|
|
|
(#)
|
|
|
($)
|
|
|
(#)
|
|
|
($)
|
|
(a)
|
|
Date
|
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
(g)
|
|
|
(h)
|
|
|
(i)
|
|
|
(j)
|
|
|
George Paz
|
|
|
5/26/99
|
|
|
|
40,000
|
|
|
|
|
|
|
|
|
|
|
$
|
8.21
|
|
|
|
5/26/09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11/23/99
|
|
|
|
104,000
|
|
|
|
|
|
|
|
|
|
|
$
|
6.4525
|
|
|
|
11/23/09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12/18/02
|
|
|
|
44,400
|
|
|
|
|
|
|
|
|
|
|
$
|
11.9875
|
|
|
|
12/18/09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/10/04
|
|
|
|
72,008
|
|
|
|
|
|
|
|
|
|
|
$
|
17.3275
|
|
|
|
2/10/11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3/5/04
|
|
|
|
83,156
|
|
|
|
|
|
|
|
|
|
|
$
|
18.79
|
|
|
|
3/5/11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3/1/05
|
|
|
|
69,014
|
|
|
|
34,506
|
(1)
|
|
|
|
|
|
$
|
19.32
|
|
|
|
3/1/12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4/11/05
|
|
|
|
106,667
|
|
|
|
53,333
|
(2)
|
|
|
|
|
|
$
|
21.40
|
|
|
|
4/11/12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/28/06
|
|
|
|
45,950
|
|
|
|
91,898
|
(3)
|
|
|
|
|
|
$
|
43.635
|
|
|
|
2/28/13
|
|
|
|
18,196
|
(5)
|
|
$
|
1,328,308
|
|
|
|
27,294
|
(7)
|
|
$
|
1,992,462
|
|
|
|
|
2/22/07
|
|
|
|
|
|
|
|
205,074
|
(4)
|
|
|
|
|
|
$
|
39.325
|
|
|
|
2/22/14
|
|
|
|
34,966
|
(6)
|
|
$
|
2,552,518
|
|
|
|
34,966
|
(8)
|
|
$
|
2,552,518
|
|
|
|
|
5/23/07
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,458
|
(6)
|
|
$
|
252,434
|
|
|
|
5,692
|
(8)
|
|
$
|
415,516
|
|
Edward Stiften
|
|
|
4/20/04
|
|
|
|
26,956
|
|
|
|
|
|
|
|
|
|
|
$
|
19.5375
|
|
|
|
4/20/11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4/20/04
|
|
|
|
80,860
|
|
|
|
|
|
|
|
|
|
|
$
|
19.5375
|
|
|
|
4/20/11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4/20/04
|
|
|
|
43,126
|
|
|
|
|
|
|
|
21,562
|
(9)
|
|
$
|
19.5375
|
|
|
|
4/20/11
|
|
|
|
|
|
|
|
|
|
|
|
17,142
|
(10)
|
|
$
|
1,251,366
|
|
|
|
|
3/1/05
|
|
|
|
24,198
|
|
|
|
12,098
|
(1)
|
|
|
|
|
|
$
|
19.32
|
|
|
|
3/1/12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/28/06
|
|
|
|
18,452
|
|
|
|
36,902
|
(3)
|
|
|
|
|
|
$
|
43.635
|
|
|
|
2/28/13
|
|
|
|
7,306
|
(5)
|
|
$
|
533,338
|
|
|
|
10,960
|
(7)
|
|
$
|
800,080
|
|
|
|
|
2/22/07
|
|
|
|
|
|
|
|
59,658
|
(4)
|
|
|
|
|
|
$
|
39.325
|
|
|
|
2/22/14
|
|
|
|
10,172
|
(6)
|
|
$
|
742,556
|
|
|
|
10,172
|
(8)
|
|
$
|
742,556
|
|
|
|
|
5/23/07
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,006
|
(6)
|
|
$
|
73,438
|
|
|
|
1,656
|
(8)
|
|
$
|
120,888
|
|
David A. Lowenberg
|
|
|
8/31/04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,214
|
(11)
|
|
$
|
234,622
|
|
|
|
|
3/1/05
|
|
|
|
|
|
|
|
15,132
|
(1)
|
|
|
|
|
|
$
|
19.32
|
|
|
|
3/1/12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/28/06
|
|
|
|
19,242
|
|
|
|
38,484
|
(3)
|
|
|
|
|
|
$
|
43.635
|
|
|
|
2/28/13
|
|
|
|
7,620
|
(5)
|
|
$
|
556,260
|
|
|
|
11,430
|
(7)
|
|
$
|
834,390
|
|
|
|
|
2/22/07
|
|
|
|
|
|
|
|
63,386
|
(4)
|
|
|
|
|
|
$
|
39.325
|
|
|
|
2/22/14
|
|
|
|
10,808
|
(6)
|
|
$
|
788,984
|
|
|
|
10,808
|
(8)
|
|
$
|
788,984
|
|
|
|
|
5/23/07
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,068
|
(6)
|
|
$
|
77,964
|
|
|
|
1,760
|
(8)
|
|
$
|
128,480
|
|
Thomas M. Boudreau
|
|
|
12/18/02
|
|
|
|
12,000
|
|
|
|
|
|
|
|
|
|
|
$
|
11.9875
|
|
|
|
12/18/09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3/5/04
|
|
|
|
26,520
|
|
|
|
|
|
|
|
|
|
|
$
|
18.79
|
|
|
|
3/5/11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10/29/04
|
|
|
|
38,620
|
|
|
|
|
|
|
|
|
|
|
$
|
16.0025
|
|
|
|
10/29/11
|
|
|
|
|
|
|
|
|
|
|
|
1,608
|
(12)
|
|
$
|
117,384
|
|
|
|
|
3/1/05
|
|
|
|
25,622
|
|
|
|
12,810
|
(1)
|
|
|
|
|
|
$
|
19.32
|
|
|
|
3/1/12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/28/06
|
|
|
|
11,719
|
|
|
|
23,437
|
(3)
|
|
|
|
|
|
$
|
43.635
|
|
|
|
2/28/13
|
|
|
|
4,640
|
(5)
|
|
$
|
338,720
|
|
|
|
6,962
|
(7)
|
|
$
|
508,226
|
|
|
|
|
2/22/07
|
|
|
|
|
|
|
|
46,608
|
(4)
|
|
|
|
|
|
$
|
39.325
|
|
|
|
|
|
|
|
7,946
|
(6)
|
|
$
|
580,058
|
|
|
|
7,946
|
(8)
|
|
$
|
580,058
|
|
|
|
|
5/23/07
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
786
|
(6)
|
|
$
|
57,378
|
|
|
|
1,294
|
(8)
|
|
$
|
94,462
|
|
Edward B. Ignaczak
|
|
|
10/29/04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,760
|
(13)
|
|
$
|
493,480
|
|
|
|
|
3/1/2005
|
|
|
|
|
|
|
|
10,050
|
(1)
|
|
|
|
|
|
$
|
19.32
|
|
|
|
3/1/12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/28/06
|
|
|
|
6,511
|
|
|
|
13,021
|
(3)
|
|
|
|
|
|
$
|
43.635
|
|
|
|
2/28/13
|
|
|
|
2,578
|
(5)
|
|
$
|
188,194
|
|
|
|
3,868
|
(7)
|
|
$
|
282,364
|
|
|
|
|
2/22/07
|
|
|
|
|
|
|
|
27,964
|
(4)
|
|
|
|
|
|
$
|
39.325
|
|
|
|
2/22/14
|
|
|
|
4,768
|
(6)
|
|
$
|
348,064
|
|
|
|
4,768
|
(8)
|
|
$
|
348,064
|
|
|
|
|
5/23/07
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
472
|
(6)
|
|
$
|
34,456
|
|
|
|
776
|
(8)
|
|
$
|
56,648
|
|
|
|
|
(1)
|
|
The unvested portion of this option
grant is scheduled to vest on March 1, 2008.
|
|
(2)
|
|
The unvested portion of this option
grant is scheduled to vest on March 31, 2008.
|
27
|
|
|
(3)
|
|
The unvested portion of SSARs grant
is scheduled to vest in two (2) substantially equal
installments on February 28, 2008 and February 28,
2009.
|
|
(4)
|
|
The unvested portion of this SSARs
grant is scheduled to vest in three (3) substantially equal
installments on February 22, 2008, February 22, 2009,
and February 22, 2010.
|
|
(5)
|
|
The unvested portion of this
restricted stock award is scheduled to vest in two
(2) substantially equal installments on February 28,
2008, and February 28, 2009.
|
|
(6)
|
|
The unvested portion of this
restricted stock award is scheduled to vest in three
(3) substantially equal installments on February 22,
2008, February 22, 2009 and February 22, 2010.
|
|
(7)
|
|
Performance shares become payable
following the end of the performance period on January 1,
2009; the number of shares payable may increase or decrease from
the target shares stated, based upon the achievement of
performance criteria.
|
|
(8)
|
|
Performance shares become payable
following the end of the performance period on January 1,
2010; the number of shares payable may increase or decrease from
the target shares stated, based upon the achievement of
performance criteria.
|
|
(9)
|
|
Stock option grant with original
vesting date of September 20, 2010, with potential for
accelerated vesting based on the achievement of certain
financial performance targets. Based upon achievement of certain
financial performance targets, 43,126 options vested on
March 31, 2007. The balance of 21,562 options remain
scheduled to vest on September 30, 2010.
|
|
(10)
|
|
Restricted stock grant with
original vesting date of April 20, 2014, with potential for
accelerated vesting based on the achievement of certain
financial performance targets. Based upon achievement of certain
financial performance targets, 34,286 shares vested on
March 31, 2007. The balance of 17,142 shares remain
scheduled to vest April 20, 2014.
|
|
(11)
|
|
Restricted stock grant with
original vesting date of August 31, 2011, with potential
for accelerated vesting based on the achievement of certain
financial performance targets. Based upon achievement of certain
financial performance targets, 54,590 shares vested on
March 31, 2006, with the balance of 3,214 shares
scheduled to vest August 31, 2011.
|
|
(12)
|
|
Restricted stock grant with
original vesting date of October 29, 2014, with potential
for accelerated vesting based on the achievement of certain
financial performance targets. Based upon achievement of certain
financial performance targets, vesting of 27,296 shares was
accelerated to March 31, 2006 and the balance of
1,608 shares scheduled to vest on October 29, 2011.
|
|
(13)
|
|
Restricted stock grant with
original vesting date of October 29, 2014, with potential
for accelerated vesting based on the achievement of certain
financial performance targets. Based upon achievement of certain
financial performance targets, vesting of 35,388 shares was
accelerated to March 31, 2007 and the balance of
6,670 shares are scheduled to vest on October 29, 2014.
|
28
OPTIONS
EXERCISES AND STOCK VESTED TABLE
The following table provides information on the value realized
by the executive officers for stock options exercised during
2007, and for restricted stock awards which vested during 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
Stock Awards
|
|
|
|
Number of Shares
|
|
|
Value Realized on
|
|
|
Number of Shares
|
|
|
Value Realized on
|
|
|
|
Acquired on Exercise
|
|
|
Exercise(1)
|
|
|
Acquired on Vesting
|
|
|
Vesting (2)
|
|
Name
|
|
(#)
|
|
|
($)
|
|
|
(#)
|
|
|
($)
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
George Paz
|
|
|
40,000
|
|
|
$
|
1,717,524
|
|
|
|
9,098
|
|
|
$
|
343,040
|
|
|
|
|
158,400
|
|
|
$
|
6,549,539
|
|
|
|
|
|
|
|
|
|
|
|
|
114,000
|
|
|
$
|
4,174,463
|
|
|
|
|
|
|
|
|
|
|
|
|
64,000
|
|
|
$
|
2,459,398
|
|
|
|
|
|
|
|
|
|
Edward Stiften
|
|
|
|
|
|
|
|
|
|
|
3,654
|
|
|
$
|
137,774
|
|
|
|
|
|
|
|
|
|
|
|
|
34,286
|
|
|
$
|
1,383,783
|
|
David A. Lowenberg
|
|
|
15,132
|
|
|
$
|
435,662
|
|
|
|
3,810
|
|
|
$
|
143,656
|
|
|
|
|
15,132
|
|
|
$
|
421,441
|
|
|
|
|
|
|
|
|
|
|
|
|
70,216
|
|
|
$
|
2,202,743
|
|
|
|
|
|
|
|
|
|
|
|
|
24,312
|
|
|
$
|
689,998
|
|
|
|
|
|
|
|
|
|
|
|
|
12,156
|
|
|
$
|
356,423
|
|
|
|
|
|
|
|
|
|
|
|
|
3,392
|
|
|
$
|
116,394
|
|
|
|
|
|
|
|
|
|
|
|
|
14,940
|
|
|
$
|
525,641
|
|
|
|
|
|
|
|
|
|
Thomas M. Boudreau
|
|
|
|
|
|
|
|
|
|
|
2,322
|
|
|
$
|
87,551
|
|
Edward B. Ignaczak
|
|
|
20,102
|
|
|
$
|
558,739
|
|
|
|
1,290
|
|
|
$
|
48,639
|
|
|
|
|
35,108
|
|
|
$
|
1,088,260
|
|
|
|
35,388
|
|
|
$
|
1,428,260
|
|
|
|
|
3,092
|
|
|
$
|
87,225
|
|
|
|
|
|
|
|
|
|
|
|
|
14,588
|
|
|
$
|
413,208
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
The amount in column
(c) reflects value of the options exercised based on the
difference between the exercise price for the options exercised
and the closing price for our stock on the exercise date.
|
|
(2)
|
|
The amount in column
(e) reflects value of the vested stock based on the closing
price for our stock on the vesting date.
|
29
NONQUALIFIED
DEFERRED COMPENSATION IN 2007
The following table provides information on contributions,
earnings and account balances for the named executives in our
Executive Deferred Compensation Plan, or EDCP:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive
|
|
|
Registrant
|
|
|
Aggregate
|
|
|
Aggregate
|
|
|
Aggregate
|
|
|
|
|
|
|
Contributions in
|
|
|
Contributions in
|
|
|
Earnings
|
|
|
Withdrawals/
|
|
|
Balance
|
|
|
|
|
|
|
Last FY
|
|
|
Last FY(1)
|
|
|
in Last FY
|
|
|
Distributions
|
|
|
at Last FYE
|
|
|
|
|
Name
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
|
|
|
George Paz
|
|
$
|
0
|
|
|
$
|
118,680
|
|
|
$
|
1,214,269
|
|
|
$
|
0
|
|
|
$
|
3,636,427
|
|
|
|
|
|
Edward Stiften
|
|
$
|
0
|
|
|
$
|
51,878
|
|
|
$
|
40,256
|
|
|
$
|
0
|
|
|
$
|
158,933
|
|
|
|
|
|
David A. Lowenberg
|
|
$
|
59,068
|
(2)
|
|
$
|
67,875
|
|
|
$
|
1,251,858
|
|
|
$
|
0
|
|
|
$
|
4,808,816
|
|
|
|
|
|
Thomas M. Boudreau
|
|
$
|
0
|
|
|
$
|
54,270
|
|
|
$
|
971,336
|
|
|
$
|
0
|
|
|
$
|
3,203,322
|
|
|
|
|
|
Edward B. Ignaczak
|
|
$
|
0
|
|
|
$
|
35,501
|
|
|
$
|
66,469
|
|
|
$
|
0
|
|
|
$
|
233,091
|
|
|
|
|
|
|
|
|
(1)
|
|
The amounts in column
(c) reflect contributions made by us during 2007 to the
named executives accounts under the EDCP. These amounts
are equal to 6% of all cash compensation (salary and annual
bonus) received by the named executives during 2006, and were
reported in the 2006 Summary Compensation Table included in our
2007 Proxy Statement. These contributions vest as of December 31
of the third year after the year with respect to which they were
calculated, in this case December 31, 2009, unless the
executive is eligible for retirement under the EDCP in which
case these contributions vest immediately.
Messrs. Lowenberg and Boudreau are both eligible for
retirement under the EDCP.
|
|
(2)
|
|
This amount reflects
Mr. Lowenbergs deferral of a portion of his base
salary during 2007, and is included in Mr. Lowenbergs
base salary in the 2007 Summary Compensation Table above.
|
The material terms of the EDCP are described in our Compensation
Discussion and Analysis under Components of Executive
Compensation Deferred Compensation on
page 19.
EMPLOYMENT
AGREEMENTS AND POTENTIAL PAYMENTS
UPON TERMINATION OR CHANGE IN CONTROL
Employment
Agreement with Mr. Paz
General Terms. On April 1, 2005, we
entered into an employment agreement with Mr. Paz in
connection with his promotion to the office of Chief Executive
Officer. This agreement with Mr. Paz, which we refer to as
the 2005 agreement was effective as of April 1,
2005 with an initial term through March 31, 2008. On
April 1, 2008, we entered into a new employment agreement
with Mr. Paz, with a term through March 31, 2011,
which we refer to as the 2008 agreement. The terms
of the 2008 agreement are described in New Employment
Agreement with Mr. Paz beginning on page 39.
The 2005 agreement provided for:
|
|
|
|
|
an initial base salary of $650,000, which could not be reduced
after any increase (current base salary is $950,000);
|
|
|
|
a guaranteed minimum annual bonus target under our bonus plan of
100% of his annual base salary, with a bonus opportunity for
each calendar year during the employment period of up to 200% of
his guaranteed minimum annual bonus in the event we achieve
certain financial goals (current annual bonus target is 130% of
base salary);
|
|
|
|
participation in our employee benefit and incentive plans (other
than bonus and incentive plans) on the same basis as such plans
are generally made available to similarly situated senior
executives;
|
|
|
|
the crediting of a deferred bonus in the amount of $200,000 to
his retirement account in the EDCP, subject to the terms and
conditions of the EDCP, generally vesting at the end of the
initial employment period except as described below;
|
|
|
|
a grant under the 2000 LTIP of an option to purchase
80,000 shares of our common stock, vesting in three equal
increments on March 31, 2006, 2007 and 2008;
|
30
|
|
|
|
|
the reimbursement of reasonable business expenses incurred in
performing his duties under the 2005 agreement; and
|
|
|
|
such perquisites and fringe benefits to which similarly situated
executives are entitled and which are suitable for
Mr. Pazs position.
|
Termination by Us for Cause or by Mr. Paz other than for
Good Reason or Retirement. If Mr. Pazs
employment is terminated before the employment period expires
for cause, as defined in the 2005 agreement, or by
Mr. Paz other than for good reason or
retirement, as those terms are defined in the 2005
agreement, he is not entitled to receive any further payments or
benefits that have not already been paid or provided, including
any unvested portion of the option grant or restricted stock
awards. However, Mr. Paz is entitled to the following
accrued rights:
|
|
|
|
|
all previously earned and accrued but unpaid base salary;
|
|
|
|
any annual bonus earned for a prior completed year but unpaid
prior to termination;
|
|
|
|
reimbursement for unreimbursed, properly incurred business
expenses; and
|
|
|
|
any employee benefits to which he may be entitled, including
with respect to stock options subject to the terms and
conditions of the applicable plan.
|
Termination by Us (other than for Cause or Disability) or
Termination by Mr. Paz for Good Reason. If
Mr. Paz is terminated other than for cause or
disability, or by him for good reason,
as those terms are defined in the 2005 agreement, he will
receive:
|
|
|
|
|
the accrued rights referred to above;
|
|
|
|
a severance benefit equal to 18 months of his annual base
salary plus a specified portion of his bonus potential for the
year based on the average percentage of the bonus potential
earned for the three prior years;
|
|
|
|
reimbursement for the cost of continuing medical insurance for
Mr. Paz, his spouse and any eligible dependents for
36 months after termination of employment; and
|
|
|
|
if termination occurs before March 31, 2008, a pro rata
portion of the deferred bonus based on the number of days worked
during the initial employment period.
|
Termination upon Death. If Mr. Paz dies
before the employment period expires, his estate will receive:
|
|
|
|
|
the accrued rights referred to above;
|
|
|
|
if his death occurs before March 31, 2008, a pro rata
portion of the deferred bonus based on the number of days worked
during the initial employment period; and
|
|
|
|
reimbursement for the cost of continuing medical insurance for
his spouse and any eligible dependents for 36 months after
termination of employment;
|
Termination for Disability or Retirement. If
Mr. Paz is terminated for disability or retirement (i.e.,
voluntary retirement on or after age 591/2 but not within
90 days after a change in control of us) before the
employment period expires, he will receive:
|
|
|
|
|
the accrued rights referred to above
|
|
|
|
if termination occurs before March 31, 2008, a pro rata
portion of the deferred bonus; and
|
|
|
|
reimbursement for the cost of continuing medical insurance for
Mr. Paz, his spouse and any eligible dependents for
36 months after termination of employment, provided, in the
case of retirement, he retires no earlier than six months prior
to March 31, 2008.
|
31
Effect of Change in Control on Deferred
Bonus. If a change in control, as
defined in the 2000 LTIP, occurs prior to March 31, 2008
Mr. Paz will receive:
|
|
|
|
|
if he remains employed through the 90th day following the
change in control date, as defined in the 2000 LTIP,
he will become vested with respect to one-half of the deferred
bonus, with the other half vesting in accordance with its
terms; and
|
|
|
|
if his employment is terminated prior to March 31, 2008
other than for cause or disability, or
by him for good reason, he shall become vested with
respect to the entire deferred bonus; and
|
|
|
|
if the change in control date occurs within the 90 day
period prior to March 31, 2008, he shall become vested with
respect to the entire deferred bonus on March 31, 2008,
whether or not he remains employed after such change in control
date.
|
Post-Employment Restrictive Covenants. Upon
termination of employment, Mr. Paz is prohibited from:
|
|
|
|
|
soliciting certain clients or prospective clients for a period
of two years after termination;
|
|
|
|
soliciting or hiring any of our employees for a period of two
years after termination;
|
|
|
|
soliciting or encouraging not to work for us any consultant then
under contract with us for a period of two years;
|
|
|
|
competing with us for a period of eighteen months after
termination, if his employment is terminated before the 2005
agreement expires for any reason, including any renewal period
in effect, or for one year after termination, if his employment
terminates solely as a result of expiration of the 2005
agreement; and
|
|
|
|
disclosing certain confidential information or disparaging our
company.
|
Mr. Paz must comply with these restrictions in order to
receive the severance benefits described above.
Section 409A Adjustments. If any
severance payments made to Mr. Paz following termination
(other than payments under the EDCP) should be subject to the
restrictions of Section 409A of the Internal Revenue Code,
then we must negotiate in good faith to amend his employment
agreement to the extent necessary to create payment terms with
respect to such post-termination payments which are as close as
possible to those originally set forth in his employment
agreement while not violating the terms of Section 409A.
Excise Tax
Gross-Up
Payment. If any severance payments would result
in Mr. Pazs liability for the payment of an excise
tax under Section 4999 of the Internal Revenue Code, or any
similar state or local tax, we will make a
gross-up
payment to him to fully offset such tax provided the aggregate
present value of the benefit amount is equal to or exceeds 125%
of the maximum total payment which could be made to him without
triggering the excise tax. If the aggregate present value of the
amount of the benefit, however, exceeds such maximum amount, but
is less than 125% of such maximum amount, then we may reduce the
benefit so that no portion of the amount is subject to the
excise tax, and no
gross-up
payment will be made.
Estimated Benefits. The table below reflects
the amount of incremental compensation which would be paid to
Mr. Paz upon the termination of his employment or upon a
change in control. These amounts assume that such termination or
change in control was effective as of December 31, 2007,
and that the price of our common stock upon which certain of the
calculations are made was the closing price of $73.00 per share
on that date. Accordingly, the computation of these amounts
requires the company to make certain estimates which are further
described in the description of the 2005 agreement above or in
the accompanying footnotes. Some of these amounts are payable
pursuant to the terms of the 2005 agreement while others arise
from the terms of the applicable grant
and/or
benefit plan. Those amounts payable pursuant to the 2005
agreement generally require the executive to sign a general
release and to comply with certain contractual terms including
those related to noncompetition, nonsolicitation and
non-disparagement.
Because the incremental amount of payments to be made depend on
several factors, the actual amounts to be paid out upon
termination of employment or a change in control can only be
determined at the time of the event. The tables do not include
the nonqualified deferred compensation that would be paid, which
is set forth in the Nonqualified Deferred Compensation
Table above, except to the extent an individual is
entitled to an additional
32
benefit as a result of the termination. The estimated payments
upon termination and change in control are as follows:
GEORGE
PAZ
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Good Reason or
|
|
|
|
|
|
|
|
|
Change in Control(1)
|
|
Executive Benefits and
|
|
|
|
|
|
|
|
Involuntary Not
|
|
|
|
|
|
|
|
|
With Offer of
|
|
|
Without Offer of
|
|
Payments Upon
|
|
Voluntary
|
|
|
|
|
|
for Cause
|
|
|
For Cause
|
|
|
Death or
|
|
|
Comparable
|
|
|
Comparable
|
|
Termination
|
|
Termination
|
|
|
Retirement
|
|
|
Termination
|
|
|
Termination
|
|
|
Disability
|
|
|
Employment
|
|
|
Employment
|
|
|
Compensation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Severance Benefit
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
2,677,908
|
(2)
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
2,677,908
|
(2)(3)
|
Accrued but Unpaid
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual Bonus
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
Long-term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Performance Shares
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
2,317,421
|
(5)
|
|
|
0
|
|
|
|
2,317,421
|
(5)
|
|
|
4,960,496
|
(6)
|
|
|
4,960,496
|
(6)
|
Stock Options/SSARs Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
14,208,717
|
|
|
|
14,208,717
|
|
|
|
14,208,717
|
|
Restricted Stock Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
2,211,106
|
|
|
|
1,900,592
|
(7)
|
|
|
3,801,183
|
|
Deferred Compensation Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
295,936
|
|
|
|
0
|
|
|
|
521,168
|
|
|
|
386,612
|
(8)
|
|
$
|
547,991
|
(3)
|
Benefits:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Post-termination Health Care
|
|
|
0
|
|
|
|
0
|
|
|
|
46,372
|
(9)
|
|
|
0
|
|
|
|
46,372
|
(9)
|
|
|
0
|
|
|
|
46,372
|
(9)
|
Accrued Vacation/PTO
|
|
|
123,846
|
|
|
|
123,846
|
|
|
|
123,846
|
|
|
|
0
|
|
|
|
123,846
|
|
|
|
123,846
|
(10)
|
|
|
123,846
|
(11)
|
280G Tax
Gross-up
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
Total:
|
|
$
|
123,846
|
|
|
$
|
123,846
|
|
|
$
|
5,461,483
|
|
|
$
|
0
|
|
|
$
|
19,428,630
|
|
|
$
|
21,580,263
|
|
|
$
|
26,366,513
|
|
|
|
|
(1)
|
|
The 2000 LTIP generally defines a
change in control as:
|
|
|
|
i.
|
|
a change in the composition of a
majority of our board of directors without the approval of the
incumbent directors;
|
|
ii.
|
|
An acquisition of more than 25% of
our Common Stock or voting power;
|
|
iii.
|
|
any merger, unless (1) our
stockholders possess more than 50% of the surviving
companys outstanding stock, (2) no person or group
who did not own 25% or more of our common stock before the
change in control owns 25% or more of the stock of the surviving
company, and (3) at least a majority of the board of
directors of the surviving company were members of the incumbent
directors of our company before the change in control;
|
|
iv.
|
|
the sale of all or substantially
all of our assets; or
|
|
v.
|
|
a stockholder-approved dissolution
of our company.
|
The 2000 LTIP defines comparable employment as
employment with us or our successor following a change in
control pursuant to which:
|
|
|
|
|
the responsibilities and duties of
the executive are substantially the same as before the change in
control, and the other terms and conditions of employment
following the change in control do not impose obligations
materially more burdensome;
|
|
|
|
the aggregate compensation is
substantially economically equivalent to or greater than the
executives aggregate compensation immediately prior to the
change in control; and
|
|
|
|
the executive remains employed in
the metropolitan area in which he was employed immediately
preceding the change in control. The definitions of change in
control and comparable employment appear in Section 2 of
the 2000 LTIP, which should be reviewed for a complete statement
of its terms.
|
|
|
|
(2)
|
|
Severance Benefit under
Mr. Pazs employment agreement equal to
(a) 18 months of base salary, plus (b) 100% of a
specified portion of his bonus potential for the year based on
the average percentage of the potential earned for the three
prior years, prorated for the portion of the calendar year
completed prior to termination. The Severance Benefit is payable
in 18 substantially equal monthly installments beginning the
first full month after termination; provided that if he is
determined to be a specified employee in accordance with
Section 409A of the Internal Revenue Code, then payment of
such benefit will be delayed six months to the extent required
under Section 409A.
|
33
|
|
|
(3)
|
|
Assumes termination of employment
agreement concurrent with change in control, either by us
without cause or by the executive for good reason.
|
|
(4)
|
|
Mr. Paz had not reached the
eligible retirement age as of December 31, 2007 for
retirement under either his employment agreement or the 2000
LTIP. If he were eligible for retirement, the payments would be
similar to those for death or disability.
|
|
(5)
|
|
Pro rated based on assumed award of
the targeted number of shares following end of relevant
performance periods. Payable in shares of our common stock
following the end of such periods. This amount is based on
involuntary not for cause termination; the amount would be $0
for a good reason termination.
|
|
(6)
|
|
Payable in cash following change in
control. Performance shares would be terminated.
|
|
(7)
|
|
This amount assumes the offer of
comparable employment is accepted; however, if offer of
comparable employment is not accepted then the amount is $0.
|
|
(8)
|
|
Assumes Mr. Paz remains
employed for at least 90 days following the change in
control.
|
|
(9)
|
|
Reimbursement for cost of
continuing health insurance under COBRA for 36 months after
termination for himself as well as his spouse and eligible
dependents under his employment agreement, as described above.
Also, Mr. Pazs right to reimbursement following
termination by the Company other than for cause or disability,
or by Mr. Paz for good reason, would end at such time as he
becomes eligible for group insurance from another employer.
Amounts calculated based on the current monthly cost for COBRA
for the highest cost options under our current health plans.
|
|
(10)
|
|
Payable if the comparable offer is
not accepted and employment is terminated.
|
|
(11)
|
|
Assumes termination of employment
agreement concurrent with change in control, either by the
Company without cause or by executive for good reason.
|
Employment
Agreements with Other Named Executive Officers
General Terms. On May 1, 2006, we entered
into executive employment agreements with several key
executives, including each of the named executive officers other
than Mr. Paz. These employment agreements are substantially
identical, except as indicated below. The initial employment
period under these agreements ran from May 1, 2006 through
March 31, 2007, and, under each of the agreements, is
automatically extended for successive one-year renewal periods
unless either party gives notice of non-renewal at least ninety
days prior to the end of the then current term. Neither party
under any of the agreements gave such notice prior to
March 31, 2007 termination date, and, as a result, each of
these agreement has been renewed through March 31, 2008;
provided, however, that Mr. Lowenbergs employment
with the Company, along with his employment agreement,
terminated as of March 1, 2008, and Mr. Stiftens
employment with the Company, along with his employment
agreement, are currently scheduled to terminate in April 2008.
Each employment agreement generally provides for:
|
|
|
|
|
the payment of an annual base salary, which may not be reduced
after any increase;
|
|
|
|
a guaranteed minimum annual bonus target equal to a fixed
percentage of the executives base salary pursuant to the
terms of our bonus plan;
|
|
|
|
participation in our employee benefit plans, other than bonus
and incentive plans, on the same basis as such plans are
generally made available to similarly situated senior executives;
|
|
|
|
the executives right to receive restricted stock, stock
options and other equity awards and deferred compensation, to
the extent determined by us, our board of directors or the
Compensation Committee from time to time;
|
|
|
|
the reimbursement of reasonable business expenses incurred by
the executive in performing his duties under the
agreement; and
|
|
|
|
such perquisites and fringe benefits to which similarly situated
executives are entitled and which are suitable for the
executives position.
|
The initial base salary and minimum bonus target amounts
(expressed as a percentage of base salary) for each of the
officers under the new agreements were:
|
|
|
|
|
for Mr. Stiften: $409,000 and 75% (currently $480,000 and
80%);
|
|
|
|
for Mr. Lowenberg: $482,000 and 75%;
|
34
|
|
|
|
|
for Mr. Boudreau: $411,000 and 65% (currently $500,000 and
70%); and
|
|
|
|
for Mr. Ignaczak: $289,000 and 50% (currently $450,000 and
75%).
|
Termination by Us for Cause or by Executive other than for
Good Reason or Retirement. If the
executives employment is terminated before the employment
period expires by us for cause, as defined in the
agreement, or by him other than for good reason or
retirement, as those terms are defined in the
agreement, he is not entitled to receive any further payments or
benefits that have not already been paid or provided, including
any unvested portion of the option grant or restricted stock
awards. However, he is entitled to the following accrued
rights:
|
|
|
|
|
all previously earned and accrued but unpaid base salary;
|
|
|
|
reimbursement for unreimbursed, properly incurred business
expenses; and
|
|
|
|
any employee benefits to which he may entitled, including with
respect to restricted stock, stock options and other equity
awards or deferred compensation, subject to the terms and
conditions of the applicable plan.
|
Termination by Us (other than for Cause or Disability) or for
Good Reason. If the executives employment
is terminated by us other than for cause or
disability, or by the executive for good
reason, as those terms are defined in the agreement, the
executive is entitled to receive:
|
|
|
|
|
the accrued rights referred to above;
|
|
|
|
any annual bonus earned for a prior completed year but unpaid as
of termination, payable to the extent the corporate bonus pool
is approved by the Compensation Committee;
|
|
|
|
subject to compliance with the restrictive covenants described
below, a severance benefit equal to 18 months of his annual
base salary plus 150% of a specified pro-rata portion of the
executives bonus potential for the year based on the
average percentage of the potential earned for the three prior
years (with a maximum of 100% for each of these years); and
|
|
|
|
reimbursement for the cost of continuing medical insurance under
COBRA for 18 months after termination of employment.
|
Termination due to Death, Disability or
Retirement. If the executives employment
terminates on account of death, disability or retirement, as
those terms are defined in the agreement, before the end of his
employment period, he (or his estate) generally is entitled to
receive:
|
|
|
|
|
the accrued rights referred to above; and
|
|
|
|
any annual bonus earned for a previously completed fiscal year
but unpaid as of the termination date, payable to the extent the
corporate bonus pool is approved by the Compensation Committee.
|
Post-Employment Restrictive Covenants. Upon
termination of employment, each executive is prohibited from:
|
|
|
|
|
soliciting certain clients or prospective clients for a period
of two years after termination;
|
|
|
|
soliciting or hiring any of our employees for a period of two
years after termination;
|
|
|
|
soliciting or encouraging not to work for us any consultant then
under contract with us for a period of two years;
|
|
|
|
competing with us for a period of eighteen months after
termination; or
|
|
|
|
disclosing certain confidential information or disparaging our
company.
|
Excise Tax
Gross-Up
Payment. If any benefit to be paid would result
in the executives liability for the payment of an excise
tax under Section 4999 of the Internal Revenue Code or any
similar state or local tax, we will make a
gross-up
payment to the executive to fully offset the excise tax provided
the aggregate present value of the amount of the benefit is
equal to or exceeds 125% of the maximum total payment which
could be made to the executive without triggering the excise
tax. If the aggregate present value of the amount of the benefit
exceeds such
35
maximum amount, but is less than 125% of such maximum amount,
then we may reduce the amount of the benefit so that no portion
of the benefit is subject to the excise tax, and no
gross-up
payment would be made.
Estimated Benefits. The tables below reflect
the amount of incremental compensation which would be paid to
each of Messrs. Boudreau, Lowenberg, Ignaczak and Stiften
upon the termination of his employment or upon a change in
control. These amounts assume that such termination or change in
control was effective as of December 31, 2007, and that the
price of our common stock upon which certain of the calculations
are made was the closing price of $73.00 per share on that date.
Accordingly, the computation of these amounts requires the
company to make certain estimates which are further described in
the description of the employment agreements above or in the
accompanying footnotes. Some of these amounts are payable
pursuant to the terms of the employment agreements while others
arise from the terms of the applicable grant
and/or
benefit plan. Those amounts payable pursuant to the employment
agreements generally require the executive to sign a general
release and to comply with certain contractual terms including
those related to noncompetition, nonsolicitation and
non-disparagement.
Because the incremental amount of payments to be made depend on
several factors, the actual amounts to be paid out upon
termination of employment or a change in control can only be
determined at the time of the event. The tables do not include
the nonqualified deferred compensation that would be paid, which
is set forth in the Nonqualified Deferred Compensation
Table above, except to the extent an individual is
entitled to an additional benefit as a result of the
termination. The estimated payments upon termination and change
in control are as follows:
EDWARD
STIFTEN
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Good Reason or
|
|
|
|
|
|
|
|
|
Change in Control(1)
|
|
|
|
|
Executive Benefits and
|
|
|
|
|
|
|
|
Involuntary Not
|
|
|
|
|
|
|
|
|
With Offer of
|
|
|
Without Offer of
|
|
|
|
|
Payments Upon
|
|
Voluntary
|
|
|
|
|
|
for Cause
|
|
|
For Cause
|
|
|
Death or
|
|
|
Comparable
|
|
|
Comparable
|
|
|
|
|
Termination
|
|
Termination
|
|
|
Retirement
|
|
|
Termination
|
|
|
Termination
|
|
|
Disability
|
|
|
Employment
|
|
|
Employment
|
|
|
|
|
|
Compensation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Severance Benefit
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
1,120,419
|
(2)
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
1,120,419
|
(2)(3)
|
|
|
|
|
Accrued but Unpaid Annual Bonus
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
|
|
Long-term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Performance Shares
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
821,119
|
(5)
|
|
|
0
|
|
|
|
821,119
|
(5)
|
|
|
1,663,524
|
(6)
|
|
|
1,663,524
|
(6)
|
|
|
|
|
Stock Options/SSARs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
4,894,789
|
|
|
|
4,894,789
|
|
|
|
4,894,789
|
|
|
|
|
|
Restricted Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
1,523,601
|
|
|
|
1,613,227
|
(7)
|
|
|
3,226,454
|
|
|
|
|
|
Deferred Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
100,731
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
|
|
Benefits:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Post-termination Health Care
|
|
|
0
|
|
|
|
0
|
|
|
|
23,186
|
(9)
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
23,186
|
(9)
|
|
|
|
|
Accrued Vacation/PTO
|
|
|
59,904
|
|
|
|
59,904
|
|
|
|
59,904
|
|
|
|
0
|
|
|
|
59,904
|
|
|
|
59,904
|
(10)
|
|
|
59,904
|
(11)
|
|
|
|
|
280G Tax
Gross-up
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
2,010,700
|
|
|
|
|
|
Total:
|
|
$
|
59,904
|
|
|
$
|
160,635
|
|
|
$
|
2,024,629
|
|
|
$
|
0
|
|
|
$
|
7,299,413
|
|
|
$
|
8,231,444
|
|
|
$
|
12,998,977
|
|
|
|
|
|
36
DAVID
LOWENBERG
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Good Reason or
|
|
|
|
|
|
|
|
|
Change in Control(1)
|
|
Executive Benefits and
|
|
|
|
|
|
|
|
Involuntary Not
|
|
|
|
|
|
|
|
|
With Offer of
|
|
|
Without Offer of
|
|
Payments Upon
|
|
Voluntary
|
|
|
|
|
|
for Cause
|
|
|
For Cause
|
|
|
Death or
|
|
|
Comparable
|
|
|
Comparable
|
|
Termination
|
|
Termination
|
|
|
Retirement
|
|
|
Termination
|
|
|
Termination
|
|
|
Disability
|
|
|
Employment
|
|
|
Employment
|
|
|
Compensation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Severance Benefit
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
1,114,000
|
(2)
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
1,114,000
|
(2)(3)
|
Accrued but Unpaid Annual Bonus
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
Long-term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Performance Shares
|
|
|
0
|
|
|
|
0
|
(6)
|
|
|
861,995
|
(5)
|
|
|
0
|
|
|
|
861,995
|
(5)
|
|
|
1,751,854
|
(6)
|
|
|
1,751,854
|
(6)
|
Stock Options/SSARs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
4,076,286
|
|
|
|
4,076,286
|
|
|
|
4,076,286
|
|
Restricted Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
873,567
|
|
|
|
828,915
|
(7)
|
|
|
1,657,830
|
|
Deferred Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(8)
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
(8)
|
|
|
0
|
|
|
|
0
|
|
Benefits:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Post-termination Health Care
|
|
|
0
|
|
|
|
0
|
|
|
|
23,186
|
(9)
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
23,186
|
(9)
|
Accrued Vacation/PTO
|
|
|
66,769
|
|
|
|
66,769
|
|
|
|
66,769
|
|
|
|
0
|
|
|
|
66,769
|
|
|
|
66,769
|
(10)
|
|
|
66,769
|
(11)
|
280G Tax
Gross-up
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
Total:
|
|
$
|
66,769
|
|
|
$
|
66,769
|
|
|
$
|
2,065,950
|
|
|
$
|
0
|
|
|
$
|
5,878,617
|
|
|
$
|
6,723,824
|
|
|
$
|
8,689,925
|
|
THOMAS
BOUDREAU
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Good Reason or
|
|
|
|
|
|
|
|
|
Change in Control(1)
|
|
Executive Benefits and
|
|
|
|
|
|
|
|
Involuntary Not
|
|
|
|
|
|
|
|
|
With Offer of
|
|
|
Without Offer of
|
|
Payments Upon
|
|
Voluntary
|
|
|
|
|
|
for Cause
|
|
|
For Cause
|
|
|
Death or
|
|
|
Comparable
|
|
|
Comparable
|
|
Termination
|
|
Termination
|
|
|
Retirement
|
|
|
Termination
|
|
|
Termination
|
|
|
Disability
|
|
|
Employment
|
|
|
Employment
|
|
|
Compensation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Severance Benefit
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
1,104,468
|
(2)
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
1,104,468
|
(2)(3)
|
Accrued but Unpaid Annual Bonus
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
Long-term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Performance Shares
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
563,601
|
(5)
|
|
|
0
|
|
|
|
563,601
|
(5)
|
|
|
1,183,746
|
(6)
|
|
|
1,183,746
|
(6)
|
Stock Options/SSARs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
2,945,392
|
|
|
|
2,945,392
|
|
|
|
2,945,392
|
|
Restricted Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
588,487
|
|
|
|
546,770
|
(7)
|
|
|
1,093,540
|
|
Deferred Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(8)
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
(8)
|
|
|
0
|
|
|
|
0
|
|
Benefits:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Post-termination Health Care
|
|
|
0
|
|
|
|
0
|
|
|
|
23,186
|
(9)
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
23,186
|
(9)
|
Accrued Vacation/PTO
|
|
|
43,063
|
|
|
|
43,063
|
|
|
|
43,063
|
|
|
|
0
|
|
|
|
43,063
|
|
|
|
43,063
|
(10)
|
|
|
43,063
|
(11)
|
280G Tax
Gross-up
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
Total:
|
|
$
|
43,063
|
|
|
$
|
43,063
|
|
|
$
|
1,734,347
|
|
|
$
|
0
|
|
|
$
|
4,140,544
|
|
|
$
|
4,718,972
|
|
|
$
|
6,392,425
|
|
37
EDWARD
IGNACZAK
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Good Reason or
|
|
|
|
|
|
|
|
|
Change in Control(1)
|
|
Executive Benefits and
|
|
|
|
|
|
|
|
Involuntary Not
|
|
|
|
|
|
|
|
|
With Offer of
|
|
|
Without Offer of
|
|
Payments Upon
|
|
Voluntary
|
|
|
|
|
|
for Cause
|
|
|
For Cause
|
|
|
Death or
|
|
|
Comparable
|
|
|
Comparable
|
|
Termination
|
|
Termination
|
|
|
Retirement
|
|
|
Termination
|
|
|
Termination
|
|
|
Disability
|
|
|
Employment
|
|
|
Employment
|
|
|
Compensation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Severance Benefit
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
824,720
|
(2)
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
824,720
|
(2)(3)
|
Accrued but Unpaid Annual Bonus
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
Long-term Incentives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Performance Shares
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
323,114
|
(5)
|
|
|
0
|
|
|
|
323,114
|
(5)
|
|
|
687,076
|
(6)
|
|
|
687,076
|
(6)
|
Stock Options/SSARs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
1,863,533
|
|
|
|
1,863,533
|
|
|
|
1,863,533
|
|
Restricted Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
0
|
(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
341,606
|
|
|
|
532,097
|
(7)
|
|
|
1,064,194
|
|
Deferred Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested & Accelerated
|
|
|
0
|
|
|
|
75,296
|
|
|
|
0
|
|
|
|
0
|
|
|
|
75,296
|
|
|
|
0
|
|
|
|
0
|
|
Benefits:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Post-termination Health Care
|
|
|
0
|
|
|
|
0
|
|
|
|
23,186
|
(9)
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
23,186
|
(9)
|
Accrued Vacation/PTO
|
|
|
37,642
|
|
|
|
37,642
|
|
|
|
37,642
|
|
|
|
0
|
|
|
|
37,642
|
|
|
|
37,642
|
(10)
|
|
|
37,642
|
(11)
|
280G Tax
Gross-up
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
Total:
|
|
$
|
37,642
|
|
|
$
|
112,938
|
|
|
$
|
1,208,662
|
|
|
$
|
0
|
|
|
$
|
2,641,192
|
|
|
$
|
3,120,348
|
|
|
$
|
4,500,351
|
|
|
|
|
(1)
|
|
See footnote 1 to the estimated
benefit chart for Mr. Paz on page 33 for a general
description of the definitions of change in control
and comparable employment under the 2000 LTIP. The
definitions of change in control and comparable employment
appear in Section 2 of the 2000 LTIP, which should be
reviewed for a complete statement of its terms.
|
|
(2)
|
|
Severance Benefit under the
executives employment agreement, equal to (a) 150% of
base salary, plus (b) 150% of specified portion of the
executives bonus potential for the year based on the
average percentage of the potential earned for the three prior
years, prorated for the portion of the calendar year completed
prior to termination. The Severance Benefit is payable in 18
substantially equal monthly installments beginning the first
full month after termination; provided that if the executive is
determined to be a specified employee in accordance with
Section 409A of the Internal Revenue Code, then the payment
such benefit shall be delayed six months to the extent required
under Section 409A.
|
|
(3)
|
|
Assumes termination of employment
agreement concurrent with change in control, either by us
without cause or by the executive for good reason.
|
|
(4)
|
|
The executive had not reached the
eligible retirement age as of December 31, 2007 for
retirement under either his employment agreement or the 2000
LTIP. If he were eligible for retirement, the payments would be
similar to those for death or disability.
|
|
(5)
|
|
Pro rated based on assumed award of
the targeted number of shares following end of relevant
performance periods. Payable in shares of our common stock
following the end of such periods. This amount is based on
involuntary not for cause termination; the amount would be $0
for a good reason termination.
|
|
(6)
|
|
Payable in cash following change in
control. Performance shares would be terminated.
|
|
(7)
|
|
This amount assumes the offer of
comparable employment is accepted; however, if offer of
comparable employment is not accepted then the amount is $0.
|
|
(8)
|
|
Mr. Boudreau and
Mr. Lowenberg became fully-vested in all of our
contributions to the EDCP prior to December 31, 2007 when
each satisfied the requirements for retirement under the EDCP
based upon his attainment of age 55 together with more than
10 years of service to our company.
|
|
(9)
|
|
Reimbursement for cost of
continuing health insurance under COBRA for 18 months after
termination. Amounts calculated based on the current monthly
cost for COBRA for the highest cost options under our current
health plans.
|
|
(10)
|
|
Payable if the comparable offer is
not accepted and employment is terminated.
|
|
(11)
|
|
Assumes termination of employment
agreement concurrent with change in control, either by us
without cause or by executive for good reason.
|
38
New
Employment Agreement with Mr. Paz
On April 1, 2008, we entered into the 2008 agreement with
Mr. Paz. The terms of the 2008 agreement are substantially
identical to the terms of the agreements with our other
executives, as described in Employment Agreements with
Other Named Executive Officers beginning on page 34,
except as follows:
|
|
|
|
|
the term of the 2008 agreement runs from April 1, 2008
through March 31, 2011 without renewal other than through
the mutual agreement of the parties;
|
|
|
|
Mr. Pazs initial base salary and minimum bonus target
under the 2008 agreement are $950,000 and 130%,
respectively; and
|
|
|
|
for any termination by us (other than for cause or disability)
or by Mr. Paz for good reason which, in either instance,
occurs within one year following a change in control,
Mr. Paz would be entitled to
|
|
|
|
|
|
all previously earned and accrued but unpaid base salary;
|
|
|
|
reimbursement for unreimbursed, properly incurred business
expenses;
|
|
|
|
any employee benefits to which he may entitled, including with
respect to restricted stock, stock options and other equity
awards or deferred compensation, subject to the terms and
conditions of the applicable plan;
|
|
|
|
any annual bonus earned for a prior completed year but unpaid as
of termination, payable to the extent the corporate bonus pool
is approved by the Compensation Committee;
|
|
|
|
subject to compliance with the restrictive covenants described
above, a severance benefit equal to 18 months of his annual
base salary plus 150% of the executives bonus potential
for the year (without pro-ration) based on the average
percentage of the potential earned for the three prior years
(with no maximum for each of these years); and
|
|
|
|
reimbursement for the cost of continuing medical insurance under
COBRA for 18 months after termination of employment.
|
VOTING
SECURITIES
On the Record Date there were approximately 253,000,000
outstanding shares of our common stock. Unless otherwise
provided, all references to shares of our common stock in this
proxy statement have been adjusted to reflect all of our
previous stock splits, including the three separate two-for-one
stock splits effective June 22, 2007, June 24, 2005
and June 22, 2001, each of which was effected in the form
of a stock dividend of one share for each outstanding share to
holders of record.
39
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table contains certain information regarding the
beneficial ownership of our common stock as of March 1,
2008 (unless otherwise noted) by (i) each person known by
us to own beneficially more than five percent of the outstanding
shares of our common stock, (ii) each of our directors and
nominees, (iii) each of our current or former executive
officers named in the Summary Compensation Table on
page 24, and (iv) all of our current executive
officers and directors as a group. The table includes shares
that may be acquired on March 1, 2008, or within
60 days of March 1, 2008, upon the exercise of stock
options by employees or outside directors. Unless otherwise
indicated, each of the persons or entities listed below
exercises sole voting and investment power over the shares that
each of them beneficially owns.
|
|
|
|
|
|
|
|
|
|
|
Shares Beneficially Owned
|
|
Name and Address
|
|
Number
|
|
|
Percent of Class(1)
|
|
|
George Paz(2)
|
|
|
1,025,372
|
|
|
|
*
|
|
Gary G. Benanav(3)
|
|
|
69,564
|
|
|
|
*
|
|
Frank J. Borelli(4)
|
|
|
233,212
|
|
|
|
*
|
|
Maura C. Breen(5)
|
|
|
6,332
|
|
|
|
*
|
|
Nicholas J. LaHowchic(6)
|
|
|
7,208
|
|
|
|
*
|
|
Thomas P. Mac Mahon(7)
|
|
|
46,332
|
|
|
|
*
|
|
Woodrow A. Myers(8)
|
|
|
10,930
|
|
|
|
*
|
|
John O. Parker, Jr.(9)
|
|
|
22,332
|
|
|
|
*
|
|
Samuel K. Skinner(10)
|
|
|
6,332
|
|
|
|
*
|
|
Seymour Sternberg(11)
|
|
|
42,780
|
|
|
|
*
|
|
Barrett A. Toan(12)
|
|
|
502,733
|
|
|
|
*
|
|
Howard L. Waltman(13)
|
|
|
178,332
|
|
|
|
*
|
|
David A. Lowenberg(14)
|
|
|
295,361
|
|
|
|
*
|
|
Thomas M. Boudreau(15)
|
|
|
186,390
|
|
|
|
*
|
|
Edward Stiften(16)
|
|
|
322,798
|
|
|
|
*
|
|
Edward Ignaczak(17)
|
|
|
76,217
|
|
|
|
*
|
|
Directors and Executive Officers as a Group (20 persons)(18)
|
|
|
3,329,348
|
|
|
|
1.32
|
%
|
New York Life Insurance Company;
NYLIFE, LLC(19)
|
|
|
40,000,000
|
|
|
|
15.82
|
%
|
|
|
|
*
|
|
Indicates less than 1%
|
|
(1)
|
|
Percentages based on
252,899,230 shares of common stock issued and outstanding
on March 1, 2008.
|
|
(2)
|
|
Consists of options for
607,084 shares and 160,257 SSARs granted under our 2000
Long Term Incentive Plan, or the 2000 LTIP and our
Amended and Restated 1992 and 1994 Stock Option Plans, which we
refer to collectively as, the Employee Stock Option
Plans, 167,349 shares owned by Mr. Paz, 60,950
restricted shares awarded under the 2000 LTIP, and 29,732
phantom shares representing fully-vested investments in the
Company Stock Fund under our Executive Deferred
Compensation Plan, or the EDCP. Excluded are 1,595
phantom shares representing unvested investments in the Company
Stock Fund under the EDCP.
|
|
(3)
|
|
Consists of options for
55,232 shares and 3,124 SSARs granted under the 2000 LTIP,
2,588 restricted shares awarded under the 2000 LTIP, and
8,620 shares owned by a trust established by
Mr. Benanav.
|
|
(4)
|
|
Consists of options for
224,000 shares and 3,124 SSARs granted under the 2000 LTIP,
2,588 restricted shares awarded under the 2000 LTIP, and
3,500 shares held in trusts for family members.
|
|
(5)
|
|
Consists of 3,124 SSARs granted
under the 2000 LTIP, and 2,588 restricted shares awarded under
the 2000 LTIP and 620 shares owned by Ms. Breen.
|
|
(6)
|
|
Consists of 4,620 shares owned
by Mr. LaHowchic and 2,588 restricted shares awarded under
the 2000 LTIP.
|
|
(7)
|
|
Consists of options for
40,000 shares and 3,124 SSARs granted under the 2000 LTIP,
and 2,588 restricted shares awarded under the 2000 LTIP, and
620 shares owned by Mr. Mac Mahon.
|
|
(8)
|
|
Consists of 8,800 shares owned
by Dr. Myers and 2,130 restricted shares awarded under the
2000 LTIP.
|
40
|
|
|
(9)
|
|
Consists of options for
16,000 shares and 3,124 SSARs granted under the 2000 LTIP,
and 2,588 restricted shares awarded under the 2000 LTIP, and
620 shares owned by Mr. Parker.
|
|
(10)
|
|
Consists of and 3,124 SSARs granted
under the 2000 LTIP, 2,588 restricted shares awarded under the
2000 LTIP, and 620 shares owned by Mr. Skinner.
|
|
(11)
|
|
Consists of options for
23,232 shares and 3,124 SSARs granted under the 2000 LTIP,
2,588 restricted shares awarded under the 2000 LTIP, and
13,836 shares owned by Mr. Sternberg, but excludes
760 shares held by Mr. Sternbergs son as to
which shares Mr. Sternberg disclaims beneficial ownership.
|
|
(12)
|
|
Consists of options for
291,200 shares and 3,124 SSARs granted under the Employee
Stock Option Plans, 2,588 restricted shares awarded under the
2000 LTIP, 159,268 shares owned by Mr. Toan, and
46,553 phantom shares representing fully-vested investments in
the Company Stock Fund under the EDCP.
|
|
(13)
|
|
Consists of options for
40,000 shares and 3,124 SSARs granted under the 2000 LTIP,
2,588 restricted shares awarded under the 2000 LTIP, and
132,620 shares owned by Mr. Waltman.
|
|
(14)
|
|
Consists of options for
15,132 shares and 59,613 SSARs granted under the Employee
Stock Option Plans, 14,941 restricted shares awarded under the
2000 LTIP, 175,030 shares owned by Mr. Lowenberg, and
30,645 phantom shares representing fully-vested investments
in the Company Stock Fund under the EDCP. Excluded are
1,650 shares held by Mr. Lowenbergs minor
children, as to which Mr. Lowenberg disclaims beneficial
ownership.
|
|
(15)
|
|
Consists of options for
38,432 shares and 38,974 SSARs granted under the Employee
Stock Option Plans, 15,623 restricted shares awarded under the
2000 LTIP, 70,015 shares owned by Mr. Boudreau, and
23,346 phantom shares representing fully-vested investments
in the Company Stock Fund under the EDCP. Excluded are
650 shares held by Mr. Boudreaus spouse, as to
which Mr. Boudreau disclaims beneficial ownership.
|
|
(16)
|
|
Consists of options for
187,238 shares and 56,789 SSARs granted under the 2000
LTIP, 28,246 restricted shares awarded under the 2000 LTIP, and
50,106 shares owned by Mr. Stiften and 419 phantom
shares representing fully-vested investments in the Company
Stock Fund under the EDCP. Excluded are 714 phantom shares
representing unvested investments in the Company Stock Fund
under the EDCP.
|
|
(17)
|
|
Consists of options for
10,050 shares and 22,344 SSARs granted under the 2000 LTIP,
17,023 restricted shares awarded under the 2000 LTIP,
25,571 shares owned by Mr. Ignaczak, and 1,229 phantom
shares representing fully-vested investments in the Company
Stock Fund under the EDCP. Excluded are 647 phantom shares
representing unvested investments in the Company Stock Fund
under the EDCP.
|
|
(18)
|
|
Consists of options for
1,690,552 shares and 438,657 SSARs granted under the
Outside Directors Plan and the Employee Stock Option Plans,
859,395 shares owned by directors and officers as a group,
207,674 restricted shares awarded under the 2000 LTIP, and
133,070 phantom shares representing fully-vested investments in
the Company Stock Fund under the EDCP. Excluded are 4,318
phantom shares representing unvested investments in the Company
Stock Fund under the EDCP.
|
|
(19)
|
|
The information with respect to the
beneficial ownership of these shares as of December 31,
2007 has been obtained from a copy of an Amendment No. 8 to
Schedule 13G filed February 13, 2008. Such filing
reports that the beneficial owner, New York Life Insurance
Company, or New York Life shares voting power with
respect to all of the shares reported, but has sole dispositive
power as to all of the shares reported, and that NYLIFE, LLC, or
NYLife, a subsidiary of New York Life, owns
18,000,000 of such shares. In August 2001, NYLife entered into a
ten-year forward sale contract with respect to 18,000,000 of the
shares of common stock, and, in April 2003 New York Life entered
into a five-year forward sale contract , which matures on
April 28, 2008, with respect to 22,000,000 of the shares of
common stock. Absent the occurrence of certain accelerating
events, New York Life or NYLife, as applicable, retains the
right to vote the shares subject to such forward sale contracts,
but is subject to restrictions on the transfer of such shares.
The address for New York Life and NYLife is 51 Madison Avenue,
New York, NY 10010. Mr. Sternberg, one of our directors, is
also a director and holds various executive positions with New
York Life, as described herein, and Mr. Benanav, one of our
directors, was also a director and held various executive
positions with New York Life, as described herein, prior to his
retirement from New York Life in March 2005. Mr. Sternberg
and Mr. Benanav have both disclaimed beneficial ownership
of the shares owned by New York Life or its subsidiaries.
|
41
SECURITIES
AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION
PLANS
The following table summarizes information as of
December 31, 2007 relating to our equity compensation plans
under which equity securities are authorized for issuance:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of securities
|
|
|
|
|
|
|
|
|
|
remaining available for
|
|
|
|
|
|
|
Weighted-average
|
|
|
future issuance under
|
|
|
|
Number of securities to be
|
|
|
exercise price of
|
|
|
equity compensation
|
|
|
|
issued upon exercise of
|
|
|
outstanding
|
|
|
plans (excluding
|
|
|
|
outstanding options,
|
|
|
options, warrants,
|
|
|
securities reflected
|
|
|
|
warrants and rights
|
|
|
rights
|
|
|
in column (a))
|
|
Plan Category
|
|
(a)
|
|
|
(b)
|
|
|
(c)
|
|
|
Equity Compensation Plans approved by security holders
|
|
|
8,547,740
|
(1)
|
|
$
|
27.22
|
(2)
|
|
|
15,113,699
|
(3)
|
Equity Compensation Plans not approved by security holders
|
|
|
0
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
8,547,740
|
(1)
|
|
$
|
27.22
|
(2)
|
|
|
15,113,699
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Includes shares which were issued
under our Employee Stock Purchase Plan for the month of January
2008. Does not include restricted stock or performance shares
awarded since December 31, 2007.
|
|
(2)
|
|
Shares allocated to the EDCP and
shares which were issued for the month of January 2008 under our
Employee Stock Purchase Plan are not included in the weighted
average computation.
|
|
(3)
|
|
The number of shares available for
distribution under the 2000 LTIP is increased by any shares made
available as a result of forfeitures of awards made under the
2000 LTIP, or any of our Amended and Restated 1992 Stock Option
Plan, Amended and Restated 1994 Stock Option Plan or Amended and
Restated 1992 Stock Option Plan for Outside Directors. Includes
11,934,975 shares remaining available for future issuance
under the 2000 LTIP. The 2000 LTIP provides for the issuance of
restricted stock awards and a portion of these remaining shares
will likely be issued as restricted stock awards. Does not
include the 1,500,000 million additional shares that would
be authorized for issuance under the Employee Stock Purchase
Plan following stockholder approval and ratification of such
increase in the number of shares at the meeting. See
III. Approve and Ratify an Increase in the Number of
Shares of the Companys Common Stock Authorized for
Issuance Under the Express Scripts, Inc. Employee Stock Purchase
Plan from 2,000,000 Shares to 3,500,000 Shares
for further information regarding this proposal.
|
REPORT OF
THE AUDIT COMMITTEE
The Audit Committee of Express Scripts, Inc. is composed of four
directors who, in the judgment of our board of directors, meet
the independence requirements of the Nasdaq Global Select
Market. Since 1992 the Audit Committee has operated under a
Charter adopted by our board of directors. The Charter, as
amended, is available through the Investor
Information section of our website at
www.express-scripts.com. The primary function of the
Audit Committee is to assist our board of directors in its
oversight of the integrity of our companys financial
reporting processes and system of internal controls with respect
to finance and accounting. Management is responsible for our
financial statements and overall reporting process, including
the system of internal controls. The independent registered
public accountants are responsible for conducting annual audits
and quarterly reviews of our financial statements and expressing
an opinion as to the conformity of the annual financial
statements with generally accepted accounting principles.
The Audit Committee submits the following report pursuant to the
Securities and Exchange Commission rules:
|
|
|
|
|
The Audit Committee has reviewed and discussed with management
and with PricewaterhouseCoopers LLP, or PwC, our
companys independent registered public accountants, the
audited consolidated financial statements of our company for the
year ended December 31, 2007 (the Financial
Statements).
|
|
|
|
PwC has advised the management of our company and the Audit
Committee that it has discussed with them all the matters
required to be discussed by Statement of Accounting Standards
114, as modified, as adopted by the Public Company Accounting
Oversight Board, or PCAOB, in Rule 3200T, which
include among other items, matters related to the conduct of the
audit of the Financial Statements.
|
42
|
|
|
|
|
The Audit Committee has received from PwC the written
disclosures and the letter required by Independent Standards
Board Standard No. 1 (which relates to the auditors
independence from our company and its related entities), as
adopted by the PCAOB in Rule 3600T, and has discussed
PwCs independence with them.
|
|
|
|
Based upon the aforementioned review, discussions and
representations of PwC, and the unqualified audit opinion
presented by PwC on the Financial Statements, the Audit
Committee recommended to the board of directors that the
Financial Statements be included in our Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007 for filing with
the SEC.
|
Respectfully submitted,
Frank Borelli, Chairman
Maura C. Breen
Nicholas J. LaHowchic
John O. Parker, Jr.
The Report of the Audit Committee will not be deemed
incorporated by reference by any general statement incorporating
by reference this proxy statement or portions thereof into any
filing under the Securities Act of 1933 or the Securities
Exchange Act of 1934, except to the extent that we specifically
incorporate this information by reference, and will not
otherwise be deemed filed under such Acts.
SECTION 16(a)
BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934
requires our directors and executive officers, persons who
beneficially own more than ten percent of a registered class of
our equity securities, and certain other persons to file reports
of ownership and changes in ownership on Forms 3, 4 and 5
with the Securities and Exchange Commission (SEC)
and Nasdaq, and to furnish the Company with copies of the forms.
Based solely on our review of the forms we received or filed
with the SEC, or written representations from reporting persons,
we believe that all of our directors, executive officers and
greater than ten percent beneficial owners complied with all
such filing requirements during 2007. However, we have
determined that Michael Holmes did not timely file a report with
respect to the purchase of 4,000 shares (split-adjusted) of
our stock on May 11, 2006, and that Thomas Boudreau did not
timely file a report with respect to the sale of 150 shares
of our stock by his spouse on January 2, 2008.
CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Relationship
with New York Life
Stock Ownership. New York Life currently owns
40,000,000 shares (or approximately 15.8%) of our
outstanding common stock, based on Amended Statement of
Ownership on Schedule 13G filed February 13, 2008.
In August 2001, New York Life and its subsidiary NYLIFE, LLC, or
NYLife entered into a ten-year forward sale contract
with an affiliate of Credit Suisse First Boston Corporation, or
CSFB, with respect to 18,000,000 of its shares of
our common stock, and, in April 2003, New York Life entered into
a five-year forward sale contract with CSFB and one of
CSFBs affiliates with respect to 22,000,000 of its shares
of our Common Stock. New York Life has reported that, absent the
occurrence of certain accelerating events, it will retain the
right to vote the shares under the forward sale contracts, or
the Forward Sale Shares, during the term of each
forward sale contract.
Stockholder and Registration Rights
Agreement. We are a party to a Stockholder and
Registration Rights Agreement with New York Life. The rights
agreement was originally entered into in connection with the
November 2000 offering of a portion of the shares of our common
stock then held by New York Life. The principal terms of this
agreement are as follows:
Rights Regarding the Board of Directors. The
rights agreement originally provided New York Life with the
right to designate for nomination two directors to our board of
directors as long as the aggregate number of shares of our
common stock held by New York Life and its non-investment
subsidiaries exceeded certain minimum levels. As
43
a result of a series of transactions involving the shares held
by New York Life and its affiliates completed during 2003, New
York Lifes nomination right was reduced to one, and,
following certain transactions completed during 2006 New York
Lifes nomination right was eliminated. Under the terms of
the rights agreement, New York Lifes nomination right
cannot be resurrected.
Registration Rights. As long as New York Life
and its non-investment subsidiaries, in the aggregate,
beneficially hold more than 12,000,000 shares of our common
stock, New York Life may request that we effect up to three
registrations of all or part of such shares with the SEC. One of
these registrations may be requested to be effected as a
shelf registration (allowing registration prior to
the actual offering), and two of these registrations may be
requested to be effected as firm underwritten offerings under
the Securities Act of 1933. We are not obligated to file a
registration statement at the request of New York Life:
(1) within a period of 90 days after the effective
date of any other registration statement filed by us (other than
a registration statement concerning employee benefit plans); or
(2) while a registration statement relating to a shelf
registration filed at the request of New York Life is effective
under the Securities Act. In addition, so long as New York Life
and its non-investment subsidiaries, in the aggregate,
beneficially hold in excess of 12,000,000 shares of the
common stock, if we propose to register shares of common stock
for our account under the Securities Act (other than a
registration concerning employee benefit plans), New York Life
will have piggy-back rights with respect to such registration.
The underwriters of any such offering have the right to limit
the number of shares included by New York Life in any such
registration if the managing underwriter indicates that, in its
opinion, the number of shares to be included by New York Life
would adversely affect the offering. We would bear the expenses
of any registration described in this paragraph.
Voting of Common Stock. New York Life and its
subsidiaries have agreed to vote any shares of our common stock
held by them in favor of the slate of nominees for the our Board
of Directors recommended by us. However, this voting requirement
does not apply to any of the Forward Sale Shares held by third
parties and which New York Life would have to recall in order to
vote, provided that (i) New York Life gives us notice
indicating that such shares are being held by third parties, and
(ii) we do not require New York Life to nonetheless recall
such shares. We do not presently intend to call for the recall
of such shares to be voted at the meeting.
Term. The Stockholder and Registration Rights
Agreement will terminate on the earlier of:
(1) November 7, 2008 or (2) at such time as New
York Life and its non-investment subsidiaries, in the aggregate,
own less than 12,000,000 shares of our common stock.
Other Relationships and Transactions. Pursuant
to agreements with New York Life, we provide pharmacy benefit
management services to employees and retirees of New York Life
and certain New York Life health insurance policyholders. During
2007, we derived approximately $35 million, or 0.19% of our
total revenues for 2007, from all services provided to New York
Life.
Our 401(k) and deferred compensation plans are administered by
affiliates of New York Life, which collected approximately
$1.1 million for such services.
Transactions
With Related Persons Policies and
Procedures
Our Corporate Governance Committee is responsible for reviewing
and approving all material transactions with any related
persons. This obligation is set forth in our Corporate
Governance Committees Charter. A copy of the Corporate
Governance Committee Charter is available in the Investor
Information section of our website at www.express-scripts.com
under the Corporate Governance Documents.
(Information on our website does not constitute part of this
registration statement).
To identify related person transactions, each year we submit and
require our directors and officers to complete director and
officer questionnaires identifying any transactions with us in
which the officer or director or their family members have a
material interest. We review related party transactions due to
the potential for a conflict of interest. Our Code of Ethics and
Corporate Code Business Conduct require all directors, officers
and employees who may have a conflict of interest to promptly
notify our General Counsel, Board, Compliance Committee or Chief
Compliance Officer.
We expect our directors, officers and employees to act and make
decisions that are in our best interests and encourage them to
avoid situations which present a conflict between our interests
and their own personal interests. In addition, we are strictly
prohibited from extending personal loans to, or guaranteeing the
personal loans of, any director or officer. A copy of our Code
of Ethics is available in the Investor Information section of
our website at www.express-scripts.com. (Information on our
website does not constitute part of this proxy statement).
44
II.
PROPOSAL TO APPROVE AND RATIFY AN AMENDMENT TO
THE EXPRESS SCRIPTS, INC. AMENDED AND RESTATED CERTIFICATE OF
INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES
OF THE COMPANYS COMMON STOCK FROM 650,000,000 SHARES TO
1,000,000,000 SHARES
The board of directors has unanimously adopted, and proposes
that the stockholders approve and ratify, an amendment to
Article 4 of our Amended and Restated Certificate of
Incorporation (the Certificate of Incorporation)
which, if adopted, would increase the number of authorized
shares of our common stock from 650,000,000 to
1,000,000,000 shares.
At March 31, 2008 there were approximately [253,000,000]
authorized shares of the Companys Common Stock
outstanding. Of the remaining unissued shares, approximately
[25,200,000] were reserved for issuance under the Companys
stock option, employee stock purchase and deferred compensation
plans, leaving a balance of approximately 372,000,000
authorized, unissued and unreserved shares of common stock.
Without the approval of additional shares, the Board would be
unable to authorize a
3-for-1
stock split, or authorize a
2-for-1
stock split while retaining a sufficient number of unissued
shares.
The board believes it is in the best interest of the Company to
increase the number of authorized shares of our common stock in
order to give us greater flexibility in considering and planning
for future business needs. The shares of common stock will be
available for issuance by the board of directors for various
corporate purposes, including but not limited to, stock splits,
stock dividends, grants under employee stock plans, financings,
corporate mergers and acquisitions and other general corporate
transactions. The Company has no current plan, commitment,
arrangement, understanding or agreement regarding the issuance
of the additional shares of common stock resulting from the
proposed increase in authorized shares. However, the board may
consider the issuance of additional shares in a stock split or a
stock dividend in the future, dependent upon then-existing
market conditions and other factors. Having this additional
authorized common stock available for future use will allow the
Company to issue additional shares without the expense and delay
of arranging a special meeting of stockholders. The additional
authorized shares would be available for issuance at the
discretion of the Board and without further stockholder
approval, except as may be required by law or the rules of The
Nasdaq Stock Market.
The issuance of additional shares of common stock could have the
effect of making it more difficult for a third party to acquire
control of the Company, or of discouraging a third party from
attempting to acquire control of the Company. Management of the
Company is not currently aware of any plans on the part of a
third party to attempt to effect a change of control of the
Company, and the amendment has been proposed for the reasons
discussed above and not for any possible anti-takeover effects
it could have.
The proposed additional shares of common stock would be part of
the existing class of common stock and would have the same
rights and privileges as the shares of common stock presently
outstanding.
Article 4 of the Certificate of Incorporation also
authorizes the issuance of 5,000,000 shares of preferred
stock, none of which are currently outstanding. The proposed
amendment will not increase or otherwise affect the authorized
preferred stock.
If the amendment to increase the number of authorized shares of
common stock is approved, the first sentence of the first
paragraph of Article 4 of the Certificate of Incorporation
will be amended to read in its entirety as follows:
4. The total number of shares of stock which the
Corporation has authority to issue is 1,005,000,000 shares,
of which (i) 5,000,000 shares are preferred stock, par
value $0.01 per share (the Preferred Stock), and
(ii) 1,000,000,000 shares are common stock, par value
$0.01 per share.
If the proposed amendment is approved, we will file an amendment
to the Certificate of Incorporation as soon as practicable after
the meeting.
Approval of this proposal requires the affirmative vote of a
majority of the outstanding shares of common stock entitled to
vote at the Meeting. Accordingly, abstentions and non-votes will
have the effect of votes against this proposal.
The board of directors unanimously recommends a vote FOR the
approval and ratification of the proposed amendment to the
Amended and Restated Certificate of Incorporation to increase
the number of authorized shares of the Companys Common
Stock from 650,000,000 shares to
1,000,000,000 shares.
45
III. PROPOSAL TO
APPROVE AND RATIFY AN INCREASE IN THE NUMBER OF SHARES OF
THE COMPANYS COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER
THE
EXPRESS SCRIPTS, INC. EMPLOYEE STOCK PURCHASE PLAN
FROM 2,000,000 SHARES TO 3,500,000 SHARES
We are asking the Companys stockholders to approve and
ratify an amendment to the Express Scripts, Inc. Employee Stock
Purchase Plan (the ESPP) which increases the maximum
number of shares of common stock authorized for issuance under
the ESPP from 2,000,000 to 3,500,000. The ESPP was originally
adopted by the Companys Board of Directors on
November 24, 1998 and approved by our stockholders on
May 26, 1999. The ESPP has since been amended by the board
or its Compensation and Development Committee, which we refer to
as the Committee, most recently on February 20, 2008. The
most recent amendment included an increase in the number of
shares of our common stock issuable under the plan from
2,000,000 to 3,500,000, subject to stockholder approval. If
stockholder approval is not obtained, no shares may be issued
beyond the 2,000,000 previously authorized, and such increase
will become void and of no force and effect.
Currently, 2,000,000 shares of the Companys common
stock are authorized for issuance under the ESPP, after taking
into account stock splits. Of these shares,
[1,850,000] shares have previously been purchased and
[150,000] shares remain available for purchase in the
current and future offering periods under the ESPP. The amended
and restated ESPP you are being asked to approve will increase
the maximum number of shares of common stock authorized for
issuance under the ESPP by 1,500,000, to 3,500,000 shares.
These additional shares may be newly issued by the Company or
may be purchased in the open market or from private sources.
Based on historical activity within the ESPP by our employees,
all, or nearly all, of the remaining shares will likely be
utilized within the next twelve months. Increasing the number of
shares authorized for issuance under the ESPP is necessary to
allow us to continue to offer participation in the ESPP to our
employees beyond that time. The board believes that the ESPP is
an important benefit to our eligible employees, and that it
provides added incentive to them through stock ownership in our
Company.
Summary
Description of the ESPP
The essential features of the ESPP are summarized below. This
summary does not purport to be a complete description of all the
provisions of the ESPP and is subject to and qualified in its
entirety by reference to the complete text of the amended and
restated ESPP, which is set forth as Exhibit A to this
proxy statement.
General. The purpose of the ESPP is to provide
employees of the Company and its designated subsidiaries with an
opportunity to purchase common stock of the Company through
accumulated payroll deductions during the offering periods under
the ESPP. The ESPP is intended to qualify as an Employee
Stock Purchase Plan under Section 423 of the Internal
Revenue Code of 1986, as amended (the Code).
Administration. The board has designated the
Committee to be responsible for the administration of the ESPP.
In connection with this responsibility, the Committee has the
authority to:
|
|
|
|
|
adopt, amend, and rescind any rules deemed desirable and
appropriate for the administration of the ESPP and not
inconsistent with the ESPP;
|
|
|
|
construe and interpret the ESPP; and
|
|
|
|
make all other determinations necessary or advisable for the
administration of the ESPP.
|
The board may amend or terminate the ESPP at any time in
accordance with the terms of the ESPP. However, stockholder
approval is required for any amendment that increases the
maximum number of shares issuable under the ESPP or if such
approval is otherwise necessary under any applicable law or
regulation.
Eligibility and Participation. Employees,
other than senior executives of the Company (as determined by
the Committee), who are customarily employed by the Company or a
designated subsidiary of the Company at least 20 hours per
week and more than five months per year and who have been
continuously employed by the Company or a designated subsidiary
for at least 31 days are eligible to participate in the
ESPP. As of March 31, 2008,
46
approximately 11,000 employees are eligible to participate
in the ESPP. None of the Companys Named Executive Officers
are eligible to participate in the ESPP.
Enrollment; Offering Periods; Payroll
Deductions. Participating employees may enroll in
the ESPP through such procedures as the Company may provide from
time to time, which may include enrollment through the plan
recordkeeper, which may be a third-party vendor selected by the
Company to administer the ESPP. Upon enrolling in the ESPP, each
participating employee is deemed to have authorized the
establishment of a brokerage account in his or her name at a
securities brokerage firm, which will serve as the custodial
agent for the purpose of holding shares purchased by a
participating employee under the ESPP.
The ESPP consists of a series of Offering Periods,
or one-month periods commencing on the first day of each month.
These Offering Periods are grouped into quarterly participation
periods which commence on January 1, April 1, July 1
and October 1 of each year, or at such other time or times as
may be determined by the board.
Participating employees may elect to have payroll deductions of
between one percent (1%) and ten percent (10%) of their
compensation credited to the participating employees
brokerage account each pay period during a participation period.
For the purposes of the ESPP, compensation includes all regular
straight time gross earnings, overtime earnings, bonuses and
commissions, without any reductions for contributions to the
Companys 401(k) plan. A participating employee may
increase or decrease payroll deductions at any time through such
procedures as may be provided by the Company from time to time
or through the plan recordkeeper, although such changes will not
be effective until the pay period following the changes. The
board or the Committee, may limit the number of participation
rate changes during any participation period or Offering Period
and may, in its discretion, require up to five business days
prior written notice. A participating employee may not make any
additional payments into his or her brokerage account and there
are limits placed on a participating employees ability to
make contributions to the ESPP that might jeopardize the
ESPPs status as an Employee Stock Purchase
Plan under Section 423 of the Code.
Purchase Price; Vesting of Options. On the
first business day of each Offering Period, each participating
employee is deemed to have been granted an option to purchase
shares of common stock at the end of the Offering Period. The
purchase price is equal to 95% of the closing sale price of the
common stock as traded on the Nasdaq Global Select Market on the
last day of the Offering Period, or if common stock is not
traded on such date, the trading day immediately preceding the
last day of the Offering Period. The closing sale price of a
share of common stock on March 31, 2008, as reported by the
Nasdaq Global Select Market, was $64.32. Options granted during
an Offering Period will vest on the last day of the Offering
Period and, unless a participating employee withdraws from the
ESPP, his or her option for the purchase of shares will be
exercised automatically upon vesting. A participating employee
shall have no interest or voting rights in common stock covered
by his or her option until such options have been exercised.
Upon exercise, the maximum number of whole shares subject to
such option are purchased at the applicable purchase price with
the accumulated contributions in each participating
employees brokerage account, subject to the limitations in
the ESPP. As promptly as practicable following the last day of
each Offering Period, the Company arranges for the delivery of
the shares purchased by the participating employee upon exercise
into the participating employees brokerage account. Any
cash remaining in the participating employees brokerage
account, other than amounts representing fractional shares, is
returned to the participating employee as soon as practicable.
Amounts representing fractional shares will be carried forward
for use in subsequent purchases. All participating employees
must hold shares purchased under the ESPP for at least six
months, unless the Board or the Committee otherwise determines.
Subject to the limitations of the ESPP and
Section 423(b)(8) of the Code, all cash dividends, if any,
paid with respect to shares of common stock purchased under the
ESPP and held in the participating employees brokerage
account are automatically invested in shares of common stock
purchased at 100% of fair market value on the last day of the
Offering Period.
No participating employee may purchase more than 333 shares
during any Offering Period. Furthermore, a participating
employee may not be granted an option during an Offering Period
if, as a result, the participating employee would own stock
and/or hold
outstanding options to purchase stock representing five percent
(5%) or more of the total combined voting power or value of all
classes of stock of the Company or any subsidiary of the
Company, or such option would permit his or her rights to
purchase stock under all employee stock purchase plans
47
of the Company and its subsidiaries to accrue at a rate which
exceeds $25,000 of the fair market value of such stock
determined at the time such option is granted, for each calendar
year in which such option is outstanding at any time.
Withdrawal; Termination of Employment. A
participating employee may withdraw from participation in the
ESPP at any time up to the fifth business day prior to the last
day of an Offering Period through such procedures as the Company
may provide from time to time including through the plan
recordkeeper. In the event of such withdrawal from the ESPP, the
participating employee may not make any further contributions
during the participation period in which the participating
employee withdrew and, if the participating employee requests,
all of the participating employees prior contributions
which were credited to his or her account and have not been used
to purchase shares of common stock will be paid to him or her as
soon as practicable after the end of the Offering Period.
Otherwise, such contributions will be used to purchase shares of
common stock under the ESPP on the last day of the Offering
Period. The participating employee may re-enroll in the ESPP the
next participation period.
In the event a participating employee ceases to be an employee
of the Company prior to the last day of an Offering Period for
any other reason, including death or retirement, the
contributions credited to his or her account and not yet applied
to the purchase of common stock, will be applied to the purchase
of common stock under the ESPP on the last day of the Offering
Period.
Transfer Restrictions. A participating
employee cannot assign, transfer, pledge or otherwise dispose
of, any contributions credited to his or her account or any
rights with regard to the participating employees exercise
of the option under the ESPP.
Adjustments. Subject to any required
stockholder approval, the board or Committee is authorized to
adjust the number of shares of common stock reserved for
issuance under the ESPP, as well as the price per share of
common stock covered by each option under the ESPP which has not
been exercised, in connection with any stock split, reverse
stock split, stock dividend, combination or reclassification of
the common stock, or any similar changes in the Companys
capitalization.
Corporate Events. In the event of a proposed
dissolution or liquidation of the Company, the Offering Period
will terminate immediately prior to the consummation of such
event, unless the board otherwise provides. In the event of a
proposed sale of all or substantially all of the assets of the
Company, or the merger of the Company into another corporation,
each option under the ESPP shall be assumed or an equivalent
option shall be substituted by such successor corporation or a
parent or subsidiary of such successor corporation, unless the
board determines, in its sole discretion, to shorten the
Offering Period by setting a new date upon which a participating
employees option will be exercised.
Federal Income Tax Consequences. As previously
noted, the ESPP is intended to qualify as an Employee
Stock Purchase Plan under Section 423 of the Code.
The following discussion summarizes the material federal income
tax consequences to the Company and the participating employees
in connection with the ESPP under existing applicable provisions
of the tax laws, regulations and rulings. The discussion is
general in nature and does not address issues relating to the
income tax circumstances of any individual employee. The
discussion is based on federal income tax laws in effect on the
date of this proxy statement and is, therefore, subject to
possible future changes in the law, regulations and rulings. The
discussion does not address the consequences of state, local or
foreign tax laws.
A participating employee is not taxed at the time of the grant
of his or her option, which we refer to in this discussion as a
stock purchase right. The employee is not taxed when shares are
purchased under the ESPP, even though they are purchased at 95%
of the market price on the purchase date.
If shares are sold or otherwise disposed of after the expiration
of two years or more from the first day of the Offering Period
in which such shares were purchased under the ESPP (the
Grant Date) and one year or more from the purchase
date, or in the event of the participants death prior to
disposing of shares purchased under the ESPP, the employee (or
the employees estate in the event of death) is required to
recognize ordinary income equal to the lesser of: (i) the
excess of the fair market value of the common stock on the date
of grant of the stock purchase right over the exercise price of
the stock purchase right, determined calculating the discount as
of the Grant Date, and (ii) the excess of the amount
realized on the disposition of the stock over the exercise price
of the stock purchase
48
right. Any additional gain or loss recognized on the disposition
of the stock is treated as long-term capital gain or loss, as
applicable. Shares sold or otherwise disposed of, including by
way of gifts, before the expiration of two years from Grant Date
or one year or more from the purchase date are considered
disqualifying dispositions. If the employee disposes of shares
prior to the expiration of two years from the Grant Date or
prior to the expiration of one year from the purchase date
(A) the difference between the price paid by the employee
and the fair market value of the shares at the date of purchase
is taxable as ordinary income, and (B) the difference
between the amount received by the employee upon disposition of
the shares and the fair market value of the shares at the date
of purchase is treated as a capital gain or loss (long-term
capital gain or loss if the shares have been held more than one
year).
The amount that a participant elects to have deducted from his
or her compensation for the purchase of Common Stock under the
ESPP constitutes taxable wages and is subject to withholding.
The Company will require any affected employee to make
arrangements to satisfy any withholding obligation.
The Company is not subject to any tax consequences due to the
offering of Common Stock under the ESPP. Moreover, in general,
the Company is not subject to any tax consequences due to the
purchase or the sale of Common Stock acquired under the ESPP.
However, the Company will be entitled to a business-expense
deduction with respect to any ordinary compensation income
recognized by a participant upon making a disqualifying
disposition. Any such deduction will be subject to the
limitations of Section 162(m) of the Code.
Participation in and amount of payroll deductions under the ESPP
are at the election of the eligible employee. Accordingly, the
dollar value and number of shares that may be granted are not
determinable.
The board of directors unanimously recommends a vote FOR the
approval and ratification of an increase in the number of shares
of the companys common stock authorized for issuance under
the Express Scripts, Inc. Employee Stock Purchase Plan from
2,000,000 shares to 3,500,000 shares.
49
IV. RATIFICATION
OF APPOINTMENT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTANTS
The firm of PricewaterhouseCoopers LLP served as our independent
registered public accountants for the year ended
December 31, 2007. The Audit Committee of the board of
directors has appointed PricewaterhouseCoopers LLP to act in
that capacity for the year ending December 31, 2008. A
representative of PricewaterhouseCoopers LLP is expected to be
present at the annual meeting with the opportunity to make a
statement if he or she desires to do so and to be available to
respond to appropriate questions from stockholders.
Although we are not required to submit this appointment to a
vote of the stockholders, the Audit Committee continues to
believe it appropriate as a matter of policy to request that the
stockholders ratify the appointment of PricewaterhouseCoopers
LLP as principal independent registered public accountants. If
the stockholders do not ratify the appointment, the Audit
Committee will investigate the reasons for stockholder rejection
and consider whether to retain PricewaterhouseCoopers LLP or
appoint another auditor. Even if the appointment is ratified,
the Audit Committee in its discretion may direct the appointment
of a different independent auditor at any time during the year
if it determines that such a change would be in the best
interests of our company and our stockholders.
Principal
Accountant Fees
The following table presents fees for professional services
rendered by PricewaterhouseCoopers LLP for the audit of our
annual financial statements for the years ended
December 31, 2006 and December 31, 2007, as well as
fees billed for other services rendered by
PricewaterhouseCoopers LLP during those periods:
|
|
|
|
|
|
|
|
|
|
|
2006
|
|
|
2007
|
|
|
Audit fees(1)
|
|
$
|
2,448,226
|
|
|
$
|
1,448,893
|
|
Audit-related fees(2)
|
|
|
|
|
|
|
22,095
|
|
Tax fees
|
|
|
|
|
|
|
|
|
All other fees(3)
|
|
|
1,500
|
|
|
|
1,500
|
|
|
|
|
|
|
|
|
|
|
Total Fees
|
|
$
|
2,449,726
|
|
|
$
|
1,472,488
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Audit fees are fees paid for
professional services rendered for the audit of our annual
consolidated financial statements, for reviews of our interim
consolidated financial statements, and for the audit of internal
controls over financial reporting. Audit fees also include fees
for work generally only the independent auditor can be expected
to provide such as services associated with documents filed with
the SEC and with assistance in responding to SEC comment
letters, as well as reports on internal control reviews required
by regulators.
|
|
(2)
|
|
Audit-related fees are fees paid
for assurance and related services performed by our independent
registered public accountant including due diligence services
related to contemplated mergers and acquisitions, internal
control reviews not required by regulators, and employee benefit
plan audits.
|
|
(3)
|
|
All other fees includes any fees
earned for services rendered by PricewaterhouseCoopers LLP
during 2006 and 2007 which are not included in any of the above
categories. The other fees for 2006 and 2007 consist of
licensing fees paid by us with respect to certain accounting
research software.
|
Policy
Regarding Pre-Approval of Services Provided by the Independent
Registered Public Accountants
The Audit Committee Charter requires the committees
pre-approval of all services, both audit and permitted
non-audit, to be performed for the Company by the independent
auditors. In determining whether proposed services are
permissible, the Audit Committee considers whether the provision
of such services is compatible with maintaining auditor
independence. As part of its consideration of proposed services,
the Audit Committee may (i) consult with management as part
of the decision-making process, but may not delegate this
authority to management, and (ii) delegate, from time to
time, its authority to pre-approve such services to one or more
committee members, provided that any such approvals are
presented to the full committee at the next scheduled Audit
Committee meeting.
The board of directors unanimously recommends a vote FOR the
ratification of PricewaterhouseCoopers LLP as our independent
registered public accountants for the year ending
December 31, 2008.
50
STOCKHOLDER
PROPOSALS
In accordance with our bylaws, a stockholder who, at any annual
meeting of our stockholders, intends to nominate a person for
election as director or present a proposal must so notify our
Corporate Secretary, in writing, describing such nominee(s) or
proposal and providing information concerning such stockholder
and the reasons for and interest of such stockholder in the
proposal. Generally, to be timely, such notice must be received
by our Corporate Secretary not less than 90 days nor more
than 120 days in advance of the first anniversary of the
preceding years annual meeting, provided that in the event
that no annual meeting was held the previous year or the date of
the annual meeting has been changed by more than 30 days
from the date of the previous years meeting, or in the
event of a special meeting of stockholders called to elect
directors, not later than the close of business on the tenth day
following the day on which notice of the date of the meeting was
mailed or public disclosure of the date of the meeting was made,
whichever occurs first. For our annual meeting to be held in
2009, any such notice must be received by us at our principal
executive offices between January 28, 2009 and
February 27, 2009 to be considered timely for purposes of
the 2009 annual meeting. Any person interested in offering such
a nomination or proposal should request a copy of the relevant
bylaw provisions from our Corporate Secretary. These time
periods also apply in determining whether notice is timely for
purposes of rules adopted by the Securities and Exchange
Commission relating to the exercise of discretionary voting
authority, and are separate from and in addition to the
Securities and Exchange Commissions requirements that a
stockholder must meet to have a proposal included in our proxy
statement.
Stockholder proposals intended to be presented at the 2009
annual meeting must be received by us at our principal executive
office no later than December
[ ],
2008, in order to be eligible for inclusion in our proxy
statement and proxy relating to that meeting. Upon receipt of
any proposal, we will determine whether to include such proposal
in accordance with regulations governing the solicitation of
proxies.
OTHER
MATTERS
Management does not intend to bring before the meeting any
matters other than those specifically described above and knows
of no matters other than the foregoing to come before the
meeting. If any other matters or motions properly come before
the meeting, it is the intention of the persons named in the
accompanying proxy to vote such proxy in accordance with the
recommendation of management on such matters or motions,
including any matters dealing with the conduct of the meeting.
HOUSEHOLDING
OF PROXY MATERIALS
The Securities and Exchange Commission has adopted rules that
permit companies and intermediaries such as brokers to satisfy
delivery requirements for proxy statements with respect to two
or more shareholders sharing the same address by delivering a
single proxy statement addressed to those stockholders. This
process, which is commonly referred to as
householding, potentially provides extra convenience
for stockholders and cost savings for companies. We and some
brokers household proxy materials, delivering a single proxy
statement to multiple stockholders sharing an address unless
contrary instructions have been received from the affected
stockholders. Once you have received notice from your broker or
us that they or we will be householding materials to your
address, householding will continue until you are notified
otherwise or until you revoke your consent. If, at any time, you
no longer wish to participate in householding and would prefer
to receive a separate proxy statement, or if you currently
receive multiple proxy statements and would prefer to
participate in householding, please notify your broker if your
shares are held in a brokerage account or us if you hold
registered shares. You can notify us by sending a written
request to Express Scripts, Inc., Attention: Investor Relations,
One Express Way, Saint Louis, Missouri 63121, and we will
promptly deliver these documents to you following our receipt of
such request.
51
SOLICITATION
OF PROXIES
We will bear the cost of the solicitation of proxies for the
meeting. Brokerage houses, banks, custodians, nominees and
fiduciaries are being requested to forward the proxy material to
beneficial owners and their reasonable expenses therefore will
be reimbursed by us. Solicitation will be made by mail and also
may be made personally or by telephone, facsimile or other means
by our officers, directors and employees, without special
compensation for such activities. We have also hired MacKenzie
Partners, Inc. to assist in the solicitation of proxies.
MacKenzie will receive a fee for such services of approximately
$[ ], plus reasonable out-of-pocket
expenses, which will be paid by us.
By Order of the Board of Directors
Thomas M. Boudreau
Executive Vice President, Law & Strategy and
Corporate Secretary
April [14], 2008
52
EXPRESS
SCRIPTS, INC.
EMPLOYEE STOCK PURCHASE PLAN
(As
amended and restated Effective for the Offering Period
Commencing March 1, 2008)
1. Purpose. The purpose of the Plan is to
provide employees of the Company and its Designated Subsidiaries
with an opportunity to purchase Common Stock of the Company
through accumulated payroll deductions. It is the intention of
the Company to have the Plan qualify as an Employee Stock
Purchase Plan under Section 423 of the Internal
Revenue Code of 1986, as amended. The provisions of the Plan
shall, accordingly, be construed so as to extend and limit
participation in a manner consistent with the requirement of
that section of the Code.
2. Definitions.
a) Board shall mean the Board of Directors of
the Company.
b) Code shall mean the Internal Revenue Code of
1986, as amended.
c) Common Stock shall mean the Common Stock
(formerly Class A Common Stock), par value $0.01, of the
Company.
d) Company shall mean Express Scripts, Inc., a
Delaware corporation, and, unless the context requires
otherwise, any Designated Subsidiary.
e) Compensation shall mean all regular straight
time gross earnings, overtime earnings, bonuses and commissions,
and without reduction for contributions to any 401(k) plan
sponsored by the Company.
f) Contributions shall mean all amounts
credited to the account of a participant pursuant to the Plan.
g) Designated Subsidiary shall mean any
Subsidiary which has been designated by the Board from time to
time in its sole discretion as eligible to participate in the
Plan.
h) Employee shall mean any person who is an
employee of the Company for tax purposes whose customary
employment with the Company is at least twenty (20) hours
per week and more than five (5) months in a calendar year.
For purposes of the Plan, the employment relationship shall be
treated as continuing intact while the individual is on short
term disability or other leave of absence approved by the
Company. Where the period of leave exceeds 90 days and the
individuals right to reemployment is not guaranteed either
by statute or by contract, the employment relationship shall be
deemed to have terminated on the 91st day of such leave.
i) Enrollment Date shall mean the first
business day of each Participation Period.
j) Exchange Act shall mean the Securities
Exchange Act of 1934, as amended.
k) Offering Date shall mean the first business
day of each Offering Period of the Plan.
l) Offering Period shall mean a period of one
(1) month commencing on the first day of each calendar
month except as otherwise indicated by the Company.
m) Participation Period shall mean a period of
three (3) months commencing on January 1,
April 1, July 1 and October 1 of each year except as
otherwise indicated by the Company.
n) Plan shall mean this Employee Stock Purchase
Plan.
o) Plan Recordkeeper shall mean a third-party
vendor which may, at the discretion of the Company, be selected
to administer the Plan.
p) Purchase Date shall mean the last day of
each Offering Period of the Plan.
q) Subsidiary shall mean a corporation,
domestic or foreign, which not less than 50% of the voting
shares are held by the Company or a Subsidiary, whether or not
such corporation now exists or is hereafter organized or
acquired by the Company or a Subsidiary.
53
3. Eligibility.
a) Any person who is an Employee of the Company as of the
first Offering Date of a given Participation Period, who has
continuously been an Employee for at least thirty-one
(31) days, and who is not a senior executive of
the Company, as such term may be defined from time to time by
the Board (or any committee administering the Plan in accordance
with Section 13 hereof), shall be eligible to participate
in Offering Periods of such Participation Period under the Plan,
subject to the requirements of Section 5(a) and the
limitations imposed by Section 423(b) of the Code.
b) Any provisions of the Plan to the contrary
notwithstanding, no Employee shall be granted an option under
the Plan (i) if, immediately after the grant, such Employee
(or any other person whose stock would be attributed to such an
Employee pursuant to Section 424(d) of the Code) would own
stock and/or
hold outstanding options to purchase stock possessing five
percent (5%) or more of the total combined voting power or value
of all classes of stock of the Company or of any Subsidiary, or
(ii) if such option would permit his or her rights to
purchase stock under all employee stock purchase plans
(described in Section 423 of the Code) of the Company and
its Subsidiaries to accrue at a rate which exceeds twenty-five
thousand dollars ($25,000) of fair market value of such stock
(determined at the time such option is granted) for each
calendar year in which such option is outstanding at any time.
4. Offering Periods. The Plan shall be
implemented by a series of Offering Periods, each with a
duration of one (1) month, with new Offering Periods
commencing on the first day of each calendar month (or at such
other time or times as may be determined by the Board of
Directors). The Plan shall continue until terminated in
accordance with Section 19 hereof. The Board shall have the
power to change the duration
and/or the
frequency of the Offering Period with respect to future
offerings without stockholder approval if such change is
announced at least fifteen (15) days prior to the scheduled
beginning of the first Offering Period to be affected.
The Offering Periods shall be grouped in to three-month
Participation Periods commencing on or about January 1,
April 1, July 1 and October 1 of each year (or at such
other time or times as may be determined by the Board of
Directors). Employees shall be allowed to make elections with
respect to their participation in the Plan with respect to each
Participation Period (subject to Section 5 and the other
terms hereof).
5. Participation.
a) An eligible Employee may become a participant in the
Plan by enrolling through such procedures as may be provided by
the Company from time to time, which may include enrollment
through the Plan Recordkeeper. An enrollment in effect for a
participant for a particular Participation Period will continue
in effect for subsequent Participation Periods if the
participant remains an eligible Employee and has not withdrawn
from participation in the Plan pursuant to Section 10.
b) Payroll deductions shall commence on the first payroll
following the Enrollment Date and shall end on the last payroll
paid in the Participation Period to which the subscription
agreement is applicable, unless sooner terminated by the
participant as provided in Section 10 hereof.
c) By enrolling in the Plan, each participant will be
deemed to have authorized the establishment of a brokerage
account in his or her name at a securities brokerage firm, which
firm shall serve as custodial agent for the purpose of holding
shares purchased under the Plan. The account will be governed
by, and subject to, the terms and conditions of a written
agreement with the firm approved by the Board or the committee
administering the Plan, which agreement shall, among other
things, reflect the restrictions contained in Section 21(c)
and Section 21(d).
d) Subject to the limitations of Section 3 hereof and
Section 423(b)(8) of the Code, all cash dividends, if any, paid
with respect to shares of Common Stock purchased under the Plan
and held in a participants account established under
Section 5(c) shall be automatically invested in shares of
Common Stock purchased at One Hundred Percent (100%) of fair
market value (as determined under Section 7(b)) on the next
Purchase Date. All non-cash distributions on Common Stock
purchased under the Plan and held in a participants
account established under Section 5(c) (other than stock
dividends which constitute, and are treated as, a change in
capitalization under Section 18(a)) shall be paid to the
participant as soon as practical.
54
6. Method of Payment of Contributions.
a) The participant shall elect to have payroll deductions
made each pay period during the Participation Period in an
amount not less than one percent (1%) and not more than ten
percent (10%), in whole number percentage increments, of such
participants Compensation in each pay period. All payroll
deductions made by a participant shall be credited to his or her
account under the Plan. A participant may not make any
additional payments into such account. Except as otherwise
provided in this Section 6(a), all Employees granted
options under the Plan shall have the same rights and privileges.
b) A participant may increase or decrease his or her
payroll deductions through such procedures as may be provided by
the Company from time to time, which may include procedures
provided through the Plan Recordkeeper. The change may be made
at any time during a Participation Period but will not become
effective sooner than the next pay period thereafter. The Board
or the committee administering the Plan, at its discretion, may
limit the number of participation rate changes during any
Participation Period or Offering Period and may, in its
discretion, require up to five (5) business days prior
written notice.
c) A participant may discontinue his or her participation
in the Plan as provided in Section 10 hereof.
d) Notwithstanding the foregoing, to the extent necessary
to comply with Section 423(b)(8) of the Code and
Section 6(a) hereof, a participants payroll
deductions may be decreased to zero percent (0%) at any time
during the Participation Period. Payroll deductions shall
recommence at the rate provided in such participants
subscription agreement at the beginning of the first Offering
Period which is scheduled to end in the following calendar year,
unless terminated by the participant as provided in
Section 10 hereof.
e) At the time of each exercise of a participants
option, and at the time any Common Stock issued under the Plan
to a participant is disposed of, the participant must adequately
provide for the Companys federal, state or other tax
withholding obligations, if any, that arise upon the exercise of
the option or the disposition of the Common Stock. At any time,
the Company may, but will not be obligated to, withhold from the
participants compensation the amount necessary for the
Company to meet applicable withholding obligations, including
but not limited to, any withholding required to make available
to the Company any tax deductions or benefits attributable to
the sale or early disposition of Common Stock by the participant.
7. Grant of Option.
a) On the Offering Date of each Offering Period, each
eligible Employee participating in such Offering Period shall
automatically be deemed to have been granted an option to
purchase on the Purchase Date a number of shares of the
Companys Common Stock determined by dividing such
Employees Contributions accumulated prior to such Purchase
Date and retained in the participants account as of the
Purchase Date by ninety-five percent (95%) of the fair market
value of the Companys Common Stock on the Purchase Date;
provided, however, that in no event shall an Employee be
permitted to purchase during each Offering Period more than
333 shares (subject to any adjustment pursuant to
Section 18) and provided further that such purchase
shall be subject to the limitations set forth in
Section 3(b). The fair market value of the Companys
Common Stock shall be determined as provided in
Section 7(b).
b) The fair market value of the Companys Common Stock
on a given date shall be equal to the closing sales price of
Common Stock on the date of determination (or, in the event that
the Common Stock is not traded on such date, on the immediately
preceding trading date on which there was a closing sales
price), as reported by The Nasdaq Global Select Market or, in
the event the Common Stock is listed on a different stock
exchange, the fair market value per share shall be the closing
sales price on such exchange on the date of determination (or,
in the event that the Common Stock is not traded on such date,
on the immediately preceding trading date), as reported in The
Wall Street Journal. In the absence of any listing of the Common
Stock on The Nasdaq Global Select Market or on any established
stock exchange, the fair market value of the Common Stock on a
given date shall be determined in good faith by the Board.
8. Exercise of Option. Unless a
participant withdraws from the Plan as provided in
Section 10 hereof, his or her option for the purchase of
shares will be exercised automatically on the Purchase Date of
the Offering Period, and the maximum whole number of shares
subject to such option will be purchased at the applicable
option price
55
with the accumulated Contributions in his or her account,
subject to the limitations in this Plan. The shares purchased
upon exercise of an option hereunder shall be held in the
participants account established under Section 5(c)
pursuant to Section 21(c) and Section 21(d). During
his or her lifetime, a participants option to purchase
shares hereunder is exercisable only by him or her.
9. Delivery. As promptly as practicable
after the Purchase Date of each Offering Period, the Company
shall arrange the delivery by direct deposit into the account
established for each participant under Section 5(c), the
shares purchased upon exercise of his or her option. Any cash
remaining to the credit of a participants account under
the Plan after a purchase by him or her of shares on the
Purchase Date, other than amounts representing fractional
shares, will be returned to him or her as soon as practicable.
Amounts representing fractional shares will be carried forward
for use in subsequent purchases.
10. Voluntary Withdrawal; Termination of Employment.
a) A participant may withdraw from participation in an
Offering Period under the Plan at any time prior to five
(5) business days prior to the Purchase Date of the
Offering Period through such procedures as may be provided by
the Company from time to time including through the Plan
Recordkeeper. Following such withdrawal from the Plan, no
further Contributions for the purchase of shares will be made
during the Participation Period and payroll deductions shall not
resume at the beginning of the succeeding Participation Period
unless the participant re-enrolls in the Plan. If a participant
specifically requests, such participant may withdraw all, but
not less than all, of the Contributions credited to his or her
account under the Plan which have not been used to purchase
shares of the Companys Common Stock which will be paid to
him or her as soon as practicable after the end of such Offering
Period, and his or her option for the current period will be
automatically terminated; otherwise, such Contributions shall be
used to purchase shares of the Companys Common Stock in
the ordinary course.
b) A participants withdrawal from an offering will
not have any effect upon his or her eligibility to participate
in a succeeding Participation Period or in any similar plan
which may hereafter be adopted by the Company.
c) Upon a participants ceasing to be an Employee
prior to the Purchase Date of an Offering Period for any reason,
including retirement or death, the Contributions credited to his
or her account and not yet applied to the purchase of shares
will be applied to the purchase of shares under the Plan on such
Purchase Date.
d) In the event an Employees salary grade level is
elevated or title or position is changed so as to make an
Employee a senior executive of the Company during
the Offering Period in which the Employee is a participant, he
or she will be deemed to have elected to withdraw from the Plan
and Contributions credited to his or her account will be
returned to him or her and his or her option terminated.
11. Interest. No interest shall accrue on
the Contributions of a participant in the Plan.
12. Stock.
a) The maximum number of shares of the Companys
Common Stock which shall be made available for purchase under
the Plan shall be 2,000,000 shares (adjusted for stock
dividends in June 2001, June 2005 and June 2007), which amount
shall be increased to 3,500,000 subject to, and effective upon,
the approval of such increase by the Companys stockholders
at the Companys 2008 Annual Meeting of Stockholders. The
maximum number of shares available for purchase under the Plan
shall be subject to further adjustment upon changes in
capitalization of the Company as provided in Section 18
hereof. These shares may be newly issued or may be purchased for
the Plan on the open market or from private sources. If the
total number of shares which would otherwise be subject to
options granted pursuant to Section 7(a) on the Offering
Date of an Offering Period exceeds the number of shares then
available under the Plan (after deduction of all shares for
which options have been exercised or are then outstanding), the
Company shall make a pro rata allocation of the shares remaining
available for option grant in as uniform a manner as shall be
practicable and as it shall determine to be equitable. In such
event, the Company shall give written notice of such reduction
of the number of shares subject to the option to each Employee
affected thereby and shall similarly reduce the rate of
Contributions, if necessary.
56
b) The participant will have no interest or voting right in
shares covered by his or her option until such option has been
exercised.
c) Shares to be delivered to a participant under the Plan
will be registered in the name of the participant or in the
Street Name of a Company approved broker, subject to
Section 21 hereof.
13. Administration. The Board, or a
committee named by the Board, shall supervise and administer the
Plan and shall have full power to adopt, amend and rescind any
rules deemed desirable and appropriate for the administration of
the Plan and not inconsistent with the Plan, to construe and
interpret the Plan, and to make all other determinations
necessary or advisable for the administration of the Plan. The
composition of the committee shall be in accordance with the
requirements to obtain or retain any available exemption from
the operation of Section 16(b) of the Exchange Act pursuant
to
Rule 16b-3
promulgated thereunder. To aid in the administration of the
Plan, the Board or the committee may appoint a Plan
administrator and allocate to it certain limited
responsibilities to carry out the directives of the Board or the
committee in all phases of the administration of the Plan.
14. Designation of Beneficiary.
a) A participant may designate a beneficiary who is to
receive shares and cash, if any, from the participants
account under the Plan in the event of such participants
death subsequent to the end of an Offering Period but prior to
delivery to him or her of such shares and cash. If a participant
is married and the designated beneficiary is not the spouse,
spousal consent shall be required for such designation to be
effective. Such designation shall be made through such
procedures as may be provided by the Company from time to time
including through the Plan Recordkeeper.
b) Such designation of beneficiary may be changed by the
participant (and his or her spouse, if any) at any time through
such procedures as may be provided by the Company from time to
time including through the Plan Recordkeeper.. In the event of
the death of a participant and in the absence of a beneficiary
validly designated under the Plan who is living at the time of
such participants death, the Company shall deliver such
shares
and/or cash
to the executor or administrator of the estate of the
participant, or if no such executor or administrator has been
appointed (to the knowledge of the Company), the Company, in its
discretion, may deliver such shares
and/or cash
to the spouse or to any one or more dependents or relatives of
the participant, or if no spouse, dependent or relative is known
to the Company, then to such other person as the Company may
designate.
15. Transferability. Neither
Contributions credited to a participants account nor any
rights with regard to the exercise of an option or to receive
shares under the Plan may be assigned, transferred, pledged or
otherwise disposed of in any way (other than by will, the laws
of descent and distribution, or as provided in Section 14
hereof) by the participant. Any such attempt at assignment,
transfer, pledge or other disposition shall be without effect,
except that the Company may treat such act as election to
withdraw all Contributions in accordance with Section 10
hereof.
16. Use of Funds. All Contributions
received or held by the Company under the Plan may be used by
the Company for any corporate purpose, and the Company shall not
be obligated to segregate such Contributions.
17. Reports. Individual accounts will be
maintained for each participant in the Plan. Statements of
account will be given to participating Employees promptly
following the Purchase Date, which statements will set forth the
amount of Contributions, the per share purchase price, the
number of shares purchased, the remaining cash balance, if any,
and the dividends received, if any, for the period covered. Such
statements may be delivered electronically by the Company or the
Plan Recordkeeper.
18. Adjustments Upon Changes in Capitalization;
Corporate Transactions.
a) Changes in Capitalization. Subject to
any required action by the stockholders of the Company, the
number of shares of Common Stock covered by each option under
the Plan which has not yet been exercised and the number of
shares of Common Stock which have been authorized for issuance
under the Plan but have not yet been placed under option
(collectively, the Reserves), as well as the price
per share of Common Stock covered by each option under the Plan
which has not yet been exercised, shall be appropriately
adjusted for any changes in the Common Stock resulting from a
stock split, reverse stock split, stock dividend, combination or
57
reclassification of the Common Stock, or any similar changes in
the Companys capitalization. Such adjustment shall be made
by the Board or the committee administering this Plan, whose
determination in that respect shall be final, binding and
conclusive. Except as expressly provided herein, no issue by the
Company of shares of stock of any class, or securities
convertible into shares of stock of any class, shall affect, and
no adjustment by reason thereof shall be made with respect to,
the number or price of shares of Common Stock subject to an
option.
b) Corporate Transactions. In the event
of the proposed dissolution or liquidation of the Company, the
Offering Period will terminate immediately prior to the
consummation of such proposed action, unless otherwise provided
by the Board. In the event of a proposed sale of all or
substantially all of the assets of the Company, or the merger of
the Company into another corporation, each option under the Plan
shall be assumed or an equivalent option shall be substituted by
such successor corporation or a parent or subsidiary of such
successor corporation, unless the Board determines, in the
exercise of its sole discretion and in lieu of such assumption
or substitution, to shorten the Offering Period then in progress
by setting a new Purchase Date (the New Purchase
Date). If the Board shortens the Offering Period then in
progress in lieu of assumption or substitution in the event of a
merger or sale of assets, the Board shall notify each
participant in writing, at least ten (10) days prior to the
New Purchase Date, that the Purchase Date for his or her option
has been changed to the New Purchase Date and that his or her
option will be exercised automatically on the New Purchase Date,
unless prior to such date he or she has withdrawn from the
Offering Period as provided in Section 10 hereof. For purposes
of this paragraph, an option granted under the Plan shall be
deemed to have been assumed or substituted if, following the
sale of assets or merger, the option confers the right to
purchase, for each share of Common Stock subject to the option
immediately prior to the sale of assets or merger, the
consideration (whether stock, cash or other securities or
property) received in the sale of assets or merger by holders of
Common Stock for each share of Common Stock held on the
effective date of the transaction (and if such holders were
offered a choice of consideration, the type of consideration
chosen by the holders of the majority of the outstanding shares
of Common Stock); provided, however, that if such consideration
received in the sale of assets or merger was not solely common
stock of the successor corporation or its parent (as defined in
Section 424(e) of the Code), the Board may, with the consent of
the successor corporation and the participant, provide for the
consideration to be received upon exercise of the option to be
solely common stock of the successor corporation or its parent
equal in fair market value to the per share consideration
received by holders of Common Stock in the sale of assets or
merger.
19. Amendment or Termination.
a) The Board may at any time terminate or amend the Plan.
Except as provided in Section 19, no such termination may
affect options previously granted, nor may an amendment make any
change in any option theretofore granted which adversely affects
the rights of any participant; provided, that no shares may be
issued or sold pursuant to any amendment increasing the maximum
number of shares issuable under the Plan unless the stockholders
of the Company have approved the amendment within 12 months
of its adoption by the Board. If such stockholder approval is
not obtained within such
12-month
period, the amendment shall be void and of no force or effect
and the amounts withheld from Employees with respect to such
increased shares shall be returned to them. In addition, to the
extent necessary to comply with
Rule 16b-3
under the Exchange Act, or under Section 423 of the Code
(or any successor rule or provision or any applicable law or
regulation), the Company shall obtain stockholder approval in
such a manner and to such a degree as so required.
b) Without stockholder approval and without regard to
whether any participant rights may be considered to have been
adversely affected, the Board (or its committee) shall be
entitled to change the Offering Periods and Purchase Periods,
limit the frequency
and/or
number of changes in the amount withheld during an Offering
Period, establish the exchange ratio applicable to amounts
withheld in currency other than U.S. dollars, permit
payroll withholding in excess of the amount designated by a
participant in order to adjust for delays or mistakes in the
Companys processing of properly completed withholding
elections, establish reasonable waiting and adjustment periods
and/or
accounting and crediting procedures to ensure that amounts
applied toward the purchase of Common Stock for each participant
properly correspond with amounts withheld from the
participants Compensation, and establish such other
limitations or procedures as the Board (or its committee)
determines in its sole discretion as advisable which are
consistent with the Plan.
58
20. Notices. All notices or other
communications by a participant to the Company under or in
connection with the Plan shall be deemed to have been duly given
when received in the form specified by the Company at the
location, or by the person, designated by the Company for the
receipt thereof.
21. Conditions Upon Issuance of Shares.
a) Shares shall not be issued with respect to an option
unless the exercise of such option and the issuance and delivery
of such shares pursuant thereto shall comply with all applicable
provisions of law, domestic or foreign, including, without
limitation, the Securities Act of 1933, as amended, the Exchange
Act, the rules and regulations promulgated thereunder, and the
requirements of The Nasdaq Global Select Market or any stock
exchange upon which the shares may then be listed, and shall be
further subject to the approval of counsel for the Company with
respect to such compliance.
b) As a condition of the exercise of an option, the Company
may require the person exercising such option to represent and
warrant at the time of any such exercise that the shares are
being purchased only for investment and without any present
intention to sell or distribute such shares if, in the opinion
of counsel for the Company, such a representation is required by
any of the aforementioned applicable provisions of law.
c) Each participant agrees, by enrolling in the Plan, to
promptly give the Company prior written notice of any withdrawal
of shares held in the participants account established
under Section 5(c), or any disposition of shares purchased
under the Plan, where such withdrawal or disposition occurs
within two (2) years after the date of grant of the option
pursuant to which such shares were purchased, provided that any
such withdrawal or disposition shall be subject to
Section 21(d).
d) Prior to the participants termination of
employment with the Company, a participant may withdraw some or
all of the whole shares of Common Stock held in the
participants account established under Section 5(c),
provided that, unless the Board or the committee administering
the Plan otherwise permits in its sole discretion, each
participant agrees, by enrolling in the Plan, that he or she may
not withdraw any shares of Common Stock purchased under the Plan
until six (6) months have expired following the Purchase
Date on which such shares were purchased.
22. Term of Plan; Effective Date. The
Plan became effective upon its adoption by the Board on
November 24, 1998, subject to its approval by the
stockholders of the Company which was obtained May 26,
1999. The Plan has been amended and restated by the Compensation
Committee of the Board effective March 1, 2008 and shall
continue in effect for a term of ten (10) years from
March 1, 2008 unless sooner terminated under
Section 19 hereof.
23. Additional Restrictions of
Rule 16b-3. The
terms and conditions of options granted hereunder to, and the
purchase of shares by, persons subject to Section 16 of the
Exchange Act shall comply with the applicable provisions of
Rule 16b-3.
This plan shall be deemed to contain, and such options shall
contain, and the shares issued upon exercise thereof shall be
subject to, such additional conditions and restrictions as may
be required by
Rule 16b-3
to qualify for the maximum exemption from Section 16 of the
Exchange Act with respect to Plan transactions.
59
EXPRESS
SCRIPTS, INC.
ONE EXPRESS WAY
ST. LOUIS, MO 63121
VOTE BY INTERNET www.proxyvote.com
Use the Internet to transmit your voting
instructions and for electronic delivery of
information up until 11:59 P.M. Eastern Time the
day before the cut-off date or meeting date. Have
your proxy card in hand when you access the web
site and follow the instructions to obtain your
records and to create an electronic voting
instruction form.
ELECTRONIC DELIVERY OF FUTURE STOCKHOLDER COMMUNICATIONS
If you would like to reduce the costs incurred by
Express Scripts, Inc. in mailing proxy materials,
you can consent to receiving all future proxy
statements, proxy cards and annual reports
electronically via e-mail or the Internet. To sign
up for electronic delivery, please follow the
instructions above to vote using the Internet and,
when prompted, indicate that you agree to receive
or access stockholder communications electronically
in future years.
VOTE BY PHONE 1-800-690-6903
Use any touch-tone telephone to transmit your
voting instructions up until 11:59 P.M. Eastern
Time the day before the cut-off date or meeting
date. Have your proxy card in hand when you call
and then follow the instructions.
VOTE BY MAIL
Mark, sign and date your proxy card and return it
in the postage-paid envelope we have provided or
return it to Express Scripts, Inc., c/o Broadridge,
51 Mercedes Way, Edgewood, NY 11717.
|
|
|
|
|
TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:
|
|
EXPSC1
|
|
KEEP THIS PORTION FOR YOUR RECORDS |
|
|
|
|
|
DETACH AND RETURN THIS PORTION ONLY |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.
|
|
|
|
|
|
|
EXPRESS SCRIPTS, INC.
|
|
For
All
|
|
Withhold
All
|
|
For All
Except |
THE BOARD OF DIRECTORS RECOMMEND A VOTE FOR
ITEMS 1, 2, 3 AND 4.
Vote on Directors
|
|
o
|
|
o
|
|
o |
|
|
|
|
|
|
|
1. |
|
ELECTION OF DIRECTORS |
|
|
Nominees: |
|
|
|
|
|
|
|
|
|
01) Gary G. Benanav
|
|
07) John O. Parker, Jr. |
|
|
|
|
02) Frank J. Borelli
|
|
08) George Paz |
|
|
|
|
03) Maura C. Breen
|
|
09) Samuel K. Skinner |
|
|
|
|
04) Nicholas J. LaHowchic
|
|
10) Seymour Sternberg |
|
|
|
|
05) Thomas P. Mac Mahon
|
|
11) Barrett A. Toan |
|
|
|
|
06) Woodrow A. Myers, Jr., M.D. |
|
|
|
|
To withhold authority to vote
for any individual nominee(s),
mark For All Except and write
the number(s) of the nominee(s)
on the line below.
|
|
|
|
|
|
|
|
|
Vote on Proposals |
|
For |
|
Against |
|
Abstain |
2.
|
|
Approval and ratification of an amendment to the Companys Amended and Restated Certificate of Incorporation to increase the number of authorized
shares of the Companys common stock from 650,000,000 shares to 1,000,000,000 shares.
|
|
o
|
|
o
|
|
o |
|
|
|
|
|
|
|
|
|
3.
|
|
Approval and ratification of an increase in the number of shares of the Companys Common Stock authorized for issuance Under the Express Scripts,
Inc. Employee Stock Purchase Plan from 2,000,000 shares to 3,500,000 shares.
|
|
o
|
|
o
|
|
o |
|
|
|
|
|
|
|
|
|
4.
|
|
Ratification of the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accountants for 2008.
|
|
o
|
|
o
|
|
o |
|
|
|
|
|
|
|
|
|
5.
|
|
In their discretion, upon such other matters that may properly come before the meeting or any adjournment or adjournments thereof.
|
|
o
|
|
o
|
|
o |
|
|
|
|
|
|
|
|
|
The shares represented by this proxy when properly executed will be voted in the manner directed herein by the undersigned Stockholder(s). If no direction is
made, this proxy will be voted FOR items 1, 2, 3 and 4. If any other matters properly come before the meeting, or if cumulative voting is required, the person
named in this proxy will vote in their discretion. |
|
o |
|
o |
|
o |
Please sign your name exactly as it
appears hereon. When signing as
attorney, executor, administrator,
trustee or guardian, please add your
title as such. When signing as joint
tenants, all parties in the joint tenancy
must sign. If a signer is a corporation,
please sign in full corporate name by
duly authorized officer.
|
|
|
|
|
|
|
Signature [PLEASE SIGN WITHIN BOX] Date
|
|
|
|
Signature (Joint Owners) Date
|
|
|
Important Notice Regarding Internet Availability of Proxy Materials for the Annual Meeting:
The Notice and Proxy Statement and Annual Report are available at www.proxyvote.com.
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
ANNUAL MEETING OF STOCKHOLDERS
May 28, 2008
The stockholder(s) hereby appoint George Paz and Thomas M. Boudreau, or either of them,
as proxies, each with the power to appoint (his/her) substitute, and hereby authorizes them to
represent and to vote, as designated on the reverse side of this ballot, all of the shares of
Common Stock of Express Scripts, Inc. that the stockholder(s) is/are entitled to vote at the Annual
Meeting of Stockholders to be held at 9:30 a.m. Central Time on May 28, 2008, at the offices of the
Company, One Express Way, Saint Louis, Missouri 63121, and any adjournment or postponement
thereof.
THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BY THE STOCKHOLDER(S). IF NO SUCH
DIRECTIONS ARE MADE, THIS PROXY WILL BE VOTED FOR THE ELECTION OF THE NOMINEES LISTED ON THE
REVERSE SIDE FOR THE BOARD OF DIRECTORS AND FOR EACH PROPOSAL.
PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY CARD PROMPTLY USING THE ENCLOSED REPLY ENVELOPE
CONTINUED AND TO BE SIGNED ON REVERSE SIDE